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Trace amines (TAs), tryptamine, tyramine, octopamine, and β-phenylethylamine, 
named for their low endogenous concentrations in mammals, are related to the classical 
monoamine transmitters, but have been understudied and thought of as false transmitters.  
They share structural, physiological, pharmacological, and metabolic similarities with the 
monoamines, including synthesis by the aromatic-L-amino acid decarboxylase (AADC) 
enzyme.  In 2001, a new class of receptors preferentially activated by the TAs, termed 
trace amine-associated receptors (TAARs), was discovered establishing a mechanism for 
TA actions independent of classic monoaminergic mechanisms.  While the TAs and some 
of their receptors are present in the mammalian central nervous system (CNS), their 
physiologic role remains uncertain.  I hypothesized that the TAs are found intrinsically in 
the spinal cord, and that they are able to modulate spinal neural networks.   
Using immunohistochemistry, numerous spinal neurons were identified that express 
AADC, the TAs (octopamine, tryptamine, and tyramine), and TAARs (TAAR1 and 
TAAR4).  Similar results were seen for AADC and TAAR1 with in situ hybridization. 
The most consistent observation was for labeling D cells associated with the central canal 
and in motoneurons.  Overall, these results provided evidence for the presence of an 
anatomical substrate onto which the TAs could have intrinsic biological actions in the 
spinal cord. 
Using exogenous application of the TAs in the isolated spinal cord in vitro, and in vivo 
in the mid-thoracic chronically spinalized, I showed that the TAs could induce rhythmic 
locomotor-like activity.  TA injection-induced hindlimb motor rhythms observed in 
chronic spinalized animals, supports TA spinal actions independent of the descending 
 xxi
monoaminergic systems.  In the presence of NMDA, TA applications recruited a variety 
of rhythmic motor patterns in the isolated spinal cord.  This ranged from locomotor 
activity indistinguishable from 5-HT/NMDA induced locomotion to complex patterns 
including, an episodic form of locomotion where there were locomotor bouts with 
intervening quiescent periods.  
TA actions of pattern generating circuits: (i) had slower kinetics of activation than 5-
HT and NA, (ii) were attenuated in the presence of monoamine transport inhibitors, and 
(iii) had increased intracellular labeling even when incubated in a nominally Na+-free 
solution.  Together these results suggest that the TAs required transport into neurons to 
exert their actions, and that transport occurred by Na+-dependent monoamine transporters 
as well as additional Na+-independent transporters.  
Finally, I used the in vitro isolated spinal cord with attached hindlimbs to record 
electromyographic (EMG) activity from various hindlimb muscles: (i) to compare the 
relationship between the TAs and serotonin (5-HT) evoked motor coordination, and (ii) 
to examine the ability of the TAs to modulate ongoing 5-HT and NMDA locomotor-like 
activity.  The TAs produced both the continuous and episodic patterns on muscles as 
observed in ventral root recordings, but EMG recordings provided more detailed insight 
into specific muscle actions.  The TAs also generally increased both frequency and 
amplitude of ongoing 5-HT locomotor frequency, with tyramine and octopamine also 






CHAPTER 1  
 INTRODUCTION  
1.1 The classical monoamine neurotransmitters 
1.1.1 General background of the monoamines  
The classical monoamine neurotransmitters are important central nervous system 
(CNS) neuromodulatory transmitters.  Projections to the spinal cord from descending 
monoaminergic nuclei are involved in modulating spinal motor, autonomic, and sensory 
functions (Gerin et al. 1995).  Altered monoamine transmitter levels are associated with 
many pathological disorders including dystonias, Parkinson’s disease, schizophrenia, 
drug addiction, and mood disorders (Premont et al. 2001).  
1.1.2 General monoamine transmission 
Like all classic neurotransmitters, the monoamines are stored in vesicles at synaptic 
terminals and released into the synaptic cleft when the neuron is depolarized.  On the 
postsynaptic side of the synapse, they bind G-protein coupled receptors, which lead to 
intracellular signaling pathways being activated.  The monoamines that do not make it 
across the synaptic cleft are taken up by the presynaptic neurons through specific 
monoamine transporters.  The monoamines are then repackaged into vesicles or are 
degraded by monoamine oxidases (Figure 1.1) (Premont et al. 2001). 
1.1.3 Structure and synthesis of the monoamines 
Monoamines have one amino group that is connected to an aromatic ring by a two-




Figure 1.1: Monoamine synaptic terminal 
Monoamines are released from synaptic vesicles when the neuron is depolarized.  The monoamines either 
bind postsynaptic monoamine receptors, where they activate intracellular signaling, or are taking up by 
monoamine transporters.  Once transported into the presynaptic neuron, the monoamines are either taken 
back up into the synaptic vesicles or are degraded by monoamine oxidases (MAOs). 
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indoleamines.  Catecholamines, such as dopamine (DA), noradrenaline (NA), and 
adrenaline, contain a catechol group, which has two hydroxyl groups attached to a 
benzene ring.  Indolamines, like serotonin (5-HT), contain an indole group, which has 
six-member benzene ring fused to a five-member nitrogen-containing pyrrole ring.   
Both groups are synthesized from the precursor aromatic amino acids in neurons 
containing the appropriate synthesis enzymes, including aromatic-L-amino acid 
decarboxylase (AADC or DOPA decarboxylase), which is required for the synthesis of 
all of the monoamines (Figure 1.2).  Catecholamines synthesis starts with tyrosine 
hydroxylase (TH).  Then DA, NA, and adrenaline are formed by the cascade of AADC, 
dopamine-β-hydroxylase (DBH), and phenylethanolamine-N-methyltransferase (PNMT), 
respectively.  5-HT synthesis requires tryptophan hydroxylase followed by AADC. 
1.1.4 Descending monoaminergic systems 
Histofluorescence studies by Dahlstrom and Fuxe (1964) first identified populations 
of monoamine-containing nuclei, which have diffuse projections throughout the CNS.  
The nomenclature for these populations follows their discovery in chronological order. A 
cells are catecholaminergic.  B cells are serotonergic (Dahlstrom and Fuxe 1965; 1964).  
The monoamines are synthesized in these nuclei, which are located in the brainstem, and 
are transported into the spinal cord, where the monoamines are widely distributed within 
the spinal cord. 
DA projects to the spinal cord from the hypothalamus.  DA labeling was identified in 
all laminae of the spinal cord.  The labeling was concentrated in the dorsal horn and 
intermediolateral cell column.  Also, there were varicosities in the motoneuronal cell 
groups (Holstege et al. 1996). 
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NA projects to the spinal cord from locus coeruleus and A5 and A7 groups in the 
pontine lateral tegmental.  Locus coeruleus neurons project to the dorsal horn and 
intermediate zone.  A5 and A7 axons project in the ventral and dorsolateral funiculi and 
terminate in the ventral horn and the intermediolateral cell column (Fritschy and Grzanna 
1990). 
There are 9 groups of 5-HT-containing neurons (B1-B9) (Tork 1990).  5-HT projects 
to the spinal cord from the raphe nuclei (medulary raphe pallidus (B1), raphe obscuris 
(B2), and raphe magnus (B3)) and are widespread, innervating all levels of the spinal 
cord (Rajaofetra et al. 1989; Schmidt and Jordan 2000).  5-HT fibers enter the ventral 
lumbar spinal cord around embryonic day 15, while the dorsal spinal cord is innervated 
around embryonic day 20 (Rajaofetra et al. 1989).  
1.1.5 Monoamine oxidases 
Monoamine oxidase (MAO) is an enzyme that catalyzes oxidative deamination of 
dietary amines, monoamines, and TAs and is found in the outer membrane of 
mitochondria.  MAOs act rapidly and are very important in maintaining monoamine 
concentrations.  Two different types of MAO, named A and B, have been characterized.  
They are encoded by different genes, and were originally defined by their sensitivity to 
MAO inhibitors. MAOA is selectively inhibited by clorgyline, and MAOB is selectively 
inhibited by deprenly and pargyline.  MAOA has a high affinity for 5-HT and NA, while 
MAOB has a high affinity for PEA.  DA and the other TAs are degraded by both.  
However, it should be noted that in rodent brains, DA is mainly degraded by MAOA, 
while MAOB plays a larger role in humans and primates (Bortolato et al. 2008; Shih et 





Figure 1.2: Biosynthesis of the monoamines and trace amines 
The monoamines [5-HT, DA, and NA] and the TAs [tryptamine, PEA, tyramine, and octopamine] have 
similar structures and synthesis.  Both the monoamines and TAs require aromatic-L-amino acid 
decarboxylase (AADC) for their synthesis from the aromatic amino acids [tryptophan, phenylalanine, and 
tyrosine].  Octopamine is the only TA that requires an additional enzyme, dopamine-β-hydroxylase, while 
all of the monoamines also require other enzymes including tyrosine hydroxylase, tryptophan hydroxylase, 
and/or dopamine- β-hydroxylase.  In the periphery, phenylalanine is also converted to tyrosine by 
phenylalanine hydroxylase. 
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In the brain, MAOA was found primarily in catecholaminergic neurons, whereas 
MAOB is mainly expressed in serotinergic and histaminergic neurons.  Both MAOs are 
also found in cerebral cortices, hippocampus, cerebellum, and spinal cord (Luque et al. 
1995; Westlund et al. 1985).  In situ hybridization demonstrated very strong expression 
of MAOA in motoneurons (Luque et al. 1995), while binding studies using selective 
MAOA and B-inhibitors suggest both MAOs are present in the spinal cord and central 
canal (Luque et al. 1995; Saura et al. 1992).  Also, a subpopulation of sensory neurons in 
dorsal root ganglion were reported to express TH and MAO (Vega et al. 1991). 
MAO inhibitors are used to treat a number of disorders, including depression, anxiety 
disorders, attention deficit disorder, Tourette’s, Parkinson’s disease, and Alzheimer’s 
disease (Bortolato et al. 2008; Shih et al. 1999).   
1.2 Trace amines 
1.2.1 General background of the trace amines 
The trace amines (TAs), named for their low endogenous concentrations in mammals, 
are a family of endogenous amines with structural, metabolic, physiological, and 
pharmacological similarities to classical monoamine neurotransmitters (Saavedra 1989). 
The TAs include tryptamine, tyramine, octopamine, and β-phenylethylamine (PEA).  
Like the classical monoamines, synthesis of the majority of the TAs is formed by the 
enzymatic decarboxylation of the precursor aromatic amino acids, phenylalanine, 
tyrosine, and tryptophan (Figure 1.2), by the enzyme AADC. Tyramine can be further 
enzymatically converted by DBH into octopamine.  Metabolism of the TAs is primarily 
via MAOs (Shimazu and Miklya 2004).  Like the classic monoamines, TAs are thought 
to play a role in human disorders such as schizophrenia, attention deficit disorder, 
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Parkinson’s disease, and depression (Branchek and Blackburn 2003).  Their presence has 
been documented in all vertebrate and invertebrate species studied, including humans 
(Axelrod et al. 1976; Berry 2004; Philips et al. 1978; Roeder 2005).  While the role of 
TAs as neurotransmitters in the sympathetic nervous system of invertebrates is well 
characterized (Roeder 2005), their role in the mammalian CNS is still being 
characterized.  Historically in mammals, TAs have been considered as metabolic by-
products (Berry 2004) or “false transmitters” that displace monoamines from storage.  
Since these compounds were not thought of as active neuromodulators, there was a loss 
of interest in TAs that began in the late 1980’s. 
1.2.1.1 Discovery of the trace amines 
PEA was first isolated from decomposing gelatin by Nencki, a contemporary of Louis 
Pasteur, in 1876.  Subsequently, PEA was isolated from putrid egg whites, decomposing 
mackerel, ripe Emmanthaler cheese, and other fermentation products (Grandy 2007).   
In 1906, Abelous and colleague demonstrated that extracts from putrefied horse meat 
dramatically increase arterial blood pressure.  In 1909, Barger and Walpole, isolated and 
purified PEA and tyramine from putrefied horse meat.  Barger and Dale demonstrated 
that PEA, tyramine, octopamine (which would be named later), and NA cause a rapid 
increase in arterial pressure when injected intravenously into the pithed cat, especially 
tyramine (Barger and Dale 1910; Barger and Walpole 1909; Grandy 2007). 
Octopamine was first detected by Erspamer and Boretti in the salivary gland of 
Octopus vulgaris, hence the name (Erspamer and Boretti 1951).  Subsequently, it was 
identified in the urine of several mammalian species, including humans and rats 
(Kakimoto and Armstrong 1962a; b). 
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1.2.1.2 Origin of the name “Trace Amines” 
The title, “trace”, was given to the TAs at the American College of 
Neuropsychopharmacology meeting in 1975 to describe their quantity (Boulton 1984; 
Usdin and Sandler 1976), which is several hundred-fold below those of the classical 
monoamines (Durden and Philips 1980; Usdin and Sandler 1976).  It has since been 
suggested that it is a misleading title that diminishes their importance (Boulton 1984; 
Burchett and Hicks 2006; Dewhurst 1984).   
As stated by Saavedra (1989): “On the basis of their low concentrations in 
mammalian brain, octopamine, β-phenylethylamine, tyramine, and tryptamine have been 
classified as “micro,” “minor,” or “trace” amines.  The connotation ‘trace’ has perhaps 
been too restrictive, since the concentrations in brain are heterogeneous under 
physiological conditions and their turnover rates are very high” (Saavedra 1989). 
1.2.1.3 Origin and understanding of the conventional view that the trace amines are 
“False Transmitters” 
In the past, the TAs in the mammal have been considered as metabolic by-products 
(Berry 2004) or “false transmitters” that displace monoamines from storage, and act on 
transporters much like the amphetamines, and have no function of their own (Boulton et 
al. 1988; Saavedra 1989; Usdin and Sandler 1976).  The first mention of “false 
neurochemical transmitter” in regard to the TAs came from Kopin et al. (1964).  A “false 
neurochemical transmitter” is defined as, “substances normally not present in significant 
amounts in sympathetic nerves, which can be made to accumulate in the nerve endings 
and which can then be discharged by sympathetic nerve stimulation” (Kopin et al. 1964).  
He further refines the definition by adding that for it to be a neurotransmitter rather than a 
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“false transmitter,” it must have the same physiological actions and pharmacological 
properties, in appropriate concentrations, as the natural transmitter” (Kopin 1968). 
During the late 1950s and 1960s, there was a substantial amount of research regarding 
the effects of different enzymes and inhibitors (like MAO inhibitors) involved in the 
regulation of monoamines and TAs and their effects on sympathetic nerve endings and 
blood pressure (Bejrablaya et al. 1958; Burn and Rand 1958a; 1957; 1958b; Davey et al. 
1963a; b; Day and Rand 1964; Kopin et al. 1964).  In interpreting the results, Kopin 
made some assumptions that lead to the propagation of the theory that the TAs are “false 
transmitters” and not endogenous amines with their own actions.  One was an important 
distinction between cause and effect.  It was thought that “false transmitters” alter the 
available amount of NA by altering catecholamine synthesis, rather than alterations to 
catecholamine synthesis forming “false transmitters” (Kopin 1968).  Second, Kopin’s 
(1964 and 1968) definition of a “false transmitter” is very limited, and basically his 
definition made anything that was produced and accumulated in sympathetic nerves that 
was not NA a “false transmitter.”  By his definition, if an amine had actions that were 
different than NA, it must be “false transmitter”. 
Unfortunately, this view was the predominant view for well over 30 years, and many 
studies were interpreted based on the idea that the TAs were “false transmitters” that 
were released with or instead of monoamines and interfered with monoamine actions 
rather than having their own independent actions.  These and other studies assume that 
there were no dedicated trace aminergic synapses so that the function of the TAs had to 
occur in other known monoamine-containing neural circuits (Boulton et al. 1988; 
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Saavedra 1989; Usdin and Sandler 1976).  TAs have NOT been thought of as active 
neuromodulators in mammals (Borowsky et al. 2001).     
1.2.2 Endogenous levels of the trace amines 
Endogenous levels of TAs are several hundred-fold below those of the classical 
neurotransmitters DA, NA, and 5-HT, yet their rate of synthesis and circulating levels are 
similar to that of DA and NA (Durden and Philips 1980; Henry et al. 1988; Paterson et al. 
1990).  As a result, the TAs have a extremely rapid turnover rate, seen as an endogenous 
pool half-life of approximately 30 seconds (Durden and Philips 1980) suggesting that the 
TAs are exquisitely attuned to moment-to-moment fluctuations in substrate. The turnover 
rates and circulating levels of these neuroactive compounds may “be a more significant 
index of their importance than their endogenous concentrations” (Saavedra 1989). It 
should be considered that the estimates on the concentrations of the TA are based on the 
assumption of a uniform distribution (Dyck 1989), and since the TAs have a 
heterogeneous distribution with variations present in the distribution of individual TAs 
(Durden and Philips 1980; Paterson et al. 1990), they may not accurately reflect local 
concentrations, which are likely to be higher.  The concentration of the TAs at the level 
of the single cell have yet to be determined (Berry 2007). 
1.2.2.1 Synthesis of the trace amines  
The TAs, PEA, tyramine, and tryptamine, are synthesized by the enzymatic 
decarboxylation of the aromatic amino acids, phenylalanine, tyrosine, and tryptophan 
(Figure 1.2), by the enzyme AADC (Dyck et al. 1983).  Tyramine can be further 
enzymatically converted by DBH into octopamine.  Conversion from the TAs to the 
monoamines does not appear to occur (Berry 2007).  
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The conversion from tyrosine to phenylalanine is via tyrosine hydroxylase in the 
CNS, but in extra-neuronal tissue it is primarily via phenylalanine hydroxylase (Berry 
2007). 
1.2.2.1.1 Dietary affects on the levels trace amines and aromatic amino acids  
TAs and aromatic amino acids are found in many of the foods we eat.  For example, 
tyramine is found in aged meat and cheese (Gardner et al. 1996), PEA is found in 
chocolate (Ghozlan et al. 2004), and the aromatic amino acids are found in all foods that 
have protein, such as meat.  It has been shown that meals cause physiologic-size changes 
in aromatic amino acid concentrations (Fernstrom 1990).  The raised levels of the 
aromatic amino acids in the brain affect the synthesis of neurotransmitters such as 
serotonin (Fernstrom and Wurtman 1971) and the catecholamines (Wurtman et al. 1974), 
and, presumably, the synthesis of the TAs.  The enzyme composition of each neuron 
dictates what it will produce (Fernstrom 1990); for example, if a neuron takes up 
tryptophan and has AADC, but no tryptophan hydroxylase, it will produce tryptamine, 
but not 5-HT.  
While diet-related central changes in aromatic amino acids were assumed to alter brain 
function by altering monoamine transmitter levels (Fernstrom 1990; 1977), the 
importance of diet to TA modulatory status may be significant, since diets rich in TAs 
and aromatic amino acids affect brain function (Branchek and Blackburn 2003) and can 
lead to excitability changes in locomotor circuits (Foldes and Costa 1975; Jackson 1975a; 
1972; 1974; 1975b; Marsden and Curzon 1978; 1974; Thurmond et al. 1977).  
Some studies saw increases in locomotion from tryptophan in MAO inhibitor-treated 
rats (Foldes and Costa 1975; Marsden and Curzon 1978), while others gave tryptophan 
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alone and saw decreases in locomotor activity (Tricklebank et al. 1978; Wurtman et al. 
1980).  It has been suggested that the differences could be due to increased relative levels 
of tryptamine (Foldes and Costa 1975; Wurtman et al. 1980).  This is plausible since 
tryptophan caused a greater percent increase in brain tryptamine than brain 5-HT in MAO 
inhibitor-treated mice (Marsden and Curzon 1978; 1974) and since 5-HT accumulation 
rates due to tryptophan do not correlate with motility increases in MAO inhibitor-treated 
rats (Foldes and Costa 1975). 
Phenylalanine and PEA both appear to have effects on the motor systems, possibly 
through PEA. Mice given phenylalanine supplements show increased motility (Thurmond 
et al. 1977), while rodents injected with PEA exhibit behaviors resembling those of 
amphetamines including locomotor activity (Jackson 1975a; b).   
1.2.2.1.2 Aromatic-L-amino acid decarboxylase 
Aromatic-L-amino acid decarboxylase (AADC) or dopa decarboxylase is the enzyme 
that decarboxylates aromatic amino acid, L-dopa, and L-5HTP into TAs and 
monoamines.  It is not considered the rate-limiting enzyme for monoamines, except in 
Parkinson’s disease patients with exogenous L-dopa; however, it is the rate-limiting 
enzyme for the synthesis of TAs (Berry et al. 1996; Dyck et al. 1983).  Thus, events that 
regulate AADC activity should alter TA levels.  Rapid changes in AADC activity, like 
phosphorylation (see below), can act to change the levels of the TAs and fine tuning their 
actions, thus allowing minute to minute regulation (Berry et al. 1996). 
AADC can be regulated at both the level of protein activity and gene expression, 
which can lead to two phases of alteration in activity.  Like the short term regulation of 
TH (Masserano et al. 1989), the short term changes in activity due to AADC are likely 
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mediated by phosphorylation, which is a reasonable mechanism for a rapid response.  
cAMP-dependent protein kinase (PKA) and cGMP-dependent protein kinase (PKG) both 
phosphorylate AADC in vitro (Duchemin et al. 2000; Duchemin et al. 2010).  Long term 
regulation is due to changes in gene expression.  There is excellent correlation between 
mRNA level and AADC activity (Coge et al. 1990).  Two forms of AADC, neuronal and 
non-neuronal, have been identified.   They are coded by a single gene, but use two 
distinct promoters followed by alternative splicing (Hahn et al. 1993; Ichinose et al. 
1989).   
In response to MAO inhibitors, AADC appears to have different short term and long 
term effects.  Short term, AADC activity decreases following MAO inhibitors and l-
DOPA (Cumming et al. 1995).  Long term AADC has increased AADC mRNA (Berry et 
al. 1996).   
In the developing rat embryo, AADC positive neurons are observed on day 12 of 
development in all cells of the notochord and in neuroepithelial cells of the ventral neural 
tube.  AADC was enzymatically active, and these cells were tyrosine hydroxylase 
negative, which indicates that the monoamines are not being produced by these cells 
(Teitelman et al. 1983).  One possibility is that the TAs are being produced. 
There is also evidence that AADC levels in hypothalamus are under circadian controls 
(Ishida et al. 2002). 
1.2.2.1.3 AADC positive neurons in the central nervous system and D cells 
Histofluorescence studies by Dahlstrom and Fuxe (1964) first identified populations of 
monoamine-containing CNS neurons.  It is known that monoaminergic neurons are 
profound modulators of CNS function with diffuse projections throughout the CNS.  The 
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nomenclature for these populations follows their discovery in chronological order. A cells 
are catecholaminergic.  B cells are serotonergic (Dahlstrom and Fuxe 1965; 1964).  C 
cells discovered later by Hokefelt (1974) are adrenaline synthesizing neurons (Hokfelt et 
al. 1974).  In the 1980s, Jaeger and colleagues identified a fourth class of neurons that 
contain AADC, but do not produce 5-HT, and lack tyrosine hydroxylase (cannot 
synthesize DA, NA, or adrenaline) (Jaeger et al. 1984a; Jaeger et al. 1983).  Following 
the nomenclature, these cells were classified as D cells.  They exist as at least 14 different 
cell clusters within various regions of the CNS (Jaeger et al. 1984a). 
The first cluster of D cells, which are also the largest, are found in the spinal cord 
distributed along the central canal, primarily in lamina X (Jaeger et al. 1984a; Jaeger et 
al. 1983). These spinal cord containing AADC positive cells, called D1 cells, were 
identified by ultrastructural identification of synapses and secretory vesicles.  D1 cells 
project at least one of their processes into the lumen of the central canal, which makes 
them part of a group of cerebrospinal fluid (CSF)-contacting neurons (Jaeger et al. 1983; 
Vigh et al. 2004).  Spinal CSF-contacting nerve cells situated around the central canal are 
found from cyclostomes to mammals including monkeys (LaMotte 1988; Vigh et al. 
2004).  No neurotransmitter was identified for these neurons, and nothing is known about 
the function of spinal cord D1 cells.  It remains a possibility that the D cells could 
produce the TAs (Jaeger et al. 1983).  In fact, they are “ideally suited to the selective 
synthesis of TAs” (Berry 2004).   
The other D cells neuron groups are found in nuclei in the hypothalamus, forebrain, 
midbrain, pons, and medulla.  Interestingly, the most occur in the hypothalamus which is 
associated with the autonomic nervous system (Jaeger et al. 1984a).  D neurons have 
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been demonstrated immunohistochemically in the brain of laboratory shrews (Karasawa 
et al. 1994), mice (Nagatsu et al. 1988), rats (Jaeger et al. 1984b; Jaeger et al. 1983; 
Nagatsu et al. 1988), and cats (Kitahama et al. 1988; Kitahama et al. 2007; Kitahama et 
al. 1990), and humans (Kitahama et al. 2009). 
One intriguing hypothesis is that D1 cells function to monitor CSF-related events and 
relay the information into modulatory commands for the motor system. Urotensin II has 
been described as one of the most potent vasoconstrictor substances known to date 
(Watson and May 2004).  Interestingly, in fish, urotensin II-immunoreactive CSF-
contacting neurons were also demonstrated (Yulis and Lederis 1988a; b) with urotensin-
immunoreactive fibers forming an ascending pathway via the ventrolateral funiculus and 
possibly also innervating motoneurons (Yulis and Lederis 1988a).  Spinal motoneurons, 
in turn, have been reported to have the most intense urotensin II gene expression of all 
CNS neurons from frog to man (Coulouarn et al. 1998).  Interestingly since all members 
of the TA family in human are expressed in kidney, and D1 cells may be part of a trace 
aminergic neuromodulatory system, a role in blood pressure regulation and electrolyte 
homeostasis is implicated (Borowsky et al. 2001). 
It was recently reported that a loss of D-cells occurs in schizophrenic patients 
(Ikemoto et al. 2003). 
1.2.2.2 Degradation of the trace amines 
TAs are degraded via both MAOA and MAOB, except for PEA, which is 
preferentially degraded by MAOB (Philips and Boulton 1979; Yang and Neff 1973). 
1.2.2.3 Concentrations and distribution of trace amines  
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There have been a number of techniques used to determine the amount of the 
different trace amines in the brain, cerebral spinal fluid, and plasma.  Some of the 
techniques include measuring radioenzymatic assays with chromatographic separation 
(Danielson et al. 1977; Henry et al. 1988; Saavedra 1974), mass spectrometry with thin-
layer chromatography, or gas chromatography (Durden and Davis 1993; Durden et al. 
1974; Durden et al. 1973; Karoum et al. 1979; Philips et al. 1974a; b; Warsh et al. 1977; 
Wilner et al. 1974), and high-performance liquid chromatography (D'Andrea et al. 2003; 
D'Andrea et al. 2004; Yonekura et al. 1988).   
The concentrations of TAs have been looked at in human, rat, rabbit, fowl, octopus, 
locust, and starfish.  While the exact quantity of the TAs reported varies, they all agree 
that the TAs are heterogenously distribution in the brain.  The TAs concentrations in 
neuronal tissue probably are in the range of 0.1-13 ng/g (Boulton and Juorio 1982; 
Durden and Davis 1993; Durden et al. 1973; Philips et al. 1974a; b).  Adding MAO 
inhibitors increases the concentration by roughly 10-300% (Boulton 1976).   
The highest concentrations of PEA were found in the caudate nucleus, olfactory 
tubercles, and hypothalamus.  Smaller amounts were found in brainstem, cerebellum, and 
spinal cord (Juorio 1988).  There are mixed reports on whether the concentration of PEA 
is higher in the spinal cord or brain (Boulton et al. 1977; Karoum et al. 1979).  
The highest concentration of tyramine was found in the caudate nucleus, followed by 
hypothalamus and olfactory tubercles, and then finally followed by hippocampus, 
brainstem, cerebellum and the “rest” of the brain (Juorio 1979; 1977a; b; 1980).  
Tyramine was found in the spinal cord at higher concentrations that other brain regions 
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(Spector et al. 1963).  Immunolabeling has confirmed a heterogeneous distribution of 
tyramine in the brain (Kitahama et al. 2005).  
1.2.3 Transporters 
1.2.3.1 Plasma membrane transporters 
Plasma membrane transporters transfer substrates across the plasma membrane in or 
out of cells.  There are a number of them discussed below that are capable of transporting 
the monoamines and/or the trace amines across the plasma membranes (Figure 1.2). 
1.2.3.1.1 Monoamine transporters 
Monoamine transporters control the extracellular concentrations of monoamines and 
maintain presynaptic function.  They are localized to the presynaptic plasma membrane 
away from the synaptic cleft in the perisynaptic area and sometimes along axons and 
dendrites (Daws 2009), suggesting that the transmitters diffuse out of the synaptic cleft to 
be transported back into the terminal.  The different monoamine transporters are 
dopamine transporters (DAT), 5-HT transporters (SERT), and NA transporters (NET).  
Monoamine transporters are expressed in neurons that contain their neurotransmitter 
(Torres et al. 2003).  DAT, NET, and SERT are Na+, Cl--dependent transporters.  
Monoamine uptake involves sequential binding and co-transport of Na+ and Cl- ions due 
to an ion gradient (Torres et al. 2003).  It has been shown that DAT and NET can 
transport both DA and NA (Giros et al. 1994).   
Monoamine transporters are thought to be involved in psychiatric and neurological 
disorders.  The monoamine transporters are important sites for therapeutic agents.  Many 
drugs have been developed to target the monoamine transporters.  There are specific 
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drugs for each of them.  For example, selective serotonin reuptake inhibitors (SSRIs) 
target SERT and are used to treat depression.  Interestingly, the more specific transport 
inhibitors are actually less clinically efficacious than those that block multiple 
transporters (Daws 2009).  Monoamine transporters are also high affinity molecular 
targets for drugs of abuse like amphetamines, cocaine, and 3,4-methylenedioxy-
metamphetamine “Ecstasy” (Jayanthi and Ramamoorthy 2005; Torres et al. 2003). 
Xie et al. (2007) looked at the effects of co-expression of TAAR1 and the monoamine 
transporters in HEK (Human Embryonic Kidney) cells, a cell line commonly used in 
tissue culture to express and characterize proteins, including receptors (Thomas and 
Smart 2005).  Monoamine transporters greatly facilitate transport of the TAs across the 
membrane (Xie et al. 2007).  Further, when TAAR1 was co-expressed with monoamine 
transporters in HEK cells, PEA activation of TAAR1 inhibited uptake of the monoamines 
and increased the efflux of the monoamines, but this did not occur when only the 
monoamine transporters were expressed, suggesting an important modulatory role of 
TAAR1 in monoamine transporter function.  Additionally, transport inhibitors blocked 
monoamine efflux in the co-expressed cells (Xie and Miller 2008).   
Sotnikova et al. (2004) looked at the effects of PEA in wildtype, heterozygous, and 
DAT knockout mice (Sotnikova et al. 2004).  PEA produced pronounced striatal DA 
release in wildtype mice without any detected in DAT knockout mice.  Behaviorally, 
PEA produced a strong transient increase in locomotion in wildtype and heterozygous 
mice.  However, in DAT knockout mice, whose phenotypes already features increases 
locomotor activity and stereotypy, PEA acted as a potent depressant. These data 




Figure 1.3: Transportation of the trace amines across the plasma membrane and their possible 
intracellular pathways  
The TAs may be transported across the cell membrane via the Na+-dependent monoamine transporters, 
SERT, NET, and DAT, and by the Na+-independent transporters, L-amino acid transporters (LATs), 
organic cation transporters (OCTs), and the plasma membrane amine transporter (PMAT).  Aromatic amino 
acids are transported across the plasma membrane via LATs, and are synthesized into TAs by AADC inside 
the cell.  Additionally, the TAs could be having actions on the trace amine-associated receptors (TAARs), 
which are presumed to be located intracellularly.  The transport of the TA, octopamine, has not been 
examined. 
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1.2.3.1.2  Organic cation transporters 
Organic cation transporters (OCT) were first clone by Grundemann et al. (1994) and 
belong to a family of solute carrier (SLC) transporters, SLC22A (Grundemann et al. 
1994; Jonker and Schinkel 2004).  They are Na+ and Cl- independent transporters (Daws 
2009).  The family contains three subtypes OCT1, OCT1, and OCT3).  OCT3 is the most 
densely expressed in the brain, followed by OCT1.  OCT2 expression in the brain is low 
(Gorboulev et al. 1997; Grundemann et al. 1997).  All three are found to be present in the 
spinal cord (Allen_Spinal_Cord_Atlas 2009).  OCT3 is also known as extraneuronal 
monoamine transporter (Jonker and Schinkel 2004).   
Tyramine is the best physiological substrate for OCT1 and OCT2 and the second best 
for OCT3.  Histamine is the best physiological substrate in rat while it is NA in humans.  
While DA, NA, and 5-HT can be transported by OCT1 and OCT2 clearance is too low 
for them to be the primary molecule transported.  The same is true for DA and 5-HT 
transport by OCT3 (Breidert et al. 1998; Grundemann et al. 1998; Schomig et al. 2006).   
1.2.3.1.3 L-type amino acid transporters 
System L amino acid transporters are plasma membrane amino acid transport system 
involved in the Na+-independent transport of large neutral amino acids (Bodoy et al. 
2005; Christensen 1990).  It is essential in the penetration of amino acids through the 
blood-brain barrier (Christensen 1990).  Four proteins have been identified: L-type amino 
acid transporter 1-4 (LAT1-4).  LAT1 and LAT2 belong to the SLC7 family and are 
obligatory exchange, which means that they move their substrates in exchange for other 
substrates.  LAT3 and LAT4 belong to the SLC43 family and are facilitative diffusion 
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transporters, which mean that they move one substrate down its concentration gradient 
(Bodoy et al. 2005).   
LAT1 prefers large neutral amino acids with branched or aromatic side chains such as 
phenylalanine, tryptophan, leucine, isoleucine, methionine, histidine, tyrosine, and valine 
(Kanai et al. 1998). LAT2 exhibits broad substrate selectivity.  It transports all L-isomers 
of neutral α-amino acids.  Among those with the largest affinity are tyrosine, 
phenylalanine, and tryptophan (Segawa et al. 1999). Dopamine and tyramine did not 
inhibit LAT1 or LAT2-mediated transport (Morimoto et al. 2008; Uchino et al. 2002). 
LAT3 preferentially transports neutral amino acids, such as leucine, phenylalanine, 
isoleucine, and valine.    LAT3 also weakly transports tyrosine and PEA, but not tyramine 
(Babu et al. 2003).  LAT4 preferentially takes up neutral amino acids, phenylalanine, 
leucine, isoleucine, and methionine (Bodoy et al. 2005). LAT2-4 are found to be present 
in the spinal cord (Allen_Spinal_Cord_Atlas 2009).   
1.2.3.1.4 Plasma membrane monoamine transporter 
Plasma membrane monoamine transporter (PMAT) was first cloned and characterized 
by the Wang group. It is a Na+-independent and membrane potential-sensitive transporter 
and is not homologous with SERT, DAT, and NET.  PMAT is a part of the SLC29 family 
(Engel and Wang 2005; Engel et al. 2004).  PMAT transports biogenic amines and the 
neurotoxin MPP+. Transport affinity varies with the affinity order of tryptamine > 
serotonin > dopamine > tyramine with NA and adrenaline having very low (millimolar) 
affinity binding to PMAT (Engel and Wang 2005). Tyramine was capable of cis and 
trans transport and is likely to be a true PMAT substrate. While tracer flux studies show 
PMAT to be a powerful substrate for tryptamine transport, it is trans-inhibitory, so 
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whether tryptamine is a true PMAT substrate remains uncertain (Engel and Wang 2005). 
PMAT has similar properties to the OCTs including bidirectional transport and prototype 
OCT inhibitors, including cimetidine, and type II cations are also PMAT inhibitors 
suggesting that PMAT functions as a polyspecific organic cation transporter.  PMAT is 
neuronally-expressed in widespread brain regions, is not found in astrocytes (Dahlin et al. 
2007), and is widely expressed in spinal cord neurons (Allen_Spinal_Cord_Atlas 2009; 
Engel et al. 2004).   
1.2.4 Storage and release of the trace amines 
The TAs are detectable in synaptosomes (Baldessarini and Vogt 1972; Boulton and 
Baker 1975), which means that they are present in nerve terminals.  PEA and tryptamine 
are unlikely to be stored or released from vesicles.  The evidence for tyramine is more 
contradictory.  Ultimately, it appears that while tyramine can be found in vesicles, it is 
unlikely to be released normally or via K+-induced depolarization (Berry 2004; Burchett 
and Hicks 2006).   
However, octopamine is likely stored in vesicles.  Once tyramine is transported into a 
vesicle it is likely converted to octopamine by vesicular DBH.  Octopamine can be 
released via K+-induced depolarization and is found in noradrenergic terminals (Burchett 
and Hicks 2006). 
1.2.5 Trace Amine actions in the spinal cord 
Intravenous PEA enhanced the monosynaptic reflex in rats (Ono et al. 1991). In earlier 
work in the neonatal rat cord, tyramine directly depolarized motoneurons with an EC50 
value comparable to DA (~50 µM) and depressed monosynaptic reflexes (Kitazawa et al. 
1985).  Tyramine has also been reported to have had antinociceptive actions (Reddy et al. 
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1980) and depress flexion and crossed-extension reflexes (Bowman et al. 1964).  Much 
less is known about octopamine in mammalian systems. In spinal dorsal horn neurons, 
octopamine facilitated spiking activity in many neurons that were depressed by NA 
(Hicks and McLennan 1978).  
1.2.6 Disorders in which the trace amines may be involved 
Like the classic monoamines, TAs are thought to play a role in human disorders such 
as depression, schizophrenia, Phenylketonuria, attention deficit disorder, Parkinson’s 
disease, migraines, addiction, and hypertension (Branchek and Blackburn 2003). 
1.2.6.1 Phenylketonuria 
Phenylketonuria (PKU) is an autosomal recessive deficiency of hepatic phenylalanine 
hydroxylase, which converts phenylalanine to tyrosine causing an accumulation of 
phenylalanine (Pietz 1998).  This accumulation of phenylalanine causes elevated levels of 
PEA in the urine and plasma, since phenylalanine is converted to PEA by AADC.  When 
left untreated, PKU is characterized by epilepsy, microcephaly, and mental retardation.  
Patients treated early by a phenylalanine-restricted diet are overall developmentally 
normal; but have motor-related neurological symptoms that include brisk deep tendon 
reflexes at lower limbs, tremor, clumsiness, and poor motor coordination (Pietz 1998).   
PEA has similar pharmacological effects, namely hyperactivity, irritability and 
excitability, to symptoms seen in PKU patients (Ghozlan et al. 2004).  Mice given 
phenylalanine supplements show increased motility (Thurmond et al. 1977), while 
rodents injected with PEA exhibit behaviors resembling those of amphetamines including 
locomotor activity and stereotypy (Boulton 1982; Jackson 1975a; 1972; 1974; 1975b; 
Paterson et al. 1990). 
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1.3 The trace amine-associated receptors 
1.3.1 Discovery of the trace amine receptors 
How the TAs were looked at needed revision when Borowsky et al. (2001) and 
Bunzow et al. (2001) independently identified a family of mammalian G protein-coupled 
receptors (GPCR) that displayed a high degree of homology to the classical monoamine 
receptors.  Importantly, two of the TA receptors, now referred to as trace amine-
associated receptors (TAARs) (Lindemann and Hoener 2005), were preferentially 
activated by TAs.  TAAR1 has high affinity for PEA and tyramine (Borowsky et al. 
2001; Bunzow et al. 2001), while TAAR4 has an affinity for PEA and tryptamine 
(Borowsky et al. 2001).  This identification gives credence to earlier binding studies on 
the presence of high-affinity sites for tyramine, tryptamine, and PEA (Hauger et al. 1982; 
Kellar and Cascio 1982; Nguyen and Juorio 1989; Vaccari 1986; van Nguyen et al. 1989) 
and establishes a mechanism by which TAs can produce effects of their own, rather than 
the conventional view of interfering with the actions of classical neuromodulators.  Also, 
it introduces the possibility of another major, currently uncharacterized, CNS aminergic 
transmitter system.  
Borowsky et al. (2001) originally identified 15 distinct receptors from human and 
rodent tissue.  Lindermann et al. (2005) set out to identify all TAAR receptors in human, 
chimpanzee, rat, and mouse.  Their genome sequence screening identified 53 TAAR 
genes in the 4 species.  They found   9 human (including 3 pseudogenes), 9 chimpanzee 
(including 6 pseudogenes), 19 in rat (including 2 pseudogenes), and 16 in mouse 
(including 1 pseudogene).  The TAAR genes maps to a narrow region of a single 
chromosome in each of the species (Lindemann et al. 2005).  In humans, this region is 
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associated with schizophrenia (Borowsky et al. 2001; Bunzow et al. 2001; Lindemann et 
al. 2005).  Phylogenetic analysis indicated that the TAAR genes are a distinct family of 
receptors, not an extension of closely related GPCR receptors like the 5-HT receptors.  
Additionally, it indicated that the TAAR genes originated from a common ancestor 
(Lindemann et al. 2005), that they evolved after the invertebrate/vertebrate split 
(Borowsky et al. 2001), and that there were nine genes at the time of the primate/rodent 
split.  These nine gene groups can be divided into three subgroups (TAAR1-4, TAAR5, 
and TAAR6-9) (Lindemann et al. 2005).   
When using pharmacophore similarity analysis to examine the amino acids in the 
binding pocket for receptor-ligand interactions, the TAARs have a high level of ligand 
binding pocket similarity.  This further agrees that the TAARs are more similar to each 
other than to other GPCRs, and that they can be divided into the same receptor subgroups 
as in the phylogenetic analysis.  The pharmacophore analysis also predicts that the 
currently unidentified TAARs ligands must be small molecular weight compounds that 
are structurally similar to the TAs (Lindemann et al. 2005; Lindemann and Hoener 2005).  
1.3.2 Nomenclature of the trace amine-associated receptors 
Initially, there were many inconsistencies with how the TA receptors were named.  
Borowsky et al. (2001) used the abbreviation TA1 for the TA receptors they found, while 
Bunzwo et al. (2001) used TAR.  As more TA receptors were discovered, it became 
obvious that a uniform nomenclature was necessary.  Since the majority of the TA 
receptors have unidentified ligands, Lindeman et al. proposed naming the receptor family 
trace amine-associated receptors (TAARs).  The nomenclature is based on the order of 
the genes on the chromosome and the phylogentic relationships (Lindemann et al. 2005).  
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This nomenclature has been accepted by The Human Genome Organization (HUGO) 
Gene Nomenclature Committee (Maguire et al. 2009) and has been adopted in the 
literature.  It is the nomenclature used here. 
The International Committee on Standardized Genetic Nomenclature for Mice and 
Rat Genome and Nomenclature Committee further recommends the use of uppercase for 
human genes and lower case italics for rodent genes (Maguire et al. 2009).   
Interestingly, although it acknowledges the use of the nomenclature TAAR, the 
International Union of Pharmacology (IUPHAR) officially calls TAAR1 TA1, which 
abides by IUPHAR convention that no R be added to the abbreviated name for receptor 
proteins (Maguire et al. 2009).  
1.3.3 Properties of the trace amine-associated receptors 
1.3.3.1 Trace amine-associated receptor 1 
1.3.3.1.1 Pharmacological characterization of trace amine-associated receptor 1 
TAAR1 is most potently activated by tyramine and PEA, and displays a low affinity 
for tryptamine, octopamine, and DA in the rat and human (Borowsky et al. 2001; 
Bunzow et al. 2001).  Numerous psychostimulant and hallucinogenic amphetamines, 
which have a very similar structure to tyramine and PEA, are also potent activators of rat 
TAAR1 (Bunzow et al. 2001).  In the rhesus monkey, octopamine and methamphetamine 
where the most potent activators of TAAR1, but TAAR1 could also be activated by other 
TAs, monoamines, and amphetamines (Xie et al. 2007).  Acetylcholine, nicotine, GABA, 
glutamate, morphine, and histamines do not activate rat TAAR1.  However, none of the 
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antagonists for the biogenic amine receptors tested were able to antagonize rat TAAR1 
(Bunzow et al. 2001).   
1.3.3.1.2 Distribution and cellular location of trace amine-associated receptor 1 
TAAR1 is localized to many regions of the CNS including the ventral horn of the 
spinal cord, olfactory bulb, cerebral cortex, amygdale, sustantia nigra, dorsal raphe, the 
locus coeruleus, and the ventral tegmental area.  Many of which are major areas of 
monoaminergic cell groups (Borowsky et al. 2001; Bunzow et al. 2001; Lindemann et al. 
2008; Xie et al. 2007).  TAAR1 expression in the CNS is found in a variety of species 
including human (Borowsky et al. 2001), rhesus monkey (Xie et al. 2007), mouse 
(Borowsky et al. 2001), and rat (Bunzow et al. 2001).   
Confocal images of HEK cells indicated that TAAR1 was found in the cytoplasm 
rather than at the cell surface (Bunzow et al. 2001; Miller et al. 2005), and was likely 
localized to intracellular membranes (Xie et al. 2008).  Immunohistochemistry of 
different brain regions clearly shows TAAR1 cytoplasmic staining within the cell body 
and extending into the axon in rhesus monkey and mice (Xie et al. 2007).  Two 
possibilities mechanisms by which the TAs have actions on an intracellular receptor are: 
first, transport into cells via transporters, LATs, OCT, PMAT, and monoamine 
transporters (see section 1.2.3) and second, synthesized in the cells where they are having 
actions (Figure 1.2). 
TAAR1 expression was also found in stomach, kidney, lung, small intestines, liver, 
pancreas, prostate, skeletal muscle, spleen, and heart (Borowsky et al. 2001; Chiellini et 
al. 2007). 
1.3.3.1.3 Facilitation of trace amine-associated receptor 1 by monoamine transporters 
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Given the probable intracellular location of TAAR1, access to TAAR1 agonists could 
be compromised in HEK cells.  Since tyramine and PEA are taken up into cells by the 
DAT (Miller et al. 2005; Sitte et al. 1998), Miller et al. (2005) found that by co-
expressing rhesus monkey TAAR1 and human DAT, PEA and tyramine significantly 
changed cAMP production compared to TAAR1 alone (Miller et al. 2005).  There are 
neurons that express TAAR1, or DAT, or co-express TAAR1 and DAT in the substantia 
nigra of both rhesus monkey and mice (Xie et al. 2007).  Further, co-expression of 
TAAR1 with the any of the monoamine transporters (DAT, SERT, and NET) enhanced 
the activation of TAAR1 by TAs, monoamines, and methamphetamine.  Blocking with 
monoamine transport inhibitors reduced the effect on TAAR1 activation (Xie et al. 2007).   
Further, when TAAR1 was co-expressed with monoamine transporters in HEK cells, 
PEA activation of TAAR1 inhibited uptake of the monoamines and increased the efflux 
of the monoamines, but this did not occur when only the monoamine transporters were 
expressed, suggesting an important modulatory role of TAAR1 in monoamine transporter 
function.  Additionally, transport inhibitors blocked monoamine efflux in the co-
expressed cells (Xie and Miller 2008).   Control experiments show that D1 receptors do 
not have the same effect as TAAR1 (Xie et al. 2007).  D2 autoreceptors have opposite 
effects as TAARs possibly providing a presynaptic balance in the control of transporter 
function (Xie and Miller 2009; Xie et al. 2007). 
1.3.3.1.4 Trace amine-associated receptor 1 knockout mice   
Wolinsky et al (2006) provided the first conclusive evidence for a role of TAAR1 in 
CNS function by demonstrating behavioral changes in TAAR1 knockout mice.  Here, the 
TAAR1 receptor agonist amphetamine, in the absence of its action on TAAR1, showed 
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an enhanced psychomotor-stimulating effect, temporally correlated with larger increases 
in striatal DA and NA release, and 2.6 fold increase in the proportion of striatal high-
affinity D2 receptors.  TAAR1 therefore appears to play a depressant modulatory role in 
catecholaminergic function (Wolinsky et al. 2007).  Lindemann et al (2008) also studied 
TAAR1 knockout mice and corroborated several of the above findings.  They also found 
that these mice display enhanced amphetamine-triggered increases in locomotor activity 
and an elevated spontaneous firing rate of dopaminergic neurons in the ventral tegmental 
area.  Tyramine specifically decreased the spike frequency of these neurons in wild-type 
but not in TAAR1 knockout mice (Lindemann et al. 2008).  Xie and Miller (2008) also 
examined TAAR1 knockout mice.  PEA significantly inhibited uptake and induced efflux 
of DA, NA, and 5-HT in transfected cells and brain synaptosome of rhesus monkeys and 
wild-type mice, but not in synaptosomes of TAAR1 knockout mice.  The PEA effect was 
blocked by transporter inhibitors demonstrating that TAAR1 signaling is required for 
PEA to alter monoamine transporter function.  They also showed these effects to be 
independent of monoamine autoreceptors (Xie and Miller 2008).  
1.3.3.2 Trace amine-associated receptor 4 
TAAR4, which was previously called TA2 (Lindemann and Hoener 2005) is activated 
by  PEA and tryptamine.  TAAR4 has “poor surface expression” and “subcellular 
localization” (Borowsky et al. 2001), which suggests that it too may be localized 
intracellularly. 
1.4 Spinal cord anatomy 
The spinal cord is an integral part of the central nervous system.  It is involved in the 
transfer of information from the brain to the rest of the body, as well as integration and 
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coordination of sensory, motor, and autonomic functions.  The spinal cord is protected by 
the vertebral column and surrounded by the meninges.  The meninges are three 
membranes that cover the spinal cord.  The outer layer is the dura mater, the middle layer 
is the arachnoid mater, and the innermost layer is the pia mater.  CSF is a clear fluid in 
the subarachnoid space and the ventricular system (central canal in the spinal cord) that 
also protects the spinal cord and maintains the electrolytic environment. 
The spinal cord is segmentally organized into cervical, thoracic, lumbar, and sacral 
segments. Spinal circuits controlling hindlimb function dominate in caudal thoracic and 
lumbar segments levels.  In humans, there are eight cervical, twelve thoracic, five lumbar, 
and five sacral segments.  In the rat, there are eight cervical, thirteen thoracic, six lumbar, 
and four sacral segments.  The spinal cord is divided into white and gray matter.  The 
white matter is located on the outside of the gray matter and consists of myelinated axons 
tracts that relay information to and from the brain and between spinal segments.  The 
gray matter, which is in the center of the cord and is shaped like a butterfly, consists of 
neuronal cell bodies and can be separated into dorsal and ventral horns.  The gray matter 
can be divided by cytological characteristics of the nerve cells and their cytoarchitectonic 
aggregation into ten anatomical layers called laminae or Rexed’s laminae (I-X) (Rexed 
1954; 1952).   
Sensory neurons enter the spinal cord via the dorsal roots and synapse onto spinal 
neurons largely within the dorsal horn, while the ventral horn contains neural elements 
associated with motor output.  These neurons orchestrate coordinated motor activity by 
projecting to motoneurons in lamina IX whose axons exit via ventral roots to innervate 
skeletal muscle at the neuromuscular junction (Hochman 2007).  Each muscles in 
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innervated by a pool of motoneurons that form longitudinal columns that may extend up 
to three spinal segments in the rat (Nicolopoulos-Stournaras and Iles 1983).  Among the 
largest neurons in the CNS, motoneurons receive large amounts of synaptic input through 
their extensive dendritic arbors which they are able to integrate.  Motoneurons are 
considered the “final common pathway” for motor processing as they are the final step in 
integrating all of the spinal cord systems, and their output creates the appropriate muscle 
contraction for the intended behavior (Brownstone 2006; Hochman 2007).   
1.5 Locomotion studies 
1.5.1 Central pattern generator 
The entire neural networks required for generating coordinated locomotor activity 
resides in the spinal cord (Grillner 1981; Kiehn and Butt 2003) and has been found in 
almost all vertebrate species studied (Hultborn and Nielsen 2007). These neuronal 
networks have been called the central pattern generators (CPGs) and consist of sets of 
interneurons that organized themselves into networks that control motor output through 
motoneurons.  Currently, the exact structure and location of the CPGs in mammals 
remains unknown, but many models exist trying to explain how the CPGs might work.  
These CPGs are present at birth (Cazalets et al. 1992; Kiehn 2006; Kudo and Yamada 
1987; Smith and Feldman 1987), and are not fully mature until a few weeks postnatal 
(Westerga and Gramsbergen 1990).   
Locomotion is defined as the act of moving from one place to another, in order to 
accomplish this goal, different vertebrate species use different strategies.  For example, 
lamprey and hagfish are today’s representatives of early vertebrates.  They employ a left-
right alternation of each segment, leading to a wave of motor activity along the body.  
 32
This strategy is also used by most fish and amphibian larva.  Fish that have fins, which 
are the precursors to limbs, use them to steer.  More complicated vertebrates with limbs, 
such as cats and rodents, must coordinate the limbs and the trunk to achieve smooth 
muscle movements and postural control.  It is thought that separate CPGs are present to 
help generate specific motor patterns whether it is simple walking or more complicated 
gait patterns such as trotting and galloping.  At its most basic level on a single limb, the 
CPG can be thought of as alternation between flexors and extensors  (Grillner and Jessell 
2009).   
1.5.1.1 Models of the central pattern generator 
1.5.1.1.1 Half-Center Model 
Graham Brown showed that rhythmic alternation of flexor and extensor muscles in 
the cat hindlimb is a central mechanism during experiments on decerebrate cats who were 
acutely spinalized and deafferented.  In order to explain the alternation between flexor 
and extensor activation in the limb, Brown proposed a simple neuronal organization, the 
“half-center” model.  Basically, two half-centers, one for flexors and one for extensors, 
receive reciprocal inhibition, so that only one of the two half centers would be active at a 
time.  The switch from one to the other would happen due to fatigue, leading to an 
alternation of flexor and extensor muscles. Before Brown and until Lundberg resurrected 
the idea of the half-center in the 1960s, the prevailing idea was that locomotor 
movements were due to a series of reflexes (Hultborn and Nielsen 2007; Stuart and 
Hultborn 2008).  Today, the idea of the half-center is still part of most models of the 
CPG.   
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1.5.1.1.2 Unit Burst Generator 
One limitation of the “half-center” model is that it assumes strict alternation of flexor 
and extensor activity.  However, it has been determined that activation of flexor and 
extensor muscles is more complex.  Instead, there are differences in the onset and offset 
of different muscles, which are activated at the appropriate time (McCrea and Rybak 
2008).  The unit burst generators model of the CPG assumes that there are multiple unit 
burst generators (or CPGs) that control the synergistic muscles at one joint (i.e.- knee 
flexors or ankle extensors).  Each unit burst generator is capable of bursting alone.  
Interconnections between the unit burst generators decide the relative phasing between 
different muscle groups and the timing during locomotion (Grillner 1981). 
1.5.1.1.3 Other CPG Models 
In order to account for more complex locomotor activity, models are becoming 
increasingly more complex.  They include more interneurons and more connections 
within the circuitry to account for experimental findings.  For example, some muscles, 
like semitendinosus, can generate two bursts per cycle; extra interneurons that provide a 
connection from both “half-centers” to both the extensor and flexor motoneurons 
populations can be added to the “half-center” model to correct for this (McCrea and 
Rybak 2008; Perret and Cabelguen 1980; Perret et al. 1988).  The “half-center” model 
also does not incorporate sensory feedback, and so extra interneurons, like Ia 
interneurons, can provide motoneurons with sensory input (McCrea and Rybak 2008; 
Orlovskiĭ et al. 1999).   
A number of models have proposed more than one level of organization to account 
for independent changes that cannot be explained single-level models (Burke et al. 2001; 
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Koshland and Smith 1989; Kriellaars et al. 1994; Perret and Cabelguen 1980; Perret et al. 
1988; Rybak et al. 2006a; Rybak et al. 2006b).  In particular, there appear to be 
independent changes in motoneurons recruitment and rhythm generation which can be 
separately affected by sensory input (Burke et al. 2001; Kriellaars et al. 1994). 
Studies of deletions, which are spontaneous reductions or absences of one or more 
expected rhythmic bursts of activity, provided clues into CPG organization (Lafreniere-
Roula and McCrea 2005).  Deletions have been observed during fictive locomotion, 
treadmill locomotion, and scratch in cats (Duysens 1977; Lafreniere-Roula and McCrea 
2005), as well as in the turtle scratch reflex (Stein 2005; Stein and Grossman 1980).  
Deletions are considered errors or failures in the rhythmic activity (Rybak et al. 2006a).  
There are different types of deletions including resetting and non-resetting deletions or 
complete deletions and partial deletions.  In a non-resetting deletion, despite the absence 
of a burst, the next burst reemerges at an integer number of the missing locomotor period 
at the time that would have been expected had the deletion not occurred, suggesting that 
the CPG “remembers” and maintains the pattern even when the motoneurons are silent.  
This pattern is not consistent with a simple “half-center” model (Lafreniere-Roula and 
McCrea 2005).   
Rybak et al. (2006a) proposed a model that combines features of both the half-center 
and the unit burst generator organizations into a two-level locomotor CPG model.  The 
model has a two-level architecture, where the first level is a half-center rhythm generator, 
which acts as the “clock.”  The second level is an intermediate pattern formation network 
that coordinates the activation of the motoneuron populations to which it projects.  This 
allows separate control of the two levels.  Therefore, sensory signals or perturbations can 
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affect one of the two levels without affecting the other.  This model was designed to have 
a great amount of flexibility and to be able to explain more complicated motoneuron 
activities, including double bursts and deletions.  For example, non-resetting deletions 
could occur due to changes in excitability to the pattern formation level and not the 
rhythm generator level.  It should be noted that while the model is quite extensive, it 
currently only models one limb (Rybak et al. 2006a). 
1.5.2 The neonatal rodent preparation  
The in vitro isolated spinal cord preparation in the neonatal rat was first developed by 
Otsuka and Konishi (1974) to allow for the precise control over the extracellular medium.  
They recorded from ventral roots using silver electrodes or glass suction electrodes, 
which they found to be stable.  They stimulated dorsal roots and were able to record 
monosynaptic and polysynaptic reflexes (Otsuka and Konishi 1974).  The preparation 
was used to study respiration (Smith and Feldman 1987; Suzue 1984).  Then by keeping 
the hindlimbs attached or using suction electrodes on ventral roots, it was demonstrated 
that locomotor patterning could be produced by chemical activation or stimulation of 
sensory pathways (Smith and Feldman 1987).   
The isolated intact neonatal rodent spinal cord can produce a coordinated hindlimb 
motor output that spatiotemporally resembles locomotion in the intact hindlimb (Atsuta et 
al. 1988; Cazalets et al. 1990; Kiehn and Kjaerulff 1996). This activity is referred to as 
locomotor-like activity (LLA), and the motor output recorded from lumbar roots L2 and 
L5 ventral roots largely corresponds to activity in flexors and extensors respectively 
(Kiehn and Kjaerulff 1998).  The muscles patterns in the neonatal rodent are similar to 
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locomotor patterns in the adult (Cowley and Schmidt 1995; Hayes et al. 2009; Juvin et al. 
2007; Kiehn and Kjaerulff 1996). 
1.5.3 Locomotor studies in the neonatal rodent 
1.5.3.1 Pharmacological activation 
Various neurochemicals have been used to initiate or induce rhythmic activity in the 
neonatal rodent spinal cord, including 5-HT (Cazalets et al. 1990; Cazalets et al. 1992; 
Kiehn and Kjaerulff 1996), NA (Kiehn et al. 1999; Sqalli-Houssaini and Cazalets 2000), 
DA (Kiehn and Kjaerulff 1996), γ-aminobutyric acid N-methyl-D-aspartate (NMDA) 
(Cazalets et al. 1990; Kudo and Yamada 1987), glutamate (Cazalets et al. 1992),  
acetylcholine (Cowley and Schmidt 1994a), Potassium (Bracci et al. 1998), and arginine 
vasopressin (Pearson et al. 2003). 
There are differences in the rhythmic patterns produced by the different 
neurochemical applications.  For example, DA induces rhythmic activity that is slower 
than 5-HT as well as differences in phase (Kiehn and Kjaerulff 1996), and NA produces a 
slow alternating pattern with clear right-left alternation, but not between flexors and 
extensors (Sqalli-Houssaini and Cazalets 2000). 
NMDA and 5-HT have been used widely both alone and in combination.  In 
combination, they are a very reliable method for inducing long lasting LLA (Kiehn et al. 
1999; Kjaerulff and Kiehn 1996; Sqalli-Houssaini et al. 1993).  
1.5.3.2 Electrical activation  
It has been shown that electrical stimulation techniques can activate the hindlimb 
locomotor CPG in the neonatal rodent spinal cord (Bonnot et al. 1998; Gabbay et al. 
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2002; Gordon and Whelan 2006; Lev-Tov et al. 2000; Lev-Tov and Pinco 1992; 
Marchetti et al. 2001).  Different areas can induce LLA, include the brainstem (Atsuta et 
al. 1990; 1988; Zaporozhets et al. 2004), the ventrolateral funiculus (Magnuson and 
Trinder 1997), dorsal roots (Marchetti et al. 2001; Whelan et al. 2000), sacrocaudal 
afferents (Lev-Tov et al. 2000; Strauss and Lev-Tov 2003), and cauda equina (Gordon 
and Whelan 2006; Whelan et al. 2000) . 
1.5.3.3 Lesioning studies  
Lesion and activity studies have mapped the core neuronal elements of the locomotor 
CPG to the ventral half of the spinal cord (Kjaerulff and Kiehn, 1996; Cowley and 
Schmidt, 1997) 
The ability to generate locomotor-like rhythms in the spinal cord is distributed 
through the lumbar enlargement; however, the more rostral segments (L1-L2 in rodents) 
have a greater ability to generate rhythmic outputs in isolation than caudal segments 
(Cazalets et al. 1996). 
1.5.3.4 The use of molecular genetics to understand CPGs 
Molecularly identification and genetic manipulation of different classes of neurons in 
the ventral half of the neural tube during development is starting to give insight into the 
roles of these neurons during locomotion.  Distinct dorsoventral gradients produced by 
expression of transcription factors trigger differentiation in the developing cord.  In the 
ventral cord, motoneurons and four ventral (V) interneuron populations (V0-V3) are 
derived (Goulding 2009; Jessell 2000).  All five classes appear to influence the CPG.  
Efforts are being made to correlate the embryonic cell type with previously identified 
adult cell types (Goulding 2009). 
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V0 interneurons are locally projecting intersegmental commissural interneurons 
(Moran-Rivard et al. 2001) that project to contralateral motoneurons and are responsible 
for left-right alternation during locomotion (Lanuza et al. 2004).  There are both 
excitatory and inhibitory subtypes (Goulding 2009). 
V1 inhibitory interneurons are a heterogeneous population of inhibitory interneurons 
that project ipilaterally to motoneurons.  They are located in region VII, which receives 
projections from muscle afferents.  Two known types of adult interneurons are derived 
from V1 intereneurons: Renshaw cells (9%) and Ia inhibitory interneurons (13%) 
(Alvarez et al. 2005).  V1 intereneurons affect the frequency of the locomotor CPG, 
specifically affecting the higher frequencies.  Three different genetic approaches were 
used to either inactivate or delete V1 interneurons, leading to an inability to burst or step 
at higher frequencies (Gosgnach et al. 2006).   
V2 interneurons are comprised of V2a excitatory and V2b inhibitory interneurons, 
both of which project ipsilaterally and to motoneurons (Al-Mosawie et al. 2007).  V2a 
interneurons play an important role in the controlling of left-right alternation.  After V2a 
neurons are ablated, there is an uncoupling of the left and right sides of the spinal cord 
and a loss of left–right alternation.  The V2a interneurons contact commissural 
interneurons, including V0 interneurons (Crone et al. 2008).  Not much is known about 
the function of V2b inhibitory interneurons (Goulding 2009). 
V3 interneurons are excitatory neurons that project primarily across the midline.  
Roughly 15% of the neurons project ipsilaterally, including some that have axonal 
processes to both sides of the spinal cord.  V3 interneurons contact motoneurons, Ia 
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inhibitory interneurons, Renshaw cells, and V2 intereneurons.  V3 help establish stable 
and balanced locomotor rhythm (Zhang et al. 2008). 
1.6 Neuromodulation 
Neurotransmission is accepted to be the primary means of communication between 
neurons and traditionally thought of as fast (milliseconds), point-to-point (neuron to 
neuron), and simple (either excitatory or inhibitory).  However, neural communication is 
not quite as simple as this.  Instead, there are many other ways that neurons can 
communicate that differ from classical neurotransmission.  One common way is through 
neuromodulation.  As a general guideline rather than a firm definition, neurotransmission 
is mediated by ionotropic receptors, which are ligand-gated ion channels responsible for 
the fast communication and neuromodulation is mediated by metabotropic receptors, 
which activate second-messenger systems (Katz 1999; Katz 1995).   
Neuromodulation is a substance that alters the cellular and synaptic properties of a 
neuron and alters the subsequent neurotransmission, so that even with the same input, the 
output will be different (Katz 1999; Katz 1995; Katz and Frost 1996).  Thus, it allows the 
circuit to become more flexible (Katz 1995). Three different types of neuromodulation 
are extrinsic neuromodulation, intrinsic neuromodulation, and biochemical integration. 
 Extrinsic neuromodulation is usually thought to originate from sources extrinsic to the 
circuit being affected and therefore not a part of the circuit itself (Katz 1995).  It is 
considered the ‘conventional’ form of neuromodulation typified by neuronal systems 
modulating the activity of other ‘hard-wired’ circuits (Katz 1995).  A classic example 
would be the monoaminergic nuclei, such as the raphe nuclei, substantia nigra, and locus 
coeruleus, which project fibers throughout the brain and spinal cord producing potent 
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modulation of spinal sensory, autonomic, and motor activity (Hochman et al. 2001; 
Millan 2002; Schmidt and Jordan 2000). 
 By contrast, with intrinsic neuromodulation, neuromodulatory substances can also be 
released by neurons that are intrinsic to a circuit, and can affect other neurons and 
synapses within the same circuit. One functional consequence of intrinsic 
neuromodulation is that it operates whenever the circuit is active because it is an integral 
part of the circuit and as such its actions are proportional to the amount of activity within 
the circuit itself (Katz and Frost 1996).  As stated by Katz and Frost (1996) “‘intrinsic 
neuromodulation is not as widely recognized as extrinsic neuromodulation, but we 
believe that it might be just as pervasive” (Katz and Frost 1996). 
Biochemical integration modulates the neuron in which it acts.  During biochemical 
integration, the biochemical intracellular signals (e.g. second messengers like cAMP) are 
integrated to affect the cellular and synaptic properties of the neuron, often across 
different time scales (Katz and Clemens 2001).  
1.7 The significance of an exquisitely regulated trace aminergic system 
The TAs have turnover rates similar to DA and NA (Durden and Philips 1980; 
Paterson et al. 1990) which is “a more significant index of their importance than their 
endogenous concentrations” (Saavedra 1989).  High turnover rates are demonstrated by 
blocking amine degradation with MAO inhibitors resulting in significant accumulation of 
TAs (Berry 2004).  In addition, it has been shown that AADC activity is physiologically-
modifiable and has dramatic influence over TA concentrations but not the classic 
monoamines levels (Berry 2004). Thus, endogenous levels of TA are much easier to 
control than the classical monoamines and represent a modulatory system whose 
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transmitter concentration can be altered several fold in a very short time (Berry 2004).  If 
the primary role for the TAs was via activation of the TAARs to modulate circuits 
activated by the classical monoamines, then control of the rate of synthesis by changing 
AADC activity could have profound modulatory actions on these circuits.  Simply 
changing the endogenous level of the TAs, could act as a switch to change the output, say 
as a “modulatory switch,” that could amplify/reinforce the circuitry. This mechanism 
could easily apply anywhere there was AADC expression.   
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CHAPTER 2  
GENERAL METHODS 
2.1 Electrophysiology 
2.1.1 The neonatal rat isolated spinal cord preparation 
The spinal cord contains all of the necessary circuitry at birth to produce complex 
motor outputs including locomotor patterning (Grillner 1981).  Over the last two decades, 
the in vitro isolated spinal cord preparation in the neonatal rodent has become the 
dominant animal model for studying the spinal mechanisms controlling the operation of 
the mammalian locomotor CPGs.  The in vitro isolated rodent spinal cord preparation can 
produce a coordinated hindlimb motor output that spatiotemporally resembles locomotion 
in the intact hindlimb (Atsuta et al. 1988; Cazalets et al. 1990; Kiehn and Kjaerulff 1996) 
as well as the adult (Cowley and Schmidt 1995; Hayes et al. 2009; Juvin et al. 2007; 
Kiehn and Kjaerulff 1996).   
Many different neurochemicals have been used to induce locomotor-like activity 
patterns.  Locomotor-like activity (LLA) can be characterized as left/right and ipsilateral 
alternation of bursts between flexors and extensors (Kiehn and Kjaerulff 1998; Sqalli-
Houssaini et al. 1993).  Locomotor-inducing neurochemicals include serotonin (5-HT), 
noradrenaline (NA), dopamine (DA), excitatory amino acids, acetylcholine, N-methyl-D-
aspartate (NMDA), glutamate, and acetylcholine (Barbeau and Rossignol 1991; Cazalets 
et al. 1990; Cazalets et al. 1992; Cowley and Schmidt 1994a; Kiehn and Kjaerulff 1996; 
Kiehn et al. 1999; Kudo and Yamada 1987; Sqalli-Houssaini and Cazalets 2000). 
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The isolated in vitro spinal cord preparation has become an important model due to its 
many advantages.  The extracellular medium can be controlled easily (Otsuka and 
Konishi 1974), and the spinal cord remains intact, which means that more of the spinal 
cord circuitry is intact than in a slice preparation (Suzue 1984).  With no blood brain 
barrier, it is possible to make all drugs accessible to the spinal cord, which means that 
instead of just studying the precursors like L-DOPA, drugs like dopamine could be tested 
on the spinal cord (Cazalets et al. 1992).  This easy access allows for manipulation of the 
system through pharmacology, stimulation, dissection of the spinal cord, and transgenics.  
Further, the surgery and electrode placement is relatively fast and easy.  Due to the small 
size of the neonatal spinal cord, passive diffusion of oxygen and the control medium 
maintain viability of the spinal cord to keep it alive for extended periods of time (Smith 
and Feldman 1987).  It also allows for intracellular recordings (Fulton and Walton 1986; 
Jahr and Yoshioka 1986).  Use of the in vitro neonatal rodent preparation has increased 
our understanding of the spinal motor system. 
In chapter 4, I used the isolated neonatal rat spinal cord maintained in vitro to study 
trace amine (TA) modulatory actions on the spinal cord and then compared them to the 
classical monoamine transmitters.  To do this, the spinal cord of postnatal (P) day 0-5 
neonatal Sprague-Dawley rats was isolated and motor activity was monitored using glass 
suction electrodes attached to ventral lumbar roots, typically bilaterally on L2 and L5 
(Figure 2.1).  Although the ventral roots contain both flexor and extensor motor axons, 
L2 ventral root activity primarily indicates activity in flexors, while L5 ventral root 
activity primarily indicates activity in extensors (Kiehn and Kjaerulff 1998).  Activity 





Figure 2.1: In vitro neonatal rat isolated spinal cord experimental setup  
A. All of the electrophysiological experiments conducted in Chapter 4 use the isolated neonatal rat spinal 
cord maintained in vitro.  For studies on locomotor-like motor rhythms, suction electrodes are placed on 
lumbar L2 and L5 ventral roots bilaterally to monitor population motoneuron flexor and extensor activity, 
respectively.  Drugs are applied to the bath.  B.  Recording of locomotor-like activity showing alternation 
between right and left L2 flexors, with each flexor rhythm alternating with the L5 extensor rhythm on the 
same side.  For most of the result subsequently displayed, raw electroneurograms are displayed below their 





Figure 2.2: In vitro neonatal rat isolated spinal cord with attached hindlimbs experimental setup   
A. All of the electrophysiological experiments conducted in Chapter 5 use the isolated neonatal rat spinal 
cord with attached hindlimbs maintained in vitro.  For studies on the output of muscle coordination, glass 
suction electrodes were placed on the left lumbar L2 ventral root and typically 7 muscles of the hindlimb.  
Drugs are applied to the bath.  B. Electromyographically recording of locomotor-like activity showing 
coordination of the muscles. 
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monoamines [5-HT, dopamine, and noradrenaline] both alone and in the presence of 
NMDA.  Locomotor-like activity was analyzed using custom MATLAB software that I 
wrote, and is described below in Section 2.3. 
2.1.2 The neonatal isolated spinal cord with attached hindlimbs  
While ventral root recordings offer a simple way to monitor the spinal motor output, 
they do not give the whole story.  Ventral root activity may not reflect recruitment of 
individual muscles (Cowley and Schmidt 1994b).  Anatomical studies have shown that 
ventral roots are actually quite heterogeneous, containing axons projecting to both flexors 
and extensors (Nicolopoulos-Stournaras and Iles 1983).  Important changes in motor 
coordination between flexor and extensor activity may be lost due to the heterogeneity of 
these roots.  It has been long known that muscle recruitment by spinal cord circuitry is 
more complicated than just simple flexor/extensor alternation.  These distinct complex 
patterns and sequential activation of muscles have more recently been demonstrated in 
the in vitro spinal cord (Grillner 1981; Kiehn and Kjaerulff 1996).  Distinct motor 
patterns of recruited muscles were observed when induced by different transmitters such 
as 5-HT and dopamine as well as pharmacological and electrical stimulation, suggesting 
that the spinal locomotor network is flexible and that extrinsic modulation can modify the 
network coordination (Kiehn and Kjaerulff 1996; Klein et al. 2010).   
In chapter 5, I used the in vitro isolated spinal cord of P day 0-5 neonatal Sprague-
Dawley rats with attached hindlimbs to record muscle activation electromyographically.  
I studied the patterns produced by the TAs and NMDA compared to 5-HT and NMDA, as 
well as the ability of the TAs to modulate ongoing 5-HT and NMDA LLA.  To do this, 
the spinal cord of neonatal Sprague-Dawley rats were isolated with the hindlimbs still 
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intact and with the dorsal roots cut.  Dorsal roots were severed to eliminate the sensory 
feedback and simplify the spinal cord output to reflect the changes in spinal cord circuitry 
due to the trace amines.  Modulatory actions of the TAs can be inferred to reflect the 
actions on motor circuits.   
Glass suction electrodes were then placed on the left lumbar L2 ventral root and up to 
7 muscles of the hindlimb (Figure 2.2).  Recordings were acquired from the following 
muscles: tibialis anterior (TibA; ankle flexor), medial gastrocnemius (MGas; ankle 
extensor), semitendinosus (SemT; knee flexor / hip extensor), semimembranosus (SemM; 
knee flexor / hip extensor), vastus medialis (VasM; knee extensor), rectus femoris (RecF; 
knee extensor / hip flexor), and adductor magnus (AddM; hip adductor).  Some of the 
muscles (e.g. TibA) were often recorded bilaterally. The left lumbar L2 ventral root was 
always recorded for two reasons: comparison of ventral root activity profile in relation to 
that obtained in the isolated spinal cord preparation reported above, and its reliable 
recruitment allowed a common comparison between experiments where muscle EMG 
recruitment was variable.  Rhythmic motor activity was evoked by two different 
pharmacological methods.  First, tryptamine, tyramine, octopamine, PEA, or 5-HT was 
co-applied with NMDA.  Second, 5-HT and NMDA were co-applied to get ongoing 
locomotor-like activity onto which tryptamine, tyramine, octopamine, and PEA were 
added.  Locomotor-like activity was analyzed using custom MATLAB software I wrote 
especially for this project, described below in Section 2.3. 
2.2 Terminology for bursting patterns 
In both chapter 4 and chapter 5, three main types of locomotor-like patterning were 
encountered.  First, there is locomotor-like bursting with a regular frequency.  Second, 
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the same locomotor-like pattern is produced, but significantly slower.  Third, there are 
multiple types of episodic bursting patterns produced; however, each is characterized by 
bouts of rhythmic bursting interrupted regularly by quiescent periods (Figure 2.3).  The 
figure below is intended to clarify the types of patterns and the terminology used to 
describe the bursting. 
2.3 SpinalMOD: A MATLAB Graphic User Interface for Burst Detection  
SpinalMOD (Spinal Motor Output Detector) is a MATLAB Graphical User Interface 
(GUI) I wrote for the analysis of locomotor-like activity.  It detects the onset and offset of 
the bursts being analyzed and calculates the bursts statistics, such as period, burst 
duration, and phase.  It is designed with a simple GUI so that it can be operated easily by 
users who are not familiar with programming languages (Figure 2.4).   
2.3.1 GUI menu structure 
 When SpinalMOD is first opened, there are a series of menus in the top left hand 
corner.  There are three first level menus, namely “File”, “Edit”, and “Settings”.  The 
“File” menu offers options to open data, save analysis, open figures into a pop-up 
window for closer examination, and for exporting analysis.  The “Edit” menu offers the 
ability to undo and redo changes in variables.  The “Settings” menu offers options to 
change the file name and set the sample frequency of the data being analyzed.  Once an 
option has been selected, most options have a pop-up window that guides the user 
through the desired action. 
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Figure 2.3: Terminology for the different types of trace amine induced bursting 
There are three different broad types of bursting for the TAs.  A. The first type is continuous locomotor-
like bursting that has a regular frequency.  The frequency of 5-HT/NMDA and TA/NMDA locomotor-like 
activity is statistically indistinguishable. B.  The second type is continuous locomotor-like bursting that has 
a significantly slower burst frequency.  C.  The third type is episodic bursting, which is characterized by 
bouts of bursting with epochs of comparatively quiescent periods.  The bursting in the bouts is typically 
locomotor-like.  The lower box in C shows a bout of bursting on the same time scale as seen in A&B. 
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Figure 2.4: SpinalMOD Graphical User Interface   
The graphical user interface (GUI) is designed to be easy to use.  The input variables are listed to the left 
under VARIABLES for all four channels.  To change the variable, the user simply clicks inside the white 
box and changes the value.  The waveforms for the data are show in the middle.  Raw data is in green.  
Filtered data is in blue.  Onset stems are in red, and offset stems are in magenta.  If the stems are not in the 
correct location, the user changes the variables and selects “Run with Updated Variables.”  If the algorithm 
fails to find the correct onset and offsets for the bursts, the stems can be manually changed with the 
“Change On/Off Stem Marks.”  To run the burst analysis, the user would push the “Run Burst Analysis” 
button, and select first the number of bursts to be analyzed and then the first burst to be analyze.  Black 
stems mark the beginning and end of the analyzed period.  Once analyzed, the values calculated are shown 
in the Burst Analysis section to the right of the GUI. 
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2.3.2 Running the burst detection 
To get started analyzing data, the user selects the file to be analyzed from the location 
it has been saved.  Currently, two types of files can be opened for analysis.  The first file 
format is the .abf, which was recorded using pCLAMP acquisition software (v8-9, 
Molecular Devices; Union City, CA).  This data is inputted into SpinalMOD via a custom 
script written by Michael Sorensen, called readabf.m.  The second file format is the .mat, 
which is the form data that has already been analyzed in MATLAB is saved. 
When new data is being entered, the user can select how many seconds of data to 
open, which channels are to be analyzed, and the name of the channels to be analyzed.  
The GUI can analyze four channels of data at one time.  For each channel, the raw data is 
rectified and processed through a low-pass Chebyshev filter.  The burst threshold is 
calculated by taking the mean of the filtered data.  Values above the threshold are tested 
to determine the onset and offset of each burst.  An algorithm (found in Appendix C) 
uses the input variables on the left side of the GUI.  A series of if statements determines 
the onset and offset of a burst by evaluating whether specific criteria are met.  The if 
statements start at the beginning of the rectified and filtered array and evaluate every 
point above threshold to determine if it fits the criteria to be first a burst onset and second 
a burst offset.  The onset of each burst crosses the threshold on an upward slope, and the 
offset of each burst crosses the threshold on a downward slope. 
The important variables for detecting the bursts are: 1st Burst’s Start Time (s), Min. 
Period (s), Min. Burst Duration (s), Min. InterBurst Time (s), and Min. Ringing Time (s) 
(Figure 2.4 and 2.5).  1st Burst’s Start Time (s) is the time in seconds that the user wants 
the GUI to start searching for the first burst onset to be detected and later analyzed.  Min. 
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Period (s) is the minimum period in seconds between the onset of each burst.  Min. Burst 
Duration (s) is the minimum time in seconds of the burst duration.  Min. InterBurstTime 
(s) is the minimum time in seconds between the offset of one burst and the onset of the 
next burst.  Min. ringing time (s) is a variable to prevent early detection of the burst 
offset.  Since the algorithm examines the array point by point, this variable is the 
minimum time in seconds after the offset has been detected that there cannot be another 
offset detected (Figure 2.5). 
Once the data has been opened and has gone through the first calculation of onset and 
offset, the raw data, filtered data, onsets, and offsets are then graphed for the user.  The 
user can change the input variables and select the “Run with Updated Variables” button, 
repeating the burst analysis to correct the burst analysis output.  If the algorithm is unable 
to detect the onset and offset correctly, typically due to noise or a poor signal to noise 
ratio, the user has the option to manually place the burst onset and offset markers.   
2.3.3 Running the burst analysis 
Once the burst markers correctly mark the beginning and end of each burst, the user 
can select the “Run Burst Analysis” button, and the burst characteristics will be 
calculated.    The burst analysis calculates frequency, average period, average burst 
duration, average duty cycle, mean peak-to-peak amplitude, mean peak amplitude, 
relative modulation amplitude, the phase between the different channels, the power 
spectrum, and the average waveform (Kjaerulff and Kiehn 1996).  To examine the data 
and analysis further, pop-up windows open graphs for the waveforms, phase, power 
spectrum, average waveform, changes in period, changes in burst duration, changes in 
duty cycle, and changes in peak amplitude. 
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Figure 2.5: SpinalMOD terminology 
The important variables to calculate the burst onset and offset are 1st Burst’s Start Time (s), Min. Period 
(s), Min. Burst Duration (s), Min. InterBurst Time (s), and Min. Ringing Time (s).  A.  A graphical 
representation of 1st Burst’s Start Time, Period, Burst Duration, and InterBurst Time are shown.  B. The 
min. ringing time variable was implemented to prevent early detection of the end of the burst.  While many 
points may fit the other criteria for being the end of the burst, ringing time helps to insure that the last of 
these points is selected.  Shown here are 4 points that fit the other criteria for the end of the burst.  If the 
time of the Min. Ringing Time is not long enough (left) then the wrong point is marked as the end of the 
burst.  When it is long enough (right), the correct point is marked.  B is a zoom in of the offset for the first 
burst in A. 
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2.4 Contributions to this dissertation 
While I did the majority of the work for this dissertation, I would like to acknowledge 
the people who helped and whose work is included in this dissertation.  The technical 
work for the in situ hybridization work for AADC and TAAR1 was carried out by Dr. 
Hong Zhu.  The technical work for all of the immunohistochemistry and DiI was carried 
out by Michael A. Sawchuck.  Michael A. Sawchuck also helped me to create the 
confocal images while I was processing the immunohistochemistry work.  Their work 
was conducted in consultation with Dr. Shawn Hochman and me.   
I was responsible for all electrophysiology and in vivo experiments, the analysis, the 
statistics, and the writing of the dissertation.  Dr. Shawn Hochman acted as an advisory 
role. 
I wrote the whole SpinalMOD program, with some help on the filtering and getting 
started on using GUIs from Kate Williams Meacham.  SpinalMOD runs a custom script 
written by Michael Sorensen, called readabf.m, that takes data recorded using pCLAMP 







CHAPTER 3  
THE LOCALIZATIONS OF AADC, THE TRACE AMINES, AND 
TAARS PROVIDE AN ANATOMICAL SUBSTRATE FOR THE 
TRACE AMINES IN THE MAMMALIAN SPINAL CORD 
3.1 Abstract 
Like the conventional monoamine transmitters, the trace amines (TAs), tryptamine, 
tyramine, octopamine, and β-phenylethylamine (PEA), are synthesized from the same 
precursor amino acids via aromatic amino acid decarboxylase (AADC) and metabolized 
via monoamine oxidases (MAOs).  While these TAs are present in the mammalian CNS, 
their physiologic role remains uncertain.  Using in situ hybridization and 
immunohistochemistry, widespread AADC labeling was observed in many spinal 
neurons, including motoneurons and D cells surrounding the central canal.  Tyramine, 
tryptamine, and octopamine also had widespread labeling in similar areas consistent with 
AADC producing them.   The trace amine-associated receptor 1 (TAAR1) and 4 
(TAAR4), which are activated by TAs, had similar labeling patterns, in total providing 
the substrate for the TAs to have intrinsic biological actions.   
3.2 Introduction 
The classical monoamine neurotransmitters, dopamine (DA), noradrenaline (NA), and 
serotonin (5-HT), play an important role in modulating spinal cord sensory and motor 
function (Clarac et al. 2004; Hochman et al. 2001; Jacobs and Fornal 1993; Millan 2002; 
Rekling et al. 2000; Schmidt and Jordan 2000).  They are not made in the spinal cord, but 
in descending monoaminergic neurons that project to the spinal cord (Gerin et al. 1995).   
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These transmitters are closely related to another group of endogenous monoamines 
called trace amines (TAs), which may also act as neuromodulatory transmitters (Berry 
2004; Burchett and Hicks 2006; Lindemann and Hoener 2005).  The TAs, tryptamine, 
tyramine, octopamine, and β-phenylethylamine (PEA), have structural, metabolic, 
physiologic, and pharmacologic similarities to the classical MA transmitters (Saavedra 
1989).  Both the monoamines and the TAs are synthesized from the same precursor 
amino acids.  However, while both require the synthesis enzyme aromatic-L-amino acid 
decarboxylase (AADC), unlike the classical monoamines, AADC is the only enzyme 
required to produce most of the TAs; octopamine (like NA) further requires dopamine-β-
hydroxylase (DBH).  Conversion from the TAs to the monoamines does not appear to 
occur (Berry 2007).  
While traditionally viewed as metabolic by-products or false transmitters in 
vertebrates (Berry 2004; Boulton 1976; Grandy 2007; Kopin et al. 1965), the recent 
discovery of trace amine-associated receptors (TAARs) establishes a mechanism by 
which TAs can produce effects of their own (Borowsky et al. 2001; Bunzow et al. 2001; 
Hauger et al. 1982; Kellar and Cascio 1982; Lindemann and Hoener 2005; Nguyen and 
Juorio 1989; Vaccari 1986; van Nguyen et al. 1989).  Tyramine and PEA activate 
TAAR1, while PEA and tryptamine activate TAAR4 (Borowsky et al. 2001).   The 
presence of other TAARs in rat spinal cord, and whether the TAs act on them remains to 
be determined (however see (Liberles and Buck 2006)).  
A trace aminergic neuronal system has yet to be identified.  Candidate cells include D 
cells, which contain the essential synthesis enzyme AADC, but not tyrosine hydroxylase 
(TH), DBH, or phenylethanolamine N-methyltransferase   (PNMT),  and hence are able 
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to produce the TAs, but not the classical monoamines (Berry 2004; Jaeger et al. 1984a; 
Jaeger et al. 1984b; Jaeger et al. 1983; Nagatsu et al. 1988).  D1 cells are associated with 
the lumen of the central canal and were the first non-monoaminergic AADC positive 
cells to be identified in the spinal cord (Jaeger et al. 1984b; Jaeger et al. 1983).  It has 
also been reported that there are more cells in the gray and white matter, but nothing is 
known of their properties (Nagatsu et al. 1988).  In the presence of the precursor amino 
acids, phenylalanine, tyrosine, and tryptophan, AADC containing cells should be able to 
synthesize the TAs, PEA, tyramine, and tryptamine, respectively. TAAR1 mRNA is also 
found in the spinal cord (Borowsky et al. 2001), but no studies have looked at TAAR1 or 
TAAR4 spinal protein expression or function. 
I hypothesized that the TAs are an intrinsic amine system in the spinal cord, and 
therefore, that the spinal cord would contain the AADC, TAs, and TAARs.  To test this 
hypothesis, immunohistochemistry was used to identify spinal neurons that express 
AADC, tyramine, tryptamine, octopamine, and the TAARs, and in situ hybridization was 
used to identify AADC and TAAR1.  Overall, AADC, tyramine, tryptamine, octopamine, 
and the TAARs were found to be present in the spinal cord.  Some of these results have 
been presented in abstract form (Gieseker et al. 2004; Gozal et al. June 15, 2007; Gozal et 
al. 2010; 2007b; Gozal et al. 2006).  
3.3 Methods 
All experimental procedures complied with the NIH guidelines for animal care and the 
Emory Institutional Animal Care and Use Committee.  Sprague-Dawley rats postnatal (P) 
day 0-5, 14, and adult were used.  
3.3.1 In situ hybridization 
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Complete adult rat spinal cords were dissected out and the whole cords were stored in 
RNAlater (Qiagen, Valencia, CA) at -80° until use.  Total RNA was extracted from the 
mouse spinal cord by using Qiagen RNeasy Mini kits (Qiagen, Valencia, CA).  Five 
microgram of total RNA was subject to cDNA synthesis with oligo-dT15 primer and 
SuperScript II Reverse transcriptase (Invitrogen, Carlsbad, CA) for one hour at 42° C.  
The reverse transcriptase was inactivated, and RNA was degraded by heating at 95° C for 
5 min. Of the 20 µl of cDNA obtained from the synthesis reaction 5 µl were directly 
added to the PCR reaction using a PCR Mastermix kit (Eppendorf, Hamburg, Germany) 
containing 1 µM gene-specific primers.  The primer used in this study was designed by 
the Invitrogen-OligoPerfect™ Designer program (Invitrogen, Carlsbad, CA).  Non-
radioactive single-stranded digoxigenin cRNA probes were used for in situ hybridization 
using methodology reported previously (Zhu et al. 2007).  Briefly, single stranded, 
digoxigenin-labeled antisense and sense probes are transcribed in vitro using T7 and Sp6 
RNA polymerase (Promega).  The probe sequence for rat dopa decarboxylase (AADC) is 
523-927bp (GenBank U31884), 404 bp product.  The probe sequence used for TAAR1 is 
400bp long (GeneBank#AF380186). Hybridization is carried out at 68 °C overnight with 
3µg/ml digoxigenin-labeled antisense cRNA probe.  Sense probes were used at identical 
concentrations and development reaction as a negative control.  Sections were washed 
with concentrated standard saline citrate (SSC) and then incubated with anti-digoxigenin-
AP, Fab fragments (1:5000, Roche) in blocking buffer overnight at 4C.  The color 
development reaction was carried out in the dark and neutralized with color stop buffer 
(10 mM Tris, pH 5, 1 mM EDTA).  Slides were then dehydrated through a series of 
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alcohol washes, coverslipped with Vectamount (Vector Labs) and viewed on a Nikon 
E800 light microscope.  Images are digitized with Nikon ACT-1 software. 
3.3.2 Thoracic transection of the spinal cord 
Rodents were anesthetized with isoflurane via inhalation.  Following dorsal 
laminectomy to expose lower-thoracic segments of the cord, one section of the cord 
between T8-T12 was removed using surgical microdissection scissors.  Gel foam was 
placed in the site of transection to maintain the gap between rostral and caudal cord.  The 
incision was closed with sutures.  Rodents recovered for 1-3 weeks before 
immunohistochemistry or lipophilic dye labeling of axonal tracts.  This is a sufficient 
time for degeneration of descending monoaminergic axon terminals (Commissiong and 
Toffano 1989).   
3.3.3 Immunohistochemistry 
Sprague-Dawley rats were anesthetized with urethane (1.5 mg/kg), perfused with 1:3 
volume/body weight of prefix (0.9%NaCl, 0.1%NaNO2 , 10units/1m heparin) followed 
by equal volume/body weight of Lana’s fixative (4% paraformaldehyde, 0.2% picric acid, 
0.16 M PO3); pH 6.9.  In a small subset of experiments, the isolated cords of P2 
littermates were incubated in regular aCSF either with or without the TAs, octopamine, 
tyramine, and tryptamine (all at 100 µM) for 2 hours and then processed.  In many of the 
experiments, Fluorogold, which does not cross the blood brain barrier, was injected 
intraperitoneal (i.p.) 24 hours prior to sacrifice to retrogradely label most spinal 
motoneurons (Ambalavanar and Morris 1989; Merchenthaler 1991).  The spinal cords 
were then isolated and post-fixed for 1 hour in Lana’s fixative than cryoprotected in 10% 
sucrose, 0.1M PO3 until sectioned into 10 um thick sections on a cryostat and processed 
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for immunohistochemistry.  All incubations and washes were performed in 0.1M PO3-
buffered saline containing 0.3% triton X-100 (PBS-T).  Tissue was washed overnight in 
PBS-T at 4°C followed by incubation in primary antibody for 48-72 hours.  Slides were 
then washed three times for 30 minutes and incubated in secondary antibody.  The 
following antibodies combinations were used:  
Table 3.1: Antibodies used for immunohistochemistry expression 
Primary Antibody Secondary Antibody Tertiary 
Rabbit anti-tyramine 1:1000 




(Sigma) Rabbit anti-TAAR1 1:1000 
(Lifespan Biosciences) 
Rabbit anti-DDC 1:00 
(Biomol Sciences) 
cy3 anti-rabbit 1:250 
(Jackson Immunoresearch) 
  
Rabbit anti-tyramine 1:100 or 1:1000 
(Chemicon) 
Rabbit anti-tryptamine 1:50 
(Chemicon) 
Rabbit anti-octopamine 1:500 
(Chemicon) 
Rabbit anti-TAAR1 1:1000 
(Lifespan Biosciences) 
Rabbit anti-TAAR4 1:5000 
(Novice Biochemicals) 
Sheep anti-DDC 1:100 
(Biomol Sciences) 
FITC anti-sheep 1:100 
(Jackson Immunoresearch) 
Mouse anti-NeuN 1:50 
(Chemicon) 
FITC anti-mouse 1:100 
(Jackson Immunoresearch) 
 
In all experiments, omission controls were used for the primary antibodies. Others 
have provided pre-absorption controls abolishing staining for AADC (Ishida et al. 2002), 
tryptamine (Dabadie et al. 1990), and octopamine (Karhunen et al. 1993), but there is 
only evidence for displaced tyramine binding (Geffard et al. 1984).  Thus, tyramine pre-
absorption controls were performed.  Appropriate antibody concentrations (1:100 and 
1:1000) were absorbed with 1mg of antigen (Cell Sciences) for 1 hour prior to 
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incubation.  This abolished staining for tyramine in 6 of 7 animals.  Images were 
photographed with a Nikon (Tokyo, Japan) digital camera through a Nikon E800 
microscope or using an Olympus FV1000 inverted confocal microscope.  Images were 
processed using Corel Draw (Corel, Ottawa, Ontario, Canada).   
3.3.4 Lipophilic dye labeling 
One week after midthoracic spinalization the P14 rats were anesthetized, and the cords 
were isolated and preserved in 2% paraformaldehyde fixative.  Cords were then 
suspended in agarose gel and labeled with the carbocyanine dye DiI.  Crystals of DiI 
were placed at the cut surface of various ventral funiculus regions.  The dye was allowed 
to diffuse to identify grey matter projections sites.  The cord was then imaged via 
fluorescent microscopy using the Neurolucida.  
3.4 Results 
3.4.1 AADC and the trace amines were widely expressed in adult rodent spinal 
cords  
In situ hybridization (Figure 3.1) and immunohistochemistry (Figure 3.2) carried out 
in adult rat lumbar spinal cord showed that AADC was detected with widespread labeling 
throughout the spinal cord.  AADC expression was most notable around the central canal, 
the ventral funiculus, and in ventral neurons, including motoneurons.  There was some 
nuclear binding for AADC in the motoneurons, which has been previously reported for 
AADC (Mann and Bell 1991).  AADC labeling around the central canal was consistent 
with labeling of D cells as reported previously (Jaeger et al. 1983).  There was also clear  
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Figure 3.1: In situ hybridization reveals AADC expression throughout the spinal gray matter  
Top row. Sense and RNAase treatment confirms specificity of antisense probe.  Lower row provides 
magnification of boxed regions in top panel. Left. Central canal regions with arrow pointing to putative D 




Figure 3.2: Immunohistochemistry reveals AADC labeling throughout the spinal gray matter 
Intense AADC labeling was found in blood vessels (pink arrows) and in the D cells (yellow arrows). Top 
row at right show a magnification of the ventromedial cord to highlight the vessel labeling, the D cells, and 
the AADC+ labeling in the ventral white matter (arrowheads).  Middle left panel is a further blow-up to 
show the AADC+ cells at the central canal.  Note that some AADC+ neurons were also found in the dorsal 
central canal.  Middle right panel show AADC+ terminal arborizations surrounding motoneurons. Most of 
these arborizations are presumably from descending monoaminergic systems. Note however that 
motoneurons also appear to be weakly AADC+ (arrowheads). Bottom row are the omission controls for 
ventromedial cord (left) and motoneurons (right). 
 63
AADC immunolabeling surrounding blood vessels (Figure 3.2, top) where AADC 
activity is known to be high (Hardebo et al. 1979; Nagatsu et al. 1988).  It is known that 
the amino acid precursors can be transported across blood vessels into the CNS (Daniel et 
al. 1976); therefore, one possible explanation for the presence of AADC in blood vessels 
is the synthesis of TAs as they cross the blood brain barrier.   
To determine the extent to which AADC labeling was related to expression in 
descending axons fibers, I performed a complete mid-thoracic spinalization of an animal 
at P4, and waited 3 weeks prior to sacrifice.  After spinalization, TH labeling was 
abolished (not shown).  There was a near-complete loss of AADC fiber labeling in the 
spinal cord consistent with most expression arising from descending aminergic systems.  
However, AADC labeling remained in the ventral funiculus, around the central canal, 
including D cells, as well as associated with blood vessels, and in ventral neurons, 
including motoneurons (Figure 3.3B).  Interestingly, even in these cells, AADC labeling 
intensity appeared reduced.  It is noteworthy that, unlike the in situ data, with widespread 
AADC expression, AADC immunolabeling post-spinalization is much more restricted.  
The most obvious explanation for these differences is that intrinsic AADC expression is 
altered by events related to spinalization.  The absence of TH labeling in lumbar cord 
suggests that after spinalization the only amines that can be intrinsically produced in 
these spinal regions are the TAs.  
To confirm the presence of AADC and absence of TH and DBH after spinalization, I 
examined expression profiles created previously in the lab by microarray analysis using 
the mouse U74Av2 Affymetrix gene chip (Cui et al. 2006).  I found that AADC cDNA 
was present in the whole spinal cord and in medial and lateral motor column 
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motoneurons both in control mice and in mice 3 weeks after thoracic spinal cord 
transection, thus confirming the above immunolabeling results.  Also, I found that TH 
and DBH cDNA were absent both in control mice and mice 3 weeks after cord 
transection. Thus, all of the immunolabeling for TH I observed in the control spinal cord, 
and the TH and DBH labeling found by others (MacDermid et al. 2004) is due to 
expression in descending projection systems.   
Next, immunolabeling was undertaken to compare octopamine, tryptamine, and 
tyramine expression in the ventral horn of the adult rat spinal cord (Figure 3.4).  
Octopamine and tryptamine immunolabeling were observed throughout the neuropil of 
the ventral horn, and for both, expression appeared to be in a subpopulation of 
motoneurons.  In comparison, tyramine expression is weak or absent in motoneurons, but 
had unique punctate labeling surrounding motoneurons.  Immunolabeling for PEA was 
not done because there is not a specific antibody commercially available for PEA. 
3.4.2 AADC and the trace amines were widely expressed in neonatal rat spinal 
cords  
Next, immunolabeling studies of AADC and TA expression were conducted in the 
neonatal spinal cord to match the age at which electrophysiological studies were 
undertaken in the subsequent chapters (Figure 3.5 and 3.6).  AADC labeling was similar 
to that found in the adult with widespread labeling.  Labeled spinal neurons were most 
notable adjacent and ventral to the central canal, the ventral funiculus, and in ventral 
neurons, including motoneurons (Figure 3.5A).  As observed in the adult, but more 
strikingly, AADC+ neurons associated with the central canal projected ventrally in a 




Figure 3.3: AADC labeling in the adult lumbar spinal cord before and after transection 
A. Labeling of AADC in the ventral spinal cord of the control P25 adult rat. Top. Arrow identifies AADC+ 
tract at the midline of the ventral funiculus white matter.  Boxes identify the central canal and motoneuron 
regions, which are magnified below.  Middle. Epithelial cell layer surrounding central canal (outlined) 
includes AADC+ neurons as well as additional neurons emanating from ventral aspect of canal (e.g. yellow 
arrows).  Some blood vessels also appear to be AADC+ (white arrows). Punctate labeling for AADC is 
associated with axonal arborizations. Bottom. AADC+ labeling surrounding motoneurons (yellow 
arrowheads). B. AADC labeling 3 weeks after midthoracic spinalization in a littermate of A.  Same format 
as in A.  Note that AADC+ puncta were lost while neuronal labeling associates with the epithelial region 
surrounding the central canal and around motoneurons, while white matter labeling in the ventral funiculus 
remain.  Also, note that motoneurons appear to be weakly AADC+.  Again, structures surrounding blood 
vessels also appear to be AADC+.  All images are confocal images taken at optical section thickness of 3.52 
µm, top panel; 0.94 µm, middle and bottom panels. 
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Figure 3.4: Trace amine labeling in the adult rat spinal cord 
A. Octopamine immunolabeling was seen throughout the neuropil of the ventral horn. Interestingly some 
motoneurons appear to be octopamine+ (arrowheads) and other are octopamine- (arrows). B. Like 
octopamine, tryptamine immunolabeling was diffuse and weak in the ventral horn neuropil and a 
subpopulation of motoneurons appear to be tryptamine+ (arrowhead) and others were tryptamine- (arrows). 
C. Tyramine immunolabeling was weak or absent from motoneurons (arrows) but, unlike tryptamine and 
octopamine, tyramine labeling was more punctate and appears to surround motoneurons.  D. Omission of 
primary antibody to show background labeling generated with the fluorescent antibody used to label the 




Figure 3.5: Distribution of AADC and tyramine in the neonatal spinal cord 
A. Left. Low power of AADC immunolabeling in spinal cord.  Superimposed on this section is an outline 
of the spinal cord (black) with interior white lines approximately demarcating dorsal and ventral gray 
matter and central canal region.  Note that strongest labeling was associated with D cells intermingled with 
epithelial cells surrounding the central canal (top arrow).  Also, note the associated vertical row of cellular 
labeling projecting ventrally, and bilateral white matter labeling in the ventral funiculus (bottom arrow). 
There was also weak AADC immunolabeling in putative motoneurons (in lamina IX below dotted lines).  
Right.  Three panels showing higher power images from separate sections illustrating the diversity of 
AADC labeling in the ventral medial grey matter region.  Epithelial cell layer surrounding central canal is 
outlined.  Common to all was the vertical stream of projections with intermingled cells ventral to the 
central canal. These appear to end in a white matter tract in the ventral funiculus (arrowheads).  B. 
Tyramine immunolabeling in motoneurons retrogradely labeled with Fluorogold.  The day before sacrifice 
the rat pup was injected i.p. with fluorogold to retrogradely label the motoneurons.  C. Tyramine labeling 
was found in a subset of neurons primarily in the ventral half of the cord.  The central region (1) and 
laminae V-IX (2) are shown magnified.  Note the tyramine labeled cells intermingled with epithelial cells 
lining the central canal in middle panel (arrows) and labeled neurons in the central gray matter (arrows) and 





Figure 3.6: Co-expression of tyramine and AADC in neuron subpopulations of the neonatal rat 
lumbar spinal cord 
A. AADC and tyramine immunolabeling in putative motoneurons. While AADC produces more uniform 
cytoplasmic labeling (left) tyramine labeling includes larger puncta, which were not co-labeled in merged 
image at right.  B. AADC and tyramine labeling in D cells associated with the central canal (yellow arrows; 
left panels for each pair)  and its ventral cellular projection stream appearing to terminate at a midline tract 
in the ventral funiculus (right panels in each pair).  White arrows identify ventral funiculus.  Note D cells, 
ventral midline cells and ventral funiculus are co-labeled.  All images in A and B are high power confocal 
images with an optical section of 0.4 µm.  C. Evidence for tryptamine and octopamine co-expression with 
AADC.  Images were obtained from 10 µm sections.  Confocal microscopy was not used for this panel. 
Scale bar; 20 µm in A and B, 50 µm in C. 
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medial portion of the ventral funiculus (Figure 3.5A, right).  In addition, AADC+ 
neurons were found often in the lateral regions near the central canal as well as in the 
dorsal horn, although more rarely.   
Tyramine immunolabeling was characterized by enormous variability between 
different animals, but with consistent motoneuronal labeling.  The identity of 
motoneurons was confirmed by prior retrograde labeling of motoneurons (Figure 3.5B).  
The most common pattern seen across animals was a widespread diffuse labeling.  This is 
consistent with the widespread distribution of the TA synthesis enzyme AADC.  In a 
subset of animals tested, tyramine preferentially labeled ventral horn interneurons.  
Figure 3.5C shows tyramine expression in an animal with particularly extensive 
interneuronal labeling in the ventral horn.  Widespread labeling was also seen for 
tryptamine and octopamine.  I presume that the variability in different animals reflects the 
exquisite sensitivity of the TAs to shifts in network activity, substrate availability, 
transport efficacy, synthesis, and degradation.   
While there was clear co-labeling of AADC and tyramine in spinal motoneurons, the 
co-labeling revealed differences; tyramine labeling also included larger puncta (Figure 
3.6A). While not shown, comparable punctate labeling was also seen for octopamine and 
tryptamine.  Tyramine, tryptamine, and octopamine were co-expressed with AADC in 
central canal D cells, in the ventral stream of cells at the midline, and in the ventral 
funiculus (Figure 3.6B and C).  These results are consistent with the notion that D cells 
and related midline neurons are tyraminergic and tryptaminergic.  With no DBH found in 
spinal cord neurons, octopamine should not be produced in the spinal cord yet significant 
labeling was observed.  As octopamine can be co-released with NA (Saavedra 1989) and 
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subsequently taken up into neurons, this may account for the observed expression. 
Additionally or alternately, a recently identified enzyme, monooxygenase, DBH-like 
1(Moxd1) may be converting tyramine to octopamine in spinal neurons. 
As mentioned above for tyramine, there was enormous variability for expression of all 
three TAs examine; the D cell and other midline neurons were not always clearly 
immunopositive for all the TAs.   
3.4.3 Central canal cells project to the ventral funiculus 
To determine whether cells at the central canal could have axonal projections to the 
ventral funiculus, DiI crystals were applied to various ventral funicular regions in the 
fixed lumbar spinal cords of a P14 rat one week after thoracic spinalization.  When dye 
placement contacted the midline tract, central canal-associated cells were retrogradely 
labeled, confirming that cells consistent with the location of D cells can project to the 
ventral funicular white matter tract (Figure 3.7), as expected based on the AADC 
labeling. 
3.4.4 The trace amines were transported into neurons 
To test whether the TAs are selectively taken up by neurons, isolated spinal cords 
were preincubated in the TAs in animals injected with Fluorogold the day before to 
retrogradely label motoneurons (Merchenthaler 1991).  Immunostaining showed that 
Fluorogold labeled motoneurons were TA+ (Figure 3.8).  Further, tyramine, tryptamine, 
and octopamine uptake appears to be selective to neurons, not glia as staining for the 
neuron specific marker, NeuN, and the TAs showed that virtually all ventral spinal cord 




Figure 3.7: Central canal cells project to the ventral funiculus 
DiI crystals were placed on fixed lumbar spinal cords at the medial ventral funiculus or just lateral to it and 
allowed to diffuse to identify grey matter projections sites.  A. When dye placement contacts the midline 
tract, neurons associated with the central canal were retrogradely labeled.  P14 rat 1 week after with a 
midthoracic spinalization.  B. Neurons in the central canal were not labeled.  Sections are 70 µm in A and 





Figure 3.8: Trace amine labeling appears to preferentially label neurons 
The isolated spinal cords of P2 rat were pre-incubated in TAs for 2 hours. The day before the treatments, 
the rat pups were injected with Fluorogold to retrogradely label motoneurons (top row).  Row 2 shows 
immunostaining for tyramine (left), tryptamine (middle), and octopamine (right).  Row 3 provides 
immunostaning for the neuron-specific marker, NeuN.  Row 4 is a merge of the trace amine with NeuN to 




Figure 3.9: TAAR1 and TAAR4 receptors are expressed in the ventral horn 
A.TAAR1 mRNA expression in spinal neurons.  In situ hybridization reveals TAAR1 labeling throughout 
the P2 rat spinal cord (compare sense to antisense).  Particularly notable was the  labeling found in the 
ventral horn, including motoneurons (arrows).  B. TAAR1  receptor immunolabeling was found in many 
spinal neurons in the gray matter of the ventral horn, with particularly strong labeling in motoneurons 
(region expanded in middle panel).  There was apparent labeling of cells surrounding the central canal (see 
asterisks in region expanded in right panel).  Note also the punctate labeling that extends as a thread 
adjacent to epithelial cells with expansion in central canal interior.  C. TAAR4  receptor immunolabeling 
was also found in many spinal neurons in the gray matter ventral horn, including strong labeling in 
motoneurons (region expanded in middle panel).  TAAR4 receptors appears to localize in cells ventral to 
the central canal.  Scale bar: 100 µm, left panels; 25 µm, middle and right panels.  All images in A and B 
are confocal images taken at optical section thickness of 1.14 µm, left panels; 0.30 µm, middle and right 
panels. 
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selective uptake via passive diffusion.  Moreover, this suggests that spinal cord neurons 
are sensitive to extracellular TA levels. 
3.4.5 Trace amine-associated receptors 1 and 4 were widely expressed in the spinal 
cord  
In situ hybridization for TAAR1 in the neonate demonstrated widespread, albeit weak, 
labeling throughout the spinal cord including motoneurons (Figure 3.9A). In P1 neonatal 
rat spinal cord, immunolabeling for both TAAR1 and TAAR4 was found throughout the 
spinal cord, especially in motoneurons (Figure 3.9B and C).  Cells around the central 
canal were also TAAR1 and TAAR4 immunopositive.  Labeling in all neurons appear 
cytoplasmic.  The cytoplasmic location of the ligand and the receptor (e.g. tyramine and 
TAAR1) supports intracellular activation of signal transduction pathways, as suggested 
previously.  The presence of TAAR1 and TAAR4 provides potential binding sites for the 
TAs to have independent actions in the spinal cord.   
3.5 Discussion 
I showed that an anatomical substrate exists for the TAs, a little studied but pervasive 
class of neuroactive molecules, to be produced and have actions in the spinal cord.  The 
synthesis enzyme, AADC, which is required for production of all of the TAs, was found 
throughout the spinal cord, but especially around the central canal, ventral funiculus, and 
in ventral neurons, including motoneurons.  Tyramine, tryptamine, and octopamine were 
also found in similar locations in the spinal cord.  It seems highly likely that tyramine, 
tryptamine, and PEA (which was not examined due to a lack of a specific antibody) are 
produced in the spinal cord by AADC.  AADC expression was still present after 
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spinalization, but TH labeling was absent, suggesting that after spinalization tyramine, 
tryptamine, and PEA can be intrinsically produced in the spinal cord.   
Octopamine further requires DBH, which is located only in descending neurons, 
implying that octopamine is only produced in descending noradrenergic neurons. 
However as stated above, another enzyme, Moxd1 has comparable function (Chambers et 
al. 1998; Xin et al. 2004) and could also theoretically convert tyramine to octopamine.  
Moxd1is strongly expressed in the mouse spinal cord including in presumed motoneurons 
and around the central canal (Appendix A.1) (Allen_Spinal_Cord_Atlas 2009).  Further 
studies will be required to determine if Moxd1 does in fact produce octopamine, and 
hence, if octopamine is also intrinsically produced in the spinal cord.  Further, as 
indicated in our studies and in those of others, the lack of both TH and DBH in the spinal 
cord indicates that the monoamines are not produced in the spinal cord neurons, but are 
made in terminal of descending neurons.  Figure 3.10 shows the possible locations of 
production of the TAs and monoamines.   
Since the TAs appear to be transported into neurons (explored in more detail later), 
this would explain how the TAs, including octopamine, could be found in neurons 
besides those where it could be produced.  The presence of the TAs into neurons is a 
mechanism by which they can be having actions on the intracellularly located TAARs.  
TAAR1 and TAAR4 also have widespread expression in the spinal cord and are activated 
by the TAs: TAAR1 by tyramine and PEA, and TAAR 4 by tryptamine and PEA 
(Borowsky et al. 2001).  That the TAs have a family of receptor to which they 




Figure 3.10: Summary of the locations that the trace amine and monoamines can be produced 
The TAs, tyramine, tryptamine, and PEA, are likely produced in the spinal cord.  AADC, the only enzyme 
required for their production, was found with widespread labeling throughout the spinal cord in neurons 
and axons that are labeled above in the spinal cord cross section.  Labeling of tyramine and tryptamine 
supports widespread production of the TAs.  DBH one of the required enzymes for octopamine is not found 
in the spinal cord; however, another enzyme Moxd1 that may also produce octopamine is found in the 
spinal cord.  Therefore, it is currently unknown whether octopamine can be produced in the spinal cord.  
The enzymes necessary for production of both the monoamines and TAs are found in descending neurons.   
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the monoamines and their receptors, thus giving an anatomical substrate for the TAs to 
have independent intrinsic biological actions.   
3.5.1 AADC and trace amines are widely expressed in the spinal cord   
Previously, many neuronal populations were observed to be AADC+ that did not 
express 5-HT or TH (cannot synthesize DA, NA, or adrenaline).  They were called D 
cells (Jaeger et al. 1984a; Jaeger et al. 1983).  One of the 14 identified groups was located 
in the spinal cord and called D1 cells (Jaeger et al. 1984a).  D1 cells project at least one 
of their processes into the lumen of the central canal, which makes them part of a group 
of cerebrospinal fluid (CSF)-contacting neurons (Jaeger et al. 1983; Vigh et al. 2004).  
No neurotransmitter was identified for these neurons, and nothing is known about their 
function.  It has been speculated that D cells could produce the TAs (Berry 2004; Jaeger 
et al. 1983).   
Here, AADC was expressed in spinal cord of adult and neonatal rat.  Labeling was 
widespread but relatively weak in most cells.  However, the cells surrounding the central 
canal, a ventral stream from this region, and blood vessels appeared strongly AADC+.  
Labeling of cells around the central canal is consistent with the previous identification of 
D1 cells  (Jaeger et al. 1983).  The additional AADC+ neurons that were identified 
confirms that there are other spinal neurons that have yet to be examined and classified in 
the vicinity (Nagatsu et al. 1988).  Motoneurons and other cells were more weakly 
labeled.  Neither the in situ hybridization nor immunodetection of AADC have been 
previously reported in rat spinal motoneurons.   However, the in situ hybridization 
performed by the Allen Mouse Spinal Cord Database confirms widespread neuronal 
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labeling in both adult and neonatal mouse spinal cord.  Labeling around the central canal 
and in motoneurons was notable (Appendix Figure A.1). 
The AADC+ D cells found near the central canal, as mentioned above, were CSF-
contacting neurons.  While the function of these D cells is still unknown, there are CSF-
contacting neurons positioned very similarly in the zerbrafish larva.  These neurons can 
initiate slow swimming by optogenetic stimulation, their genetic silencing reduces the 
frequency of spontaneous locomotion, and they provide the necessary tone for 
spontaneous forward swimming (Wyart et al. 2009).  Based on the similarity in location, 
it seems plausible that the D cells may be contributing to the frequency and tone of 
locomotion in the rat, but further studies will be needed to determine this conclusively. 
It is noteworthy that while the in situ hybridization labeling shows widespread AADC 
expression in a normal animal, AADC immunolabeling post-spinalization was much 
more restricted after the degradation of descending monoaminergic terminals.  The most 
obvious explanation for these differences is that intrinsic AADC expression was altered 
by events related to spinalization.  AADC can be regulated at both the level of protein 
activity and gene expression with long term regulation being due to changes in gene 
expression.  It has been shown that there is an excellent correlation between mRNA level 
and AADC activity (Coge et al. 1990).   
The most consistent observation common among all TAs tested was the central cell, 
midline, and motoneuronal labeling.  These locations were consistent with the locations 
of AADC.  The apparent specificity of tyramine to a population of ventral horn 
interneurons was seen in only a small number of animals tested.  I presume the variability 
reflects the exquisite sensitivity of the TAs to shifts in network activity, substrate 
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availability, transport efficacy, synthesis, and degradation.  Also, there were differences 
in motoneuron expression of the TAs compared with the adult, suggesting that there were 
developmental differences. This is not surprising given that AADC expression changes 
from embryonic to adult rats (Teitelman et al. 1983).  For example, somatic 
motoneuronal tyramine immunolabeling is found in neonate but appears absent in the 
adult and replaced instead by apparent pericellular labeling. The explanation for this 
difference in expression pattern is currently unknown.  
TA incubation studies showed that tyramine, tryptamine, and octopamine were 
transported specifically into neurons and not glia, arguing against global uptake via 
passive diffusion.  Many transporters are bi-directional, meaning that the TAs are likely 
both taken up and released from neurons via transporters.  Once in neurons, the TAs 
would be available to activate TAARs, which I showed to be intracellular.  Also, since 
the TAs are produced in neurons, like motoneurons, they could be acting in the neurons 
in which they were made, in addition to being transported out of these neuron and acting 
at nearby neurons. A more detailed discussion of transport mechanisms is provided in 
Chapter 4. 
3.5.2 Trace amine-associated receptors 1 and 4 were widely expressed in the spinal 
cord  
TAAR1 and TAAR4 both had widespread expression in the spinal cord.  Of particular 
relevance was that TAAR expression overlapped with the expression of AADC and TAs.  
Thus, mechanisms for TA synthesis and actions are anatomically coincident, providing a 
substrate by which TAs can produce effects on their own. As has been observed before 
for TAAR1 in HEK cells (Bunzow et al. 2001; Miller et al. 2005), I observed cytoplasmic 
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labeling for TAAR1 and TAAR4, both of which are activated by the TAs.  Tyramine and 
PEA activate TAAR1, while PEA and tryptamine activate TAAR4 (Borowsky et al. 
2001).  The cytoplasmic location of the ligand and the receptor (e.g. tyramine and 
TAAR1) supports intracellular activation of signal transduction pathways, as suggested 
previously (Miller et al. 2005).  Such a co-localization would not require release from 
vesicles and could explain why the TAs do not appear to be found in vesicles.  It could 
also explain the relatively trace amounts of TAs found in the spinal cord.  If the 
production of the TAs was typically by or adjacent to the cells that had cytoplasmic 
TAARs, there would be no need to keep the concentration high.   
Since access to the TAARs is limited by the presence of transporters (Xie et al. 2007), 
this would explain the observed low potency of the TAs for TAAR4 expressed in HEK 
cells (Borowsky et al. 2001).  Further, the intracellular location may also explain why 
studies to identify the ligands for other TAARs have failed despite the prediction that the 
ligands must be small molecular weight compounds that are structurally similar to the 
TAs (Lindemann et al. 2005; Lindemann and Hoener 2005).  The assays assume cell 
surface expression of the receptor.  
Previously, In situ hybridization, RT-PCR and LacZ reporter expression studies all 
observed labeled TAAR1 in the brain (Borowsky et al. 2001; Bunzow et al. 2001; 
Lindemann et al. 2008) with one report also examining spinal cord (Borowsky et al. 
2001).  Additionally, immunohistochemistry for TAAR1 in rhesus monkey observed 
labeling in substantia nigra, thalamus, and cerebellum, as well as in mouse brain (Torres 
et al. 2003).  On the other hand, Liberles and Buck (2006) could not detect any TAARs in 
mouse brain with RT-PCR (Liberles and Buck 2006) and the Allen Mouse Spinal Cord 
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Database in situ hybridization expression studies report the TAARs to be absent in both 
P4 and P56 with similarly little to no expression in brain (Appendix Figure A.3)  
(Allen_Spinal_Cord_Atlas 2009).  Here, I present evidence that TAAR1 and TAAR4 are 
expressed in the neonatal rat spinal cord (Figure 3.9), most notably with labeling in 
motoneurons.  Furthermore, close inspection of the Allen Mouse Spinal Cord Database 
shows clear weak diffuse labeling for both TAAR1 and TAAR4 in both P4 and P45, 
including in putative motoneurons (Appendix Figure A.4A). I assume their designation 
‘absent’ is based on conservative threshold detection.    
Wolinsky et al (2007) provided the first conclusive evidence for a role of TAAR1 in 
CNS function by demonstrating behavioral changes in TAAR1 knockout mice.  There, 
the TAAR1 receptor agonist amphetamine, in the absence of its action on TAAR1, 
showed an enhanced psychomotor-stimulating effect, temporally correlated with larger 
increases in striatal DA and NA release, and 2.6 fold increase in the proportion of striatal 
high-affinity D2 receptors.  TAAR1 therefore appears to play a depressant modulatory 
role in brain catecholaminergic function (Wolinsky et al. 2007).  Lindemann et al (2008) 
also studied TAAR1 knockout mice and corroborated several of the above findings.  
They also found that these mice display enhanced amphetamine-triggered increases in 
locomotor activity and an elevated spontaneous firing rate of dopaminergic neurons in the 
ventral tegmental area.  Tyramine specifically decreased the spike frequency of these 
neurons in wild-type but not in TAAR1 knockout mice (Lindemann et al. 2008).  It is 
important to note that the locomotor-enhancing actions of TAAR1knockout mice is 
associated with modulation of basal ganglia dopaminergic neurons. Here, in the isolated 
spinal cord it is possible that the effects would be different, and based on our 
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electrophysiologiy studies described below, I would predict that TAAR1 knockout would 
depress spinal locomotion. Xie and Miller (2008) also examined TAAR1 knockout mice.  
PEA significantly inhibited uptake and induced efflux of DA, NA, and 5-HT in 
transfected cells and brain synaptosome of rhesus monkeys and wild-type mice, but not in 
synaptosomes of TAAR1 knockout mice.  The PEA effect was blocked by transporter 
inhibitors demonstrating that TAAR1 signaling is required for PEA to alter monoamine 
transporter function. They also showed these effects to be independent of monoamine 
autoreceptors (Xie and Miller 2008).  As TAAR1 receptor knockout mice have shown 
clear modifications in CNS behavior, these receptors seem to play a functional role in the 
nervous system (Sotnikova et al. 2009; Wolinsky et al. 2007).   
3.5.3 Summary 
This chapter establishes an anatomical substrate onto which the TAs could be having 
intrinsic spinal cord biological actions.  AADC, the TAs, and TAARs were found to be 
widely present in the spinal cord and in neurons with similar locations.  Since the TAARs 
are intracellular there are two likely mechanisms by which the TAs could have effects in 
spinal neurons.  The first would be paracrine signaling of nearby neurons with the TAs 
using transporters to enter the cell, and the second would be that the TAs, with the 
possible exception of octopamine, were acting in autocrine fashion in the neurons in 
which they are produced. 
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CHAPTER 4  
NEUROMODULATORY ACTIONS OF TRYPTAMINE, 
TYRAMINE, OCTOPAMINE, AND Β-PHENYLETHYLAMINE ON 
MOTOR AND LOCOMOTOR ACTIVITY IN THE MAMMALIAN 
SPINAL CORD  
4.1 Abstract 
An anatomical substrate for trace amine (TA) effects in the spinal cord was 
demonstrated.  Here, I tested whether the TAs were able to have effects on motor activity 
by comparing the actions of the TAs to those of the classical monoamine transmitters in 
the in vitro isolated neonatal rat spinal cord.  Tyramine and tryptamine most consistently 
increased motor activity, including by direct actions on motoneurons.  When applied 
alone tyramine, tryptamine, and octopamine could also activate spinal pattern-generating 
circuits.  In the presence of NMDA, all TAs produced a locomotor-like activity 
indistinguishable from that observed with serotonin (5-HT), supporting TA-induced 
actions on conventional locomotor central pattern generating interneurons. Intriguingly, 
the TAs also produced unique rhythms characterized by episodic bouts of rhythmic 
bursting. In vivo injections of the TAs into previously spinalized animals also activated 
hindlimb locomotor patterns consistent with bath application thereby supporting a role of 
the TAs independent of descending monoaminergic systems.   
TA and DA evoked actions were observed to be initiated at much longer latency than 
5-HT or NA, supporting a requirement for intracellular transport.  To test whether TA 
and DA transport into neurons was required for their effects, I blocked Na+-dependent 
uptake with monoamine transport inhibiters.  TA and dopamine-induced bursting events 
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were attenuated but not blocked while 5-HT and noradrenaline actions were unaffected. 
Evidence of a further contribution from Na+-independent transporters was shown with 
increased neuronal labeling after incubation of the spinal cord with TAs in a nominally 
Na+-free solution.  As multiple Na+-independent transporters that transport the TAs are 
shown to be widely expressed in the spinal cord, an intrinsic spinal neuronal transport 
system likely exists that is independent of transport-mediated action at descending 
monoaminergic.   
These results demonstrate that the TAs are capable of producing complex and 
differentiable modulatory actions on motor function. It is likely that distinct actions of the 
TAs are complex and based on interactions with transporters, synthesis and metabolic 
enzymes, and receptors found heterogeneously in the spinal cord.  Overall, I assert that 
the TAs represent an intrinsic modulatory control system that works with the 
conventional monoamines to control spinal motor behavior. 
4.2 Introduction 
The classical monoamine neurotransmitters, dopamine (DA), noradrenaline (NA), and 
serotonin (5-HT), modulate spinal cord sensory and motor function (Clarac et al. 2004; 
Hochman et al. 2001; Jacobs and Fornal 1993; Millan 2002; Rekling et al. 2000; Schmidt 
and Jordan 2000).  They have structural, metabolic, physiologic, and pharmacologic 
similarities to another group of endogenous amines called trace amines (TAs) (Saavedra 
1989), whose function is unknown.  The TAs, tryptamine, tyramine, octopamine, and β-
phenylethylamine (PEA), are synthesized from the same precursor amino acids by the 
enzyme aromatic-L-amino acid decarboxylase (AADC) with octopamine (like NA) 
further requiring dopamine β-hydroxylase (DBH).  Conversion from the TAs to the 
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monoamines does not appear to occur (Berry 2007).  Degradation is primarily via 
monoamine oxidases (Shimazu and Miklya 2004).  TA synthesis rates are comparable to 
the classical monoamines, but their exceedingly rapid turnover rates (half-life ~ 30 s) and 
limited vesicular storage results in low endogenous levels (Boulton et al. 1977; Durden 
and Philips 1980; Dyck 1989; Juorio et al. 1988; Wu and Boulton 1973; 1974; 1975).   
The discovery of the trace amine-associated receptors (TAARs) establishes a 
mechanism by which the TAs can produce effects on their own (Borowsky et al. 2001; 
Bunzow et al. 2001; Hauger et al. 1982; Kellar and Cascio 1982; Lindemann and Hoener 
2005; Nguyen and Juorio 1989; Vaccari 1986; van Nguyen et al. 1989) rather than 
function as metabolic-by-products or false transmitters as the TAs have traditionally been 
viewed (Berry 2004; Boulton 1976; Grandy 2007; Kopin et al. 1965).   
In the previous chapter, I established that AADC, the TAs, TAAR1, and TAAR4 were 
found in the spinal cord, and hence provide and anatomical substrate by which the TAs 
can have their own actions.  I also found that the TAs were able to be transported into 
neurons, and that the TAARs were found intracellularly.  Consistent with the TAARs 
being intracellular, activation of TAAR1 by the TAs was shown to be greatly enhanced 
after co-expression of monoamine transporters in HEK cells, an enhancement that is 
subsequently reduced by monoamine transport inhibitors (Xie et al. 2007).  
I hypothesized that TA affect spinal motor networks and can produce rhythmic motor 
behaviors.  To test this hypothesis, I used the isolated intact neonatal rat spinal cord 
maintained in vitro. The spinal cord contains neural circuitry capable of generating 
locomotion, and its properties have been thoroughly studied in this model system in 
rodents.  Fundamental insights into the neuromodulatory role of the classical 
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monoamines have been gained through the use of this model system, which makes in 
appropriate for studying the TAs (Hochman et al. 2001; Schmidt and Jordan 2000; Wallis 
1994; Whelan 2003).  I show that the TAs can produce rhythmic motor behaviors and 
have distinct actions.  Some of these results have been presented in abstract form 
(Gieseker et al. 2004; Gozal et al. 2007a; Gozal et al. 2010; Gozal et al. 2006). 
4.3 Methods 
All experimental procedures complied with the NIH guidelines for animal care and the 
Emory Institutional Animal Care and Use Committee.   
4.3.1 Electrophysiology  
4.3.1.1 General setup 
Sprague-Dawley rats postnatal (P) day 0-5 were decapitated, eviscerated, and placed 
in a bath containing oxygenated (95% O2, 5% CO2) artificial cerebral spinal fluid (aCSF) 
containing the following (in mM): 128 NaCl, 1.9 KCl, 1.2 KH2P04, 26 NaHCO3, 2.4 
CaCl2, 1.3 MgSO4, and 10 glucose (pH of 7.4).  The spinal cord was exposed by a ventral 
vertebrectomy and carefully dissected out of the body cavity leaving the dorsal and 
ventral roots attached.  The spinal cord was secured with insect pins to a chamber with 
Sylgard (Dow) on the bottom.  Glass suction electrodes were applied to dorsal and/or 
ventral roots, after which the preparation was allowed to recover for at least 1 hour before 
experimentation at room temperature.  The ventral root electroneurographic activity was 
amplified (10,000x), band-pass filtered at 10-3,000 Hz and digitized at 5 kHz (Digidata 
1321A, 16-bit; Axon Instruments). Band-pass filter frequency settings were selected with 
consideration to observed frequency components with the low-pass filter set ant mush 
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greater than the Nyqist frequency. Data was captured on a computer with the pCLAMP 
acquisition software (v8-9, Molecular Devices; Union City, CA).    Electrophysiological 
data analysis was performed using pCLAMP analysis software (Clampfit) or software 
written in-house using MATLAB.  Statistical comparisons were made in MATLAB using 
ANOVA or Student’s t-test.  The means is reported as mean ± SD. 
4.3.1.2 Motor activity and motor patterning experiments 
Motor activity was monitored using glass suction electrodes attached to ventral lumbar 
roots, typically bilaterally to L2 and L5.  L2 ventral root activity primarily indicates 
activity in flexors, while L5 ventral root activity primarily indicates activity in extensors 
(Kiehn and Kjaerulff 1998).   
4.3.1.2.1 General motor activity 
General motor activity was examined by first applying a RC high-pass filter at 1Hz to 
reduce drift and then calculating the root mean square (RMS) of a representative ventral 
root signal and comparing 100 second periods before application of these TAs and 
monoamines and during their period of maximal response.  Changes were expressed as a 
percent increase over baseline. 
4.3.1.2.2 Locomotor-like activity 
Locomotor-like activity was analyzed using the in-house MATLAB software, 
SpinalMOD, which calculated the frequency, peak amplitude, and phase, which was 
calculated using the middle of the burst (Matsushima and Grillner 1992). I wrote 
SpinalMOD, and it is discussed in chapter 2. 
4.3.1.2.3 Neurochemicals 
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Neurochemicals, which were stored in 10mM or 100mM stock solutions at -20°C, 
were added to the bath (typically 30mL) to achieve the final concentration in the 
chamber.  Neurochemicals were obtained from Sigma-Aldrich (St. Louis, MO), including 
N-methyl-D-aspartate (NMDA) (3-5 µM) and methysergide (5-HT1, 5-HT2, 5-HT7 and 
tryptamine binding site antagonist; 1-10 µM).   
The following monoamines were used: 5-HT (50 µM), noradrenaline (50 µM), and 
dopamine (50 µM). Drug concentrations were chosen at values comparable to those 
previously used. The following TAs were used: tryptamine (50 µM), tyramine (1-100 
µM), octopamine (50-100 µM), PEA (50-100 µM). TA doses were chosen to match those 
of the monoamines under the assumption that they have equivalent transporter uptake and 
degradation following exogenous application. Due to the efficiency of the monoamine 
transporters, it has been estimated that the actual dose is 1/30th that applied (David 
Bennett, personal communication).  
4.3.1.3 Reflex experiments 
To evoke the reflexes, constant current stimuli were applied to the dorsal roots while 
motor activity was recorded from ventral lumbar roots, typically L5.  Stimulus intensities 
were 500 µA and durations ranging from 100 to 500 µs.  For experiments examining 
motoneuron activity in the absence of synaptic transmission, reflexes were abolished after 
switching from regular aCSF to with high Mg2+, low Ca2+ aCSF or zero Ca2+ aCSF.   
4.3.1.4 Transport inhibitors 
First, either the TAs or monoamines were applied with NMDA to induce motor 
rhythmicity.  The bath was then washed, and a cocktail of transport inhibitors was 
applied.  Finally, the TAs and monoamines were re-applied with NMDA in the transport 
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inhibitors and compared. The following monoamine uptake transport blockers were used: 
citalopram (SERT inhibitor, 1 µM), bupropion (DAT inhibitor, 1 µM), and clomipramine 
(SERT and NET inhibitor, 5 µM). 
4.3.2 Behavioral studies in transected neonates 
Rodents were anesthetized with isoflurane via inhalation.  Following dorsal 
laminectomy to expose lower-thoracic segments of the cord, one section of the cord 
between T8-T12 was removed using surgical microdissection scissors.  Gel foam was 
placed in the site of transection to maintain the gap between rostral and caudal cord 
before being closed up.   
Rats were spinalized at P2-3 and behavioral experiments were conducted at either P4-
5 to complement the in vitro work or at P11-12 to allow a longer time from transection to 
allow sufficient time for degeneration of descending monoaminergic axonal terminals 
(Commissiong and Toffano 1989).  The spinal cord-transected rats were intraperitoneal 
(i.p.) injected with TAs at 50 mg/kg (or saline control) and videotaped.  .  The rhythmic 
locomotor hindlimb movements were observed with the rats either held in a harness to 
monitor air-stepping or in a half-body chamber with hindlimbs resting on a moving 
treadmill belt.  The half-body chamber was an adjustable horizontal apparatus where the 
neonatal rats voluntarily crawl into a size-limited and depth-adjustable tube with their 
hindlimbs suspended, similar to the harness, except that the rats were more supported, 
less stressed, and in a more physiologic relevant postural position.  The results for the 
harness and half-body chamber were considered equivalent regarding the ability to 
monitor leg movements and were grouped together.  A rough frequency of leg 
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movements was calculated by counting leg movements over a period of time and dividing 
the leg movements by the time. 
4.3.3 Immunohistochemistry 
The spinal cord was isolated from rats who had been i.p. injected with Fluorogold 24 
hours prior to sacrifice to retrogradely label most spinal motoneurons (Ambalavanar and 
Morris 1989) (Merchenthaler 1991).  A set of incubation experiments was done to 
examine whether exogenously applied TAs could increase cytoplasmic expression levels 
in spinal neurons, and whether uptake was NA+-dependent.  Isolated cords were 
incubated in one of three different treatments for 2 hours: (1) control regular aCSF, (2) 
the TAs, octopamine, tyramine, and tryptamine (all at 100 µM), in regular aCSF, and (3) 
the TAs (all at 100 µM) in zero Na+ (replaced with equimolar choline).   
The spinal cords were then post-fixed for 1 hour in Lana’s fixative than cryoprotected 
in 10% sucrose, 0.1M PO3 until sectioned into 10 um thick sections on a cryostat and 
processed for immunohistochemistry.  All incubations and washes were performed in 
0.1M PO3-buffered saline containing 0.3% triton X-100 (PBS-T).  Tissue was washed 
overnight in PBS-T at 4°C followed by incubation in primary antibody for 48-72 hours.  
Slides were then washed three times for 30 minutes and incubated in secondary antibody.  
The following antibodies combinations were used:  
Table 4.1: Antibodies used for immunohistochemistry expression 
Primary Antibody Secondary Antibody 




Rabbit anti-tryptamine 1:50 
 (Chemicon) 




In all experiments, omission controls for the primary antibodies were used. Others 
have provided pre-absorption controls abolishing staining for tryptamine (Dabadie et al. 
1990) and octopamine (Karhunen et al. 1993), but there is only evidence for displaced 
tyramine binding (Geffard et al. 1984). Thus, tyramine pre-absorption controls were 
performed. Appropriate antibody concentrations (1:100 and 1:1000) were absorbed with 
1 mg of antigen (Cell Sciences) for 1 hour prior to incubation.  This abolished staining 
for tyramine in 6 of 7 animals.  Images were photographed with a Nikon (Tokyo, Japan) 
digital camera through a Nikon E800 microscope or using an Olympus FV1000 inverted 
confocal microscope.  Images were processed using Corel Draw (Corel, Ottawa, Ontario, 
Canada).   
4.4 Results 
4.4.1 Trace amines can induce motor activity and rhythmic locomotor bursting 
patterns 
To examine whether the TAs have actions on the recruitment of motoneurons while 
synaptic transmission was intact, the motor output before and after application of the TAs 
and monoamines were compared).  As shown in Figure 4.1A and C, the increases in 
activity were overt and significant for 5-HT and NA, where the increases in activity were 
279% (n=11) and 253% (n=14), respectively.  DA, tyramine, and tryptamine, also 
significantly increased activity by 50% (n=14), 67% (n=10), and 80% (n=18), 
respectively.  Octopamine and PEA did not have significant actions on motor activity 
(26±50% [n=9] and -3±5% [n=7], respectively).   
In a subset of experiments, monoamine application initiated rhythmic motor activity.  
5-HT (n=4), NA (n=8), and DA (n=1) produce rhythmic motor activity similar to that  
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Figure 4.1: continued 
A. All TAs and monoamines were able to significantly increase lumbar ventral root activity, except 
octopamine and PEA.  B1. Dorsal root stimulation evoked reflexes (left) were abolished when synaptic 
transmission was blocked in low Ca2+, high Mg2+ ACSF (right). B2.  Under these conditions, direct 
excitatory actions were still observed.  C. The changes in ventral root activity were quantified with and 
without synaptic transmission for the TAs and monoamines. (* indicates p<0.05 and ** indicates p<0.01).  
D. Dopamine produced high frequency bursting overlaid by a slow frequency bursting, typically on only 
one ventral root.  E. Tryptamine, tyramine, and octopamine occasionally induced rhythmic motor bursting 
patterns. Here, tryptamine and tyramine produced synchronous bursts on the L5 ventral roots and 
alternating bursts on the L2 ventral roots.  Octopamine generated alternating bursts on the L2 ventral roots.  
Drug concentrations in the figure were 50 µM for tyramine, octopamine, tryptamine, dopamine, and 
noradrenaline, and 100 µM for PEA, except in E2 were the concentration was 10 µM for tyramine.  The 
ventral roots are denoted as right lumbar segment 2 (r-L2), left lumbar segment 2 (l-L2), left lumbar 
segment 5 (l-L5), and right lumbar segment 5 (r-L5). In D, E, and subsequent figures, the upper traces in 
black at each lumbar root have been rectified and low-pass filtered. 
 94
 previously reported (Barriere et al. 2004; Cazalets et al. 1990; Cowley and Schmidt 
1994a; Kiehn and Kjaerulff 1996; Kiehn et al. 1999; Sqalli-Houssaini and Cazalets 
2000); however, in my experiments DA (n=2) also produced higher frequency bursting, 
on only the right L5 ventral root (0.125 ± 0.002 Hz, n=2) that was overlaid by a second 
slower bursting frequency (0.012 ± 0.001 Hz, n=2; Figure 4.1D).   
A subset of tryptamine, tyramine, and octopamine experiments also produced 
rhythmic motor activity that was different than the rhythmic patterns produced by the 
monoamines.  Tryptamine (n=3) induced rhythms varied with a mean frequency of 0.026 
± 0.001 Hz (n=3).  The patterns observed were: alternation between L3 roots, rhythmicity 
in an individual root, and synchronous bursts on the L5 ventral roots with alternating 
bursts on L2 (Figure 4.1E1).  Tyramine (n=3) produced two different bursting patterns.  
First, tyramine produced synchronous bursts on the L5 ventral roots and alternating 
bursts on the L2 ventral roots (0.018 ± 0.003 Hz, n = 2).  The pattern was relatively stable 
and lasted until tyramine was removed (40 minutes or 3 hours) (Figure 4.1E2).  The 
second pattern was restricted to the right L5 ventral root with a very slow frequency 
(0.008 Hz; not shown).  Octopamine (n=1) produced a faster motor rhythm (0.12 Hz) 
with alternating bursts recorded from L2 ventral roots and tonic activity from L5 ventral 
roots (Figure 4.1E3).  These results demonstrate that tyramine, octopamine, and 
tryptamine can act on pattern-generating circuits.   
To test whether the TAs were acting directly on motoneurons, chemical synaptic 
transmission was minimized by replacing the regular aCSF with either a high Mg2+, low 
Ca2+ aCSF or zero Ca2+ aCSF. Under these conditions, recorded reflexes were completely 
abolished (Figure 4.1B1).  Subsequently, the motor output before and after application of 
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the TAs and monoamines were compared (Figure 4.1B2 and C). 5-HT, tryptamine, and 
tyramine significantly increased activity (397±312% [n=4], 98±61% [n=4], and 13% ± 
10% [n=4], respectively); however, these changes in activity were not statistically 
different than observed with intact synaptic transmission. Octopamine (n=4), PEA (n=4), 
NA (n=3), and DA (n=3) did not have significant effects on motor activity, although 
there were visual increases in activity in some experiments.  Only the changes in activity 
for NA were significantly different (reduced) following synaptic isolation, supporting 
activity derived more prominently from premotoneuronal actions.  Despite not having 
synaptic transmission, 5-HT, NA, DA, and tyramine had rhythmic bursting (Figure 
4.1B2), which was likely due to synchronization of motor neuron oscillations across gap 
junctions (Tresch and Kiehn 2000).   
4.4.2 Trace amines produce both regular locomotor-like rhythms and episodic 
rhythms 
NMDA is commonly co-applied with 5-HT to produce stable, regular, and 
physiologically comparable locomotor-like rhythm (Kiehn et al. 1999; Kjaerulff and 
Kiehn 1996; Sqalli-Houssaini et al. 1993).  The locomotor-like pattern seen with 5-HT 
and NMDA is seen as left/right and ipsilateral alternation of bursts between flexors (L2) 
and extensors (L5) (Kiehn and Kjaerulff 1998; Sqalli-Houssaini et al. 1993).  Here, 
NMDA was applied at concentrations that never produced rhythmic motor locomotor-like 
activity on its own (3-5 µM; n=15).  In the presence of NMDA, tryptamine (n=14/19), 
tyramine (n=24/26), octopamine (n=11/13), PEA (n=10/10), NA (n=14/14), DA 
(n=14/14), and 5-HT (n=24/24) almost always recruited rhythmic motor activity.  
4.4.2.1 Trace amines can produce locomotor-like rhythms comparable to 5-HT 
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In several instances, all monoamines and TAs could recruit a locomotor-like pattern 
broadly comparable to 5-HT (n=22).  Incidences are: tryptamine (13/14), tyramine 
(12/24), octopamine (3/11), PEA (3/10), DA (5/14), and NA (2/14).  Examples are shown 
in Figure 4.2A. All amines burst at frequencies statistically indistinguishable from 5-HT 
(Figure 4.3).  Tyramine also produced a second rhythm that was significantly slower, but 
with comparable coordination (p<0.0001; n=5/24) (Figure 4.2B and Figure 4.3).  Since 
the bursting patterns produced by the TAs and NMDA are often similar to 5-HT and 
NMDA, the TAs can recruit either the same pattern-generating circuits or different 
circuits that lead to the same output. 
4.4.2.2 Trace amines also produce episodic rhythmic motor behaviors 
Additionally, tryptamine (n=1/14), tyramine (n=8/24), octopamine (n=9/11), and PEA 
(n=7/10) were able to generate a bursting pattern never seen with 5-HT in this 
preparation.  The pattern was more complex with episodic bouts of bursting where the 
frequencies of the bursts within the bouts were statistically indistinguishable compared to 
that observed during stable 5-HT locomotion.  The episodic bouts of bursting alternated 
with comparatively quiescent periods.  The average frequencies of these episodic bouts 
were very slow (Figure 4.4A-D and Figure 4.3).  Notably, this was the dominant 
temporal pattern of bursting for octopamine and PEA.  Overall, the profile of the episodic 
bursting was highly variable, containing 1-47 bursts within a bout and with quiescent 
periods varying from 5 to 230 seconds.  Typically, there were progressive increases and 
decreases in the locomotor burst amplitude within each episode, which are noticeable in 
at least some bouts for all TAs tested (Figure 4.4).  Similarly, locomotor frequency  
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Figure 4.2: The trace amines and monoamines can all produce a continuous locomotor-like activity 
pattern 
A. Tryptamine, tyramine, octopamine, PEA, 5-HT, dopamine, and noradrenaline can all produced a 
continuous locomotor-like activity pattern in the presence of NMDA.  The patterns were similar.  B. 




Figure 4.3: Differences in frequency between the different types of bursting activity for the 
monoamines and trace amines 
The monoamines and TAs were able to produce different types of bursting activity in the presence of 
NMDA.  The frequencies varied depending on the type of bursting.  Note that not every monoamine or TA 
produced each type of activity.  The DA pattern and the episodic pattern that the TAs produced were 
grouped together and classified as alternate LLA.  Since the episodic TA LLA has both a fast and a slow 
component in the same traces, both were represented in the graph under high frequency bursts of alternate 
LLA and slow frequency episodes of alternate LLA.  The frequencies of the slow LLA, slow frequency 
episodes of alternate LLA, and non-LLA bursting were statistically slower than the frequencies for LLA 




Figure 4.4: The trace amines produce episodic bursting patterns that are different than the regular 
pattern seen with  5-HT in the presence of NMDA 
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Figure 4.4: continued 
A-D. Tyramine, tryptamine, PEA, and octopamine can produce episodic rhythmic motor bursting patterns 
where bouts of locomotor-like bursting were interrupted by relative quiescent periods.  Typically, the bouts 
were concurrently bursting on all of the ventral roots.  However, occasionally, as shown for octopamine (D) 
and also seen with PEA, the bouts of bursting alternated on the right and left side.  E. Episodic bouts of 
locomotor activity were commonly associated with wax and wane changes in amplitude and frequency.  
Shown is the bout highlighted in the tyramine example for r-L2 in panel A.  The burst numbers in the bout 
are on the x-axis, and overlaid plots of instantaneous locomotor frequency and peak amplitude of the 
rectified filtered response are on the y-axis.  Note the trend for both amplitude and frequency to increase 
then decrease over the episodic bout of locomotion. Events within the shaded box emphasize the higher 
frequency, higher amplitude values observed in the middle of the bout. 
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appeared to wax and wane during these bouts, supporting a sinusoidal drive to the CPG.  
This is highlighted in Figure 4.4A in a bout of r-L2 rhythmical activity, whose amplitude 
and frequency are further quantified in Figure 4.4E.  As shown, there are large 
progressive increases then decreases in burst amplitude, and locomotor frequency 
increased then decreased with the middle bursts clearly being of the highest frequency. 
Coordination between roots was also variable for this pattern.  The predominant 
pattern for all the TAs was that the bouts would be concurrent on all of the ventral roots, 
while the bursts within these bouts were locomotor-like (shown for tyramine, tryptamine, 
and PEA in Figure 4.4A-C) (cf. (Beato and Nistri 1999; Whelan et al. 2000)).  The 
number of bursts within these bouts varied between roots, but typically with clear 
transitions between bouts of bursting and quiescent periods.  Besides this pattern, 
octopamine (n=2/9) and PEA (n=1/7) produced bouts of bursting that alternated between 
the right and left side of the spinal cord (shown for octopamine in Figure 4.4D).  
Sometimes there was a slight overlap between bouts on the right and the left, and during 
these times coordination was consistent with locomotor-like pattern (not shown).  For 
tyramine and octopamine, there was an experiment for each where the bursting pattern 
changed from the continuous locomotion shown in Figure 4.2 to the more complex 
pattern with quiescent periods shown in Figure 4.4.   
4.4.3 Dopamine can produce fast and slow locomotor-like rhythms simultaneously 
DA (n=3/14) in the presence of NMDA produced its own unique alternate pattern 
where the typical locomotor-like frequency occurs in conjunction with a much slower 
locomotor-like rhythm (Figure 4.3 and Figure 4.5A).  In essence there appear to be two 
distinct locomotor CPGs operating simultaneously. These longer bursts interact with the 
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Figure 4.5: Dopamine and noradrenaline produce bursting patterns that are different than the 
regular pattern seen with  5-HT in the presence of NMDA 
A. DA produced a pattern where the typical locomotor-like pattern occurs and then a long burst appears to 
overlay the bursting, increasing the amplitude at the time, but not disrupting the frequency of bursts.  Grey 
boxes provide expanded timescale to highlight burst structure within bouts of bursting.  B. NA and DA (not 
shown) often produced continuous bursting that was slow and not locomotor-like.  Pink highlighted areas 
identify duration of the slow rhythms in A and B.   
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 higher frequency locomotor bursts to increase their amplitudes.  However, they do not 
alter locomotor frequency of the bursts or produce quiescent periods.   
In many experiments also in the presence of NMDA, DA (0.04 ± 0.02 Hz; n=6/14) 
and NA (0.02 ± 0.02; n=12/14) also produced continuous bursting that was not 
locomotor-like (Figure 4.5B shows NA), and was significantly slower than 5-HT and its 
own locomotor-like rhythm (Figure 4.3). 
4.4.4 Trace amines can cause locomotor-like behavior in transected neonates 
To investigate behavioral relevance of TAs on spinal motor behavior, the TAs were 
i.p. injected into spinalized neonatal rats in vivo at P4-5 or P11-12 to determine whether 
actions on spinal motor circuits. A great advantage of the spinal cord is that a chronic 
transection can lead to near-complete to complete loss of descending monoaminergic 
transmission (Commissiong and Toffano 1989).  Therefore, especially in the P11-12 rats, 
any change in motor behavior would be due to the effect of the TAs independent of 
descending monoaminergic axonal terminals. 
Octopamine, PEA, and tryptamine were tested in different animals, but not tyramine, 
since it is not thought to be transported across the blood-brain barrier (Oldendorf 1971).  
Aside from a transient injection-induced pain reflex response, saline control injections in 
all of these animals were without effect.   
In 9/9 transects, the TA injected produced hindlimb motor activity.  Octopamine 
abruptly activated hindlimb locomotion that lasted several minutes with frequencies 
ranging between 1.2-1.8 Hz (n=4/4).  As observed in vitro, octopamine induced 
locomotion was episodic, occurring in bouts with intervening quiescent periods.  PEA 
activated alternating locomotor-like activity (n=3/3).  Also similar to the in vitro, the legs 
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alternated between periods of rhythmic leg movements and quiescent periods.  In 
comparison, tryptamine produced adduction / hyperflexion (n=2/2), which was 
accompanied by very slow alternating leg movements that were ~0.2 Hz.  These studies 
support TA actions on spinal motor systems independent of descending monoaminergic 
systems. 
4.4.5 Transport inhibitors attenuate trace amine and dopamine induced bursting  
The monoamine transporters, SERT, DAT, and NET, are expressed in monoaminergic 
neurons. In spinal cord, they are located on presynaptic descending aminergic axon 
terminals, but not in spinal neurons. These transporters are responsible for both 
monoamine and TA uptake.  To examine whether the motor actions of the TAs observed 
here require transport via monoamine transporters, I examined their actions in the 
presence of monoamine transport inhibitors: Citalopram, a SERT Inhibitor; Bupropion, a 
DAT Inhibitor; and Clomipramine, a SERT and NET Inhibitor] Figure 4.6). 
Application of the transport inhibitors alone did not change motor activity. 5-HT 
(n=3/3) and NA (n=4/4) produced similar motor patterns both before and after transport 
inhibitor application.  In comparison, the motor patterns for DA and the TAs were 
attenuated and variably affected (Figure 4.6).  There was a trend toward decreasing 
frequency for all the TAs and DA (Figure 4.7A), which reached statistical significance 
when the TAs and DA were pooled (p<0.05).  Burst amplitude was significantly reduced 
after application of the transport inhibitors for NA, tryptamine, and tyramine (Figure 
4.7B; p<0.05) with a trend toward reduction for octopamine (p=0.08).  There was also a 
trend towards a reduction in total number of induced bursts for the TAs and DA 
(Figure4.7C).  The effect was significant for octopamine (p<0.05).  For all applied 
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Figure 4.6: The monoamine transport inhibitors preferentially depress trace amines and dopamine 
modulatory actions.  
The monoamines and TAs were applied in the presence of NMDA before and after the transport inhibitors 
[1 µM Citalopram, a SERT Inhibitor; 1 µM Bupropion, a DAT Inhibitor; 5 µM Clomipramine, a SERT and 
NET Inhibitor].  The waveforms show before transport inhibitors on the left and after transport inhibitors 
on the right. The patterning of 5-HT and NA remained similar before and after transport inhibitors, 




Figure 4.7: Effects of monoamine transport inhibitors on bursting properties 
A. There was a trend toward reduced burst frequency in the presence of the TAs and DA, which when 
pooled attained statistical significance.   B. There were significant decreases in the peak amplitude for NA, 
tryptamine, and tyramine.  The percent change is in reference to before the addition of the transport 
inhibitors. C. There was a trend toward a reduced number of evoked motor bursts in the presence of the 
transport inhibitors which reached statistical significance for octopamine. (* indicates p<0.05). 
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neurochemicals, there was a trend for longer times to initiate bursting in the presence of 
transport inhibitors.  Only for NA was this significant (p=0.02).  However, if all TAs and 
DA were pooled, significance also emerges (p<0.05). 
Overall, it appears that unlike 5-HT and NA, the action of TAs and DA were 
attenuated after block of intracellular transport.  This suggests that TA and DA transport 
into presynaptic terminals contributes to the bath application-induced motor activity, but 
that the bursting is partially independent since bursting remains following transporter 
inhibition. 
4.4.6 Trace amines can be transported into spinal neurons by a Na+-independent 
mechanism  
In the previous chapter, I found that spinal neurons increased cytoplasmic expression 
levels in spinal neurons. To confirm this and determine whether the uptake was NA+-
dependent or Na+-independent, spinal cords were incubated in control aCSF, control 
aCSF in the presence of TAs, or TAs in a solution having nominally zero Na+ aCSF.  
Qualitative increases in the immunolabeling of the TAs suggested that the TAs were 
taken up in a Na+-independent manner (Figure 4.8).  Importantly, since the monoamine 
transporters SERT, DAT, and NET are all Na+-dependent (Torres et al. 2003) and not 
produced in the spinal cord (Allen_Spinal_Cord_Atlas 2009), uptake in zero Na+ must be 
by other mechanisms.  Three families of Na+-independent transporters are known to 
transport TAs across the plasma membrane in the spinal cord.  These are the L-type 
amino acid transporters (LATs), the organic cation transporters (OCTs), and the plasma 
membrane monoamine transporter (PMAT) (Appendix Figures A.6-7) 
(Allen_Spinal_Cord_Atlas 2009).  
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Figure 4.8: The trace amines were transported into spinal neurons by a Na+-independent mechanism  
Apparent increase in TA expression following pre-incubation in TAs.  Presented are low-power 
photomicrographs of a 10 µm section showing a complete hemicord.  The isolated cords of P2 littermates 
were incubated in one of 3 different treatments for 2 hours: (1) control aCSF, (2) control aCSF in the 
presence of TAs, or (3) TAs in a solution having nominally zero Na+ aCSF.  Note that TA transport was 
Na+-independent and thus independent of the monoamine transporters. 
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4.4.7 Trace amines and dopamine actions have much slower kinetics of activation 
Given the intracellular location of the TAARs and that the TAs may need to be 
transported into the neurons to be activated, I compared the time to burst onset after bath 
application of the TAs and monoamines in the presence of NMDA (Figure 4.9).  5-HT 
(n=12) and NA (n=4) had rapid burst onset with medians of 7.5 and 2.5 seconds 
respectively.  In comparison, it took dramatically longer for DA (480 seconds, n=4), 
tryptamine (300 seconds, n=5), tyramine (300 seconds, n=7), octopamine (300 seconds, 
n=5), and PEA (540 seconds, n=3) to initiate bursting (all are p<0.05).  That the time to 
initiate bursting was longer for the TAs and DA indicates that they are not acting 
predominantly at classical plasma membrane monoaminergic receptors.  Behaviorally, it 
would appear that the TAs would not be recruited to initiate descending commands for 
burst initiation. Rather it seems their recruitment is more consistent with modulation of 
ongoing activity. The actions of the TAs during ongoing 5-HT-induced locomotion are 
explored in Chapter 5. 
4.4.8 Differences in methysergide sensitivity to activity block 
Methysergide is a 5-HT1, 5-HT2, 5-HT7 and tryptamine binding site antagonist.  To 
test whether the TAs and monoamines bound the receptor sites with similar affinities, 
methysergide was added to TA and monoamine–induced rhythms (with NMDA) at 
progressively increasing doses.  Concentration dependent differences were discovered 
(Table 4.1).  Tryptamine was by far the most sensitive with 1 µM of methysergide 
always stopping locomotion.  Methysergide generally blocked 5-HT locomotion at 2 µM.  
In comparison, tyramine and octopamine were more insensitive to methysergide, while 
PEA, NA, and DA were methysergide insensitive even at the highest dose tested (10  
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Figure 4.9: Differences in time to burst onset of bursting between the monoamines and trace amines. 
DA and the TAs take a significantly longer time to initiate bursting than 5-HT and NA.  The time was 
defined as the time it took to initiate bursting after the drugs were added (always in the presence of 
NMDA).  The box-and-whisker plots show the time it takes to initiate bursting.  The black line is the 
median. Outliers were defined as more than 1.5 times the interquartile range.  An outlier for tryptamine at 
1800 seconds is not shown. (* indicates p<0.05). 
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µM).  Based on methysergide sensitivity it appears likely that tyramine, octopamine, and 
PEA do not act predominantly on the 5-HT receptors implicated in locomotion, while 
tryptamine may act either at a tryptamine binding site, possibly TAAR4, or at 5-HT 
receptors. 
Table 4.2: Methysergide blocks tryptaminergic bursting.   
The number of animals in which locomotion was blocked following methysergide administration in the 
presence of the listed drug and NMDA. 
 Total Methysergide 
Drug 1µM 2µM 5µM 10µM 
5-HT 2 / 8 5 / 5   
tryptamine 6 / 6    
tyramine 1 / 6 0 / 5 2 / 5 0 / 3 
octopamine 0 / 3 0 / 3 1 / 3 0 / 2 
PEA 0 / 3 0 / 3 0 / 3 0 / 3 
noradrenaline 0 / 4 0 / 4 0 / 4 0 / 4 
dopamine 0 / 6 0 / 4 0 / 4 0 /4 
 
4.5 Discussion 
I have shown that the TAs have distinct actions on the spinal motor circuitry.  
Tryptamine, tyramine, octopamine, and PEA all recruited locomotor-like patterns similar 
to that observed for 5-HT as well as more complex episodic patterning.  Both continuous 
and episodic locomotor phenotypes could be observed within individual animals 
indicating that the episodic pattern involves activation of additional cellular/network 
interactions that influence the output of the spinal locomotor central pattern generator.  
I have shown evidence that the TAs are likely having actions both at descending 
terminals of monoaminergic neurons, as well as in spinal cord neurons.  The high-affinity 
Na+-dependent monoamine transporters NET, DAT and SERT, are found only on 
descending adrenergic, dopaminergic and serotonergic terminals, respectively.  As 
monoamine transport inhibitors attenuated the action of the TAs on the motor system, TA 
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uptake into descending terminals contributes to the observed response.  However, as 
responses were not abolished and rhythmicity persisted, additional TA effects must be 
due to actions at other sites.  Further, support of TA actions occurring independent of 
descending monoaminergic systems was provided with in vivo i.p. TA administration 
experiments in rats having undergone chronic mid-thoracic cord transection.  Under these 
conditions, all TAs tested induced rhythmic hindlimb motor activity, strongly supporting 
TA-induced actions via intrinsic modulation of spinal neural networks.  While it is 
possible the TA actions on spinal circuits are secondarily due to unknown TA action on 
peripheral primary afferent receptors, the similarity in patterning seen to that in the in 
vitro isolated spinal cord makes this unlikely.  
One possible means of TA actions is via activation of TAAR receptors, as I have 
shown that TAAR1 and TAAR4 receptors are found intracellularly in spinal neurons (see 
Chapter 3).  To activate the intracellular receptors, the TAs must be transported into the 
neurons.  However, spinal neurons lack the Na+-dependent monoamine transporters 
known to transport TAs.  To demonstrate that alternate routes of transport exist for spinal 
neurons, I showed that TAs can be transported into spinal neurons in the absence of 
external Na+, supporting the presence of Na+-independent transport mechanisms in spinal 
neurons.  Indeed, as shown in the Allen Institute in situ hybridization studies provided in 
the Appendix figures, multiple Na+-independent transporters, including LATs, OCTs and 
PMAT, have been shown to transport PEA, tyramine, and tryptamine and the are widely 
expressed in the spinal cord. Based on these data, an intrinsic TA transport system for 
spinal neurons seems highly likely.   
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4.5.1 Trace amines can induce motor activity and rhythmic locomotor bursting 
patterns 
When applied alone, the monoamines, tryptamine, and tyramine increased motor 
activity, including excitatory actions on motoneurons.  This agrees with a previous study 
showing that tyramine can act directly on motoneurons (Kitazawa et al. 1985).  NA 
action of motor activity was significantly reduced following synaptic isolation, 
supporting a more prominent NA-induced activity derived from premotoneuronal actions. 
PEA is an agonist at both TAAR1 and TAAR4 (Borowsky et al. 2001; Bunzow et al. 
2001), and therefore, the prediction would be that it would facilitate motor activity.  
However, no overt actions were observed.  One possibility is that PEA is also acting on 
one of the other TAARs whose ligand has yet to be determined and which are Gi-
coupled.  Another possibility is that PEA has currently unstudied actions on classical 
monoamine receptors which are Gi-coupled (e.g. 2-adrenergic) and compete with 
TAAR1 and TAAR4 Gs-coupled activity. 
Application of 5-HT, NA, and DA are each known to produce signature patterns of 
rhythmic motor activity when applied alone.  I found them to produce rhythmic motor 
activity similar to those previously reported (Barriere et al. 2004; Cazalets et al. 1990; 
Cowley and Schmidt 1994a; Kiehn and Kjaerulff 1996; Kiehn et al. 1999; Sqalli-
Houssaini and Cazalets 2000).  However, I also saw a pattern not reported for DA where 
the high frequency bursting was overlaid by a second slower bursting frequency (Figure 
4.1D).  Both DA frequencies observed were within the range found previously (Kiehn 
and Kjaerulff 1996).  Like the monoamines, the TAs, tyramine, octopamine, and 
tryptamine, but not PEA, can recruit rhythmic motor patterns and with distinctive 
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appearance.  Tyramine and tryptamine produced patterns of long and variable cycle 
periods whereas octopamine had a much shorter cycle period.   
4.5.2 Trace amines produce continuous and episodic rhythmic bursting patterns 
when added with NMDA 
NMDA is commonly used to stabilize 5-HT induced locomotor–like activity (Kiehn et 
al. 1999; Kjaerulff and Kiehn 1996; Sqalli-Houssaini et al. 1993).  The use of NMDA as 
an adjunct neuroexcitant to facilitate TA and monoamine-induced rhythmical motor 
behavior in complicated by the fact that it can activate locomotion by itself at higher 
doses, and even at the doses I used as reported by other labs (e.g. (Beato and Nistri 1998; 
Bracci et al. 1998)).  Regardless, there is well documented inter-strain and intra-strain 
differences in spinal cord function (Shay et al. 2005), and I emphasize that the doses I 
used here never activated locomotion in my studies.  Moreover, it is clear that there is a 
complex interplay between 5-HT and NMDA receptors in motor rhythm generation 
(MacLean et al. 1998). 
Here, in the presence of sub-locomotor concentrations of NMDA, the TAs produced 
locomotor-like activity similar to 5-HT suggesting that the TAs can recruit either the 
same pattern-generating circuits or different circuits that lead to the same output.  Based 
on flexor/extensor and left/right coordination during the continuous locomotor-like 
pattern, it is very likely that the TAs are acting on neurons at the level of the central 
pattern generator (CPG) to produce the patterning.  The TAs also produced episodic burst 
patterns.  Whelan et al (2000) reported spontaneous episodes of rhythmic ventral root 
activity in the mouse very similar to those seen here (Whelan et al. 2000).  This supports 
the observed TA-induced episodic pattern of motor activity as a physiologic pattern also 
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recruited by endogenous mechanisms.  Speculation on behavioral relevance is in the 
discussion of Chapter 5. 
Both continuous and episodic locomotor phenotypes could be observed within 
individual animals indicating that the episodic pattern involves activation of additional 
cellular/network interactions that influence the output of the spinal locomotor central 
pattern generator.  Assuming that these different modulatory actions were due to actions 
at distinct spinal cord sites, there are three possible levels of network neurons that could 
be affected by tyramine, octopamine, and PEA to give the unique episodic patterns 
(Figure 4.10).  In all cases in Figure 4.10, it was assumed that the regular locomotor-like 
activity pattern was produced at the CPG level by the TAs (Figure 10A).  The first level 
where the modulation could be occurring would be in neurons that project onto the CPG 
(Figure 10B, left circuit).  These neurons could produce an alternation of excitatory and 
inhibitory drive to the CPG, thus causing the waxing and waning of activity.  The second 
level where the modulation could be occurring would be in neurons within the CPG 
where both slow episodic events and locomotor rhythmicity co-exist (Figure 10B, middle 
circuit).  For example, rhythms at locomotor frequency could be associated with synaptic 
network interactions while a second slower modulation of neural excitability could be via 
non-synaptic somatic biochemical pathways (Katz and Clemens 2001).  As the slow 
rhythm changes, locomotor frequency changes (e.g. Figure 4.4E).  The third level where 
the modulation could be occurring would be in neurons downstream of the CPG (Figure 
10B, right circuit).  For example, motoneurons can enter high conductance states 
(Heckman et al. 2003; Kiehn 1991).  Conceivably, a high conductance state may be 



































































Figure 4.10: continued 
Both the monoamines and the TAs were able to produce continuous bursting, while tryptamine, tyramine, 
octopamine, and PEA additionally produced episodic bursting.  Continuous locomotion is depicted in panel 
A, and putative episodic locomotor circuits are shown in panel B.  There are three possible levels of TA 
actions that could result in unique episodic patterns.  The first level where the modulation could be 
occurring would be neurons that project onto the CPG.  The second level where the modulation could be 
occurring would be in neurons within the CPG where two events co-exist with distinct time courses.  The 
third level where the modulation could be occurring would be in neurons downstream of the CPG (e.g. 
motoneurons).   
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 motor output (Alaburda et al. 2005; Prescott et al. 2006; Raastad et al. 1996).  In this 
case, locomotor frequency would be unchanged, but amplitude would alternate between 
more excitable and less excitable states.  I think that since there appears to be 
coordination between the bouts of bursting across flexors/extensors and left/right 
alternation, that the first two possibilities are more likely. 
Reith and Sillar (1998) observed episodic locomotor rhythms in Xenopus larvae with 
5-HT and NMDA which was associated with a ‘slow’ NMDA receptor dependent 
motoneuron membrane bistability.  However, their ‘slower’ modulatory rhythm (~0.5 
Hz) is comparable to frequencies of NMDA receptor-induced oscillations in neonatal rat 
motoneurons (Hochman et al. 1994b; MacLean et al. 1997) and orders of magnitude 
faster than the slow rhythms here (~0.013 Hz).  NMDA receptor dependent oscillations 
of comparable frequency to those observed here are more consistent with that seen in 
medial intermediate grey interneurons (Hochman et al. 1994a) and so would be more 
consistent with actions occurring in spinal interneurons.   
4.5.3 Dopamine can produce fast and slow rhythms simultaneously 
The observation that both a slow rhythm and normal locomotor rhythm can be 
observed simultaneously has important implications regarding the organization of the 
CPG.  First, it suggests that, as with larval zebrafish (McLean et al. 2007), there are two 
distinct CPGs with network connectivity consistent with a coordination required for 
locomotion.  Thus, the presumption that V1 interneurons are responsible for locomotor 
speed but not locomotor CPG operation may be incorrect (Gosgnach et al. 2006).  
Instead, it is seems possible that genetic deletion of the V1 interneurons was actually 
essential for the fast locomotor CPG, and in its absence, the slow rhythm with locomotor-
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like coordination becomes predominant.  Here, it is possible that DA activated two 
distinct neuronal interneuron populations; both a fast CPG and a slow rhythm generator 
whose outputs were integrated.  That both rhythms have not been previously reported to 
be observed concurrently suggests that under normal conditions these circuits may be 
mutually inhibitory.  In this regard, they may related to the observed short- and long-
latency flexor reflex afferent (FRA) pathways observed with administrations of L-dopa in 
the cat (Jankowska et al. 1967; Lundberg 1969).  FRA pathways represent higher 
threshold afferent-evoked reflex pathways. Afferents involved include group II-IV 
muscle, joint, and high threshold cutaneous afferents.  It has been shown that following 
intravenous administration of L-dopa in the acute spinal cat, short-latency FRA pathways 
that normally produce the flexion reflex are depressed and longer-latency pathways 
emerge that are associated with the production of spinal stepping (Jankowska et al. 1967).  
While it has been assumed that L-dopa acted by increasing NA, the present observations 
with DA support a contribution of dopaminergic mechanisms in this switch as well, given 
that both tend to recruit the slower rhythms.  It is also possible that the slow rhythms 
occasionally seen with the TAs in the absence of NMDA activate the same slow CPG 
recruited by NA and DA in the presence of NMDA. Additional studies are required to 
examine these interactions at the synaptic, cellular and network level. 
4.5.4 Trace amines can cause locomotor-like behavior in transected neonates 
Assuming that the duration of spinalization was sufficient to permit complete or near-
complete degeneration of descending monoaminergic terminals, the observation that i.p. 
administered TAs were capable of evoking robust and consistent rhythmical hindlimb 
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movements in previously spinalized animals provides the strongest evidence that TAs can 
modulate function independently of  monoamine transmitter release.  
 It could be argued that the injected doses of TAs (50 mg/kg) were not within 
therapeutic dose range. It is difficult to estimate the circulating levels of injected drugs 
without formal quantitative study. This could be done using high performance liquid 
chromatography and mass spectrometry or negative chemical ion gas chromatography 
and mass spectrometry (Durden and Davis 1993). Based on similarity of actions to the in 
vitro studies it is not unreasonable to assume that these injected doses lead to 
concentration in the high µM range (e.g. 50-250 µM).  The injected doses chosen were 
based on those used by others (Borison et al. 1977) and so may have clinical relevance  
for subsequent pharmacological approaches aimed at modulating motor function after 
spinal cord injury.   
4.5.5 Transport inhibitors attenuate trace amine and dopamine induced bursting  
Two differences common to all TAs were their slow onset time and sensitivity to the 
transport inhibitors.  Both differences support a requirement for the TAs to be transported 
across the membrane prior to having biological action.  The 5-HT, DA, and NA 
transporters SERT, DAT, and NET respectively, are symporters that move these 
monoamines across the cell membrane by coupling their movement to the movement of 
Na+ down its concentration gradient.  In the spinal cord, only descending monoaminergic 
axons contain the monoamine transporters.  Indeed, the Allen Institute in situ 
hybridization studies in spinal cord show an absence of SERT, DAT, and NET 
expression in either neonatal or adult spinal cord neurons (Appendix Figure A.4A); 
therefore, in my experiments, the attenuation of motor activity in the isolated spinal cord 
 121
caused by the transport blockers is likely via prevention of TA entry into descending 
monoaminergic nerve terminals.  However, we cannot exclude the possibility that the 
transport blockers had actions at other sites, including at Na+-independent transporters on 
spinal neurons (discussed below) (Haenisch and Bonisch 2010). 
Xie et al. (2007) found that TA uptake is facilitated by monoamine transporters, and 
that such uptake greatly enhances activation of TAAR1 in HEK cells (Xie et al. 2007).  
Further, when TAAR1 was co-expressed with monoamine transporters in HEK cells, 
PEA activation of TAAR1 inhibited uptake and increased efflux of the monoamines, 
which did not occur when only the monoamine transporters were expressed (Xie and 
Miller 2008).  Since it has been reported that TAs can facilitate monoamine transmitter 
efflux in the CNS via reverse transport (Paterson et al. 1990; Sulzer et al. 2005), it seems 
likely that TAARs play an important modulatory role in regulating monoamine 
transporter function.  Therefore, one very plausible site for TAs actions is on presynaptic 
descending terminals by causing monoamine efflux (Figure 4.11).  Based on the above, 
such release may depend on the descending systems expressing TAARs. Once the 
monoamines have been released they can act at receptors on the postsynaptic neuron.  For 
tryptamine, transport across SERT and activation of TAAR4, for which it is an agonist 
(Borowsky et al. 2001), could lead to 5-HT release with subsequent 5-HT receptor 
activation mediated induction of locomotion.  Like 5-HT, tryptamine-induced locomotion 
is blocked by methysergide, so efflux of 5-HT from descending monoaminergic axons 
may explain the observed actions of tryptamine.  It is important to note however that even 
after complete inhibition of monoamine transport with inhibiters, TA actions including 
those of tryptamine remained albeit attenuated (Figure 4.6 and 4.7). I conclude that 
 122
while TA induced monoamine efflux contributes to the observed motor actions, TAs are 
also binding at sites independent of descending monoamine presynaptic terminals.   
There is evidence that at least PEA has actions both at DAT and independent of DAT.  
Sotnikova et al (2004) looked at the effects of PEA in wildtype, heterozygous, and DAT 
knockout mice.  PEA produced pronounced striatal DA release in wildtype mice, but no 
DA release was detected in DAT knockout mice.  Behaviorally, PEA produced a strong 
transient increase in locomotion in wildtype and heterozygous mice, whereas in knockout 
mice, PEA acted as a potent depressant (Sotnikova et al. 2004).  
It was unexpected that DA had actions resembling those of the TAs.  Both the slow 
onset time and sensitivity to transport inhibitors of DA support a requirement for the DA 
to be transported across the membrane prior to having biological actions.  Since 
dopamine receptors are thought to exert their actions on the plasma membrane, and there 
is no evidence that they are active once internalized, DA actions could be via activation 
of TAARs.  Indeed, it is known that the monoamines also bind to TAAR1, although at 
lower affinity (Borowsky et al. 2001; Bunzow et al. 2001).  In HEK cells co-expressing 
DAT and TAAR1, at high enough concentrations, DA halts DA uptake and initiate DA 
efflux starting around 3 minutes of incubation.  This was not seen in cells expressing only 
DAT (Xie and Miller 2007).  This suggests that DA transport across DAT and subsequent 
activation of TAARs similarly to the TAs, and would be consistent with the common 
actions observed between DA and the TAs in the Results section above.   
4.5.6 Possible trace amines actions on monoamine receptors 
In addition to the presynaptic actions just described, the TAs are likely acting on 
postsynaptic neurons as well.  Since the TAs are structurally similar to the classical 
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monoamines and the TAARs have a high homology to the monoamine receptors 
(Borowsky et al. 2001), the possibility must be considered that the TAs are acting as 
agonists to the monoamine receptors in the spinal cord.  Tryptamine directly activates 
5HT2 and 5HT7 receptors (Boess and Martin 1994), on which 5-HT induced locomotion 
is dependent (Liu et al. 2009; Liu and Jordan 2005; Madriaga et al. 2004).  This would 
explain why tryptamine and 5HT locomotion appear the same.  It is also consistent with 
its sensitivity to block with methysergide.  In comparison to tryptamine, all other TAs 
appear to have very low affinity to the monoamine receptors tested, such that the applied 
doses would not be expected to have direct actions on monoamine receptors (Peddi et al. 
2003; Shen et al. 1993; U'Prichard et al. 1977).  
4.5.7 Evidence supporting trace amine uptake by Na+-independent transporters 
While inhibition by monoamine transport inhibitors attenuated TA bursting, it did not 
abolish it, suggesting that the TAs are acting at sites in the spinal cord other than just the 
presynaptic descending monoaminergic terminals.  Incubation of spinal cords in TAs and 
zero Na+ aCSF showed that the TAs can be transported into spinal neurons via a Na+-
independent mechanism, strongly supporting the presence of Na+-independent TA 
transporters.  Three families of Na+-independent plasma membrane transporters, LATs, 
OCTs, and the PMAT, have been shown to transport TAs across the plasma membrane.  
They are widely expressed in the spinal cord according to the in situ performed by the 
Allen Institute for Brain Science (Appendix Figure A.5 and Figure A.6) 
(Allen_Spinal_Cord_Atlas 2009), providing an intrinsic substrate for independent actions 
within spinal neurons (Figure 4.11).  Importantly, as transport across these transporters is 
bidirectional, the TAs can be synthesized and effluxed.  In this scenario, observed TA 
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selectivity and expression patterns would depend on levels of available substrate 
(aromatic amino acids), circulating TAs, synthesis enzymes (AADC and DBH), 
degradative/metabolic enzymes (MAOA, MAOB, and PNMT), and presence of 
membrane transporters. 
There are three OCTS (OCT1-3), all of which can transport tyramine (Schomig et al. 
2006).  There are four LATs (LAT1-4).  The LATs preferentially transport amino acids, 
including the aromatic amino acid precursors (Babu et al. 2003; Bodoy et al. 2005).  
Additionally, LAT3 transports PEA (Babu et al. 2003).  Moreover, both tyramine and 
tryptamine are transported by PMAT.  PMAT transport affinity order for the TAs and 
monoamines were: tryptamine > serotonin > dopamine > tyramine with NA and 
adrenaline having very low (millimolar) affinity binding to PMAT (Engel and Wang 
2005).  Importantly, it is possible that the transport inhibitors used in this study are 
having actions at PMAT, as PMAT is inhibited by commonly used monoamine transport 
inhibitors, albeit at lower affinity (Haenisch and Bonisch 2010).  In particular, I used 
citalopram, whicht has a much higher affinity to SERT than sertraline, currently the most 
potent PMAT transport blocker of the antidepressants tested (Ki = 5 µM) (Haenisch and 
Bonisch 2010).  Future studies on the effects of known inhibitors of PMAT on TA 
modulation should be undertaken to support their role in observed TA and monoamine 
neuromodulatory actions (e.g. cimetidine).  
4.5.8 Possible mechanism for trace amine actions in the spinal cord 
It seems highly-likely that the TAs are exerting at least part of their observed actions 
through the TAARs, since the TAs and the TAARs are found in similar locations in the 
spinal cord and both TAAR1 and TAAR4 are activated by TAs.  The TAs must be found 
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intracellularly to act on the intracellular TAARs.  I showed in Chapter 3 that TAAR1 and 
TAAR4 are present in spinal neurons.  There are two ways that the TAs could be found in 
spinal neurons (Figure 4.11).  First, they could be made in AADC-expressing spinal 
neurons from aromatic amino acids precursors.  Second, they could be transported there.  
Transport presynaptically into descending monoaminergic neurons is likely via the 
monoamine transporters, which when blocked here, attenuated rhythmic bursting.  
Postsynaptically, transport is likely via the LATs, OCTs, and PMAT, which are all Na+-
independent.  This is consistent with the incubation experiments here where I showed that 
uptake into neurons was Na+-independent, as well as with electrophysiological studies 
where I showed a slow activation time.  While transporter mechanisms dominate when 
TAs are bath applied to the spinal cord, endogenous actions are more likely dominated by 
autocrine TA synthesis in neurons having AADC and TAARs as well as paracrine actions 
in local neurons having TAARs via transport across bidirectional Na+-independent 
transporters. 
   Presynaptically, once the TAs are in the neurons, they likely act on TAARs, which lead 
to modulation of neuronal function that induces an efflux of monoamines into the 
synapse.  This efflux is consistent with reports that the TAs can facilitate monoamine 
transmitter efflux in the CNS via reverse transport (Paterson et al. 1990; Sulzer et al. 
2005).  Extracellular TAs could also have action on presynaptic monoamine receptors. 
Postsynaptically, there are two major routes by which the TAs actions could lead to 
modulation of neuronal function.  First, they could act on TAARs and modulate neuronal 
function by altering signal transduction pathways.  Second, extracellular TAs could act 




Figure 4.11: Possible intracellular mechanism for trace amine actions 
The TAs could be having actions both pre and post-synaptically.  It is possible for them to be both made 
and transported into both neurons.  Once inside, the TAs could be having effects on intracellular TAARs.  
Presynaptically, it appears that the activation of the TAARs could lead to an efflux of monoamines.  This 
efflux of monoamines can lead to activation of monoamine receptors on the postsynaptic neuron, which can 
lead to intracellular signaling that can activate the phosphorylation of AADC and an increase in TA 
production.  This increase in TAs could activate TAARs, hence leading to modulation of neuronal function.  
What exactly this modulation is has yet to be determined, but one likely possibility is that it is refining or 
reinforcing the output of the neuron.  Currently, octopamine transport has not been tested at these 
transporters. 
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   It also seems likely that activation of conventional monoamine receptors interacts with 
TA signaling. For example, previous reports suggest that the monoamine receptors, 5-
HT2, 5-HT7, D1, and α1, are involved in mediating actions on the locomotor network 
(Gabbay and Lev-Tov 2004; Liu et al. 2009; Liu and Jordan 2005; Madriaga et al. 2004).  
Activation of these receptors leads to downstream signal transduction pathways capable 
of phosphorylating AADC, which increases the activity of AADC and increases the 
levels of the TAs (Berry 2004; Duchemin et al. 2000; Duchemin et al. 2010; Neff and 
Duchemin 2002). In this manner, monoaminergic action could lead to subsequent 
modulation of intrinsic spinal function via enhanced activation of the TAARs. 
5-HT7 and D1 both activate the Gsα subunit, which stimulates adenylate cyclase (AC) 
to produce cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). 
cAMP, a second messenger, activates protein kinase A (PKA, cAMP-dependent protein 
kinase) (Gervasi et al. 2007), and PKA phosphorylates AADC (Duchemin et al. 2000).   
5-HT2 and α1 both activate the Gqα subunit, which stimulates phospholipase C (PLC) 
to hydrolyzes phosphatidylinositol 4,5-biophosphate (PIP2) into two second messengers, 
diacyl glycerol (DAG) and inositol triphophate (IP3).  IP3 causes the release of calcium 
from intracellular stores, leading to the activation of Calcium/calmodulin-dependent 
protein kinase type II (CaMKII) (Dash et al. 2007).  CaMKII phosphorylates AADC 
(Neff and Duchemin 2002). 
Currently, the role of the TAARs in the spinal cord is unknown.  However, it is known 
that they that they are Gαs-coupled proteins able to activate cAMP (Borowsky et al. 2001; 
Bunzow et al. 2001).  There are a number of classes of downstream substrates which 
cAMP signaling can activate including transcription factors, voltage-gated ion channels, 
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ion pumps, and neurotransmitter receptors, all of which are candidates after TAAR 
activation (Greengard 2001).   
An interesting and very plausible role for the anatomical substrate created by the 
widespread expression of AADC, the TAs, and the TAARs would be as an activity 
amplifier / reinforcement mechanism.  Changes in excitability observed could be based 
on AADC activity and TAAR activation.  Such a role would support a tight 
interdependence of the TAs with the monoamines on spinal motor function.  If true, the 
the TAs may predominantly serve a downstream role of refinement of monoamine-
induced locomotor pattern, not necessarily the initiation of it.  This implies that the 
monoamines and the TAs work together, but that each has its own role.   
It is important to emphasize that in this scenario, other pathways independent of the 
monoamine and their receptors that also co-activate the same signal transduction 
pathways could also recruit the TAARs leading to the unique intrinsic modulatory actions 
of the TAs.  
4.5.8.1 Possible mechanism for contribution by NMDA in vitro  
As many of my in vitro experiments also used NMDA, intracellular cascades 
following NMDA receptor activation could also potentially increase TA levels. NMDA 
receptor activation-induces Ca2+ entry into the neurons, which activates CaMKII and 
nitric oxide synthase (NOS) (Matsumura et al. 2010) (Figure 4.12).  CaMKII 
phosphorylates AADC (Neff and Duchemin 2002).  NOS produces nitric oxide (NO), 
which can lead to inhibition of MAO activity (Muriel and Perez-Rojas 2003), and thereby 
reducing TA degradation.  Further, NO leads to the activation of cGMP-dependent 
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protein kinase (PKG) (Schlossmann and Hofmann 2005), which can then phosphorylate 
AADC (Duchemin et al. 2010) and lead to modulation of neural function. 
Another important role for NMDA to consider is that there may be a critical activity 
level which a neuron needs to reach for the TA modulatory actions to be significantly 
altered, and adding NMDA to the bath may help the neuron to achieve this level. 
4.5.9 Conclusions 
Overall, the present work has laid the groundwork for understanding the complex 
interplay between the well established role of the monoamine transmitters and the 
existence of a more diffuse, more variable, more modifiable class of structurally related 
neuromodulatory amines.  Based on the distribution of transporters, the synthesis enzyme 
AADC, and the TAAR receptors, these so called ‘trace’ amines appear capable of 
exerting profound neuromodulatory actions.  
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Figure 4.12: Possible mechanism for contribution by NMDA 
 When NMDA activates the NMDA receptor, it can set off and intracellular cascade that can lead to 
modulation of the TAs.  Increasing intracellular levels of Ca2+ leads to activation of CaMKII and PKG, 
which can phosphorylation of AADC, which increases activity of AADC and hence production of the TAs.  
The TAs can then activate TAARs, leading to modulation of neural function.  Further, NOS produces NO, 





CHAPTER 5  
MODULATORY ACTIONS OF THE TRACE AMINES ON 
HINDLIMB MOTOR COORDINATION 
5.1 Abstract 
In the previous chapter, I showed that when recording from ventral roots, the trace 
amines (TAs), in the presence of NMDA, can produce a continuous locomotor pattern as 
well as a unique episodic rhythm characterized by bouts of rhythmic bursting.  Here, 
using the in vitro isolated spinal cord with attached hindlimbs to record 
electromyographic (EMG) activity from various hindlimb muscles, I found that that the 
TAs induced the previously observed continuous and episodic locomotor patterns as well 
as previously undescribed episodic bursting phenotypes.  There were differences in 
phasing as well as amplitude when comparing the TAs to 5-HT.  
When the TAs were applied during ongoing 5-HT/NMDA locomotion, all TAs except 
for tryptamine increased frequency, and all TAs except for PEA increased L2 ventral root 
amplitude.  The most pronounced effects in patterning to 5-HT locomotion were to a 
subgroup of tyramine and octopamine applications where dramatic changes were 
observed.  By recording from both ventral roots and muscles, the EMG recordings 
revealed patterns that were undetected by the ventral root alone, demonstrating that 
ventral root activity can be an inaccurate reflection of the actual motor patterns generated.  
Overall, I conclude that the TAs increase the strength and frequency of ongoing 5-HT 
locomotion while also being capable of modifying the rhythmic motor pattern generated.  
5.2 Introduction 
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The spinal cord contains all of the necessary circuitry at birth to produce complex 
motor outputs including locomotor patterning (Grillner 1981).  In the isolated in vitro 
neonatal rodent spinal cord, many different neurochemicals have been used to induce 
locomotor-like activity (LLA) patterns, which can be characterized as left/right and 
ipsilateral alternation of bursts between flexors and extensors (Kiehn and Kjaerulff 1998; 
Sqalli-Houssaini et al. 1993).  Locomotor-inducing neurochemicals include serotonin (5-
HT), noradrenaline (NA), dopamine (DA), excitatory amino acids, acetylcholine, N-
methyl-D-aspartate (NMDA), glutamate, acetylcholine, (Barbeau and Rossignol 1991; 
Cazalets et al. 1990; Cazalets et al. 1992; Cowley and Schmidt 1994a; Kiehn and 
Kjaerulff 1996; Kiehn et al. 1999; Kudo and Yamada 1987; Sqalli-Houssaini and 
Cazalets 2000) and most recently my work with the trace amines (TAs) (see previous 
chapter). 
The TAs, named for their low endogenous concentrations in mammals, are a family 
of endogenous amines with structural, metabolic, physiological, and pharmacological 
similarities to classical monoamine neurotransmitters (Saavedra 1989).  The TAs include 
tryptamine, tyramine, octopamine, and β-phenylethylamine (PEA).  In chapter 3, I found 
that an anatomical substrate exists for the TAs to be produced in the spinal cord, and then 
in chapter 4, I found that the TAs can produced rhythmic bursting patterns.  Using ventral 
root recordings in the isolated spinal cord preparation, the TAs in the presence of NMDA 
can produce both a continuous LLA pattern similar to 5-HT and NMDA as well as an 
episodic pattern characterized by bouts of activity with intervening quiescent periods.  
The episodic bouts of bursting had a locomotor-like pattern and frequency statistically 
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indistinguishable from the continuous LLA pattern.  The quiescent periods had relatively 
low activity and no bursting. 
While ventral root recordings offer a simple way to track the spinal motor output, 
they do not give the whole story.  Ventral root activity may not reflect recruitment of 
individual muscles (Cowley and Schmidt 1994b).  Anatomical studies have shown that 
ventral roots are actually quite heterogeneous, containing axons projecting to both flexors 
and extensors (Nicolopoulos-Stournaras and Iles 1983).  Important changes in motor 
coordination between flexor and extensor activity may be lost due to the heterogeneity of 
these roots.  It has been long known that muscle recruitment by spinal cord circuitry is 
more complicated than just simple flexor/extensor alternation.  These distinct complex 
patterns and sequential activation of muscles have been demonstrated in the in vitro 
spinal cord (Grillner 1981; Kiehn and Kjaerulff 1996).  Distinct motor patterns of 
recruited were observed between different transmitters such as 5-HT and DA as well as 
pharmacological and electrical stimulation, suggesting that the spinal locomotor network 
is flexible and that extrinsic modulation can modify the network coordination (Kiehn and 
Kjaerulff 1996; Klein et al. 2010).   
I hypothesized that TA would have distinct differentiable actions on motor pool 
recruitment during rhythmic motor behaviors and that the TAs can modulate recruited 
activity with distinct actions.  To test this, I used the in vitro isolated spinal cord with 
attached hindlimbs to record muscle activation electromyographically.  I found that the 
TAs can activate distinct motor patterns and modulate ongoing activity in complex 
fashion.  Some of these results have been presented in abstract form (Gozal et al. 2008; 
Gozal et al. 2007b). 
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5.3 Methods 
All experimental procedures complied with the NIH guidelines for animal care and 
the Emory Institutional Animal Care and Use Committee.   
5.3.1 General setup 
  Sprague-Dawley neonatal rats postnatal day 0-5 were decapitated, eviscerated, and 
the skin was removed except that covering the feet.  The preparation was placed in a bath 
containing continuously oxygenated (95% O2 and 5% CO2) high magnesium, low 
calcium artificial cerebral spinal fluid (aCSF) [containing (in mM): 128 NaCl, 1.9 KCl, 
1.2 KH2P04, 26 NaHCO3, 0.85 CaCl2, 6.5 MgSO4, and 10 glucose (pH of 7.4)].  The 
spinal cord was exposed by a ventral vertebractomy and a dorsal laminectomy.  The dura 
mater, connective tissue, and dorsal roots were carefully cut by angled scissors.  The 
ventral roots were cut rostrally down to the thoracic roots 12-13 (T12-13) or lumbar 1 
(L1), leaving the spinal cord, lumbar and sacral ventral roots, and innervated hindlimbs 
intact.  To increase superfusion to the spinal cord, the vertebral column surrounding the 
cervical and most of the thoracic spinal cord was removed.  The spinal cord and attached 
hindlimbs were immobilized ventral side upward with insect pins to a chamber with 
Sylgard on the bottom.  All dorsal roots were cut to remove the influence of afferent 
feedback on the neurochemically-induced rhythm and simplify the spinal cord output to 
reflect the changes in spinal cord circuitry due to the TAs.  Modulatory actions of the 
TAs can be inferred to reflect the actions on motor circuits.  The perfusing medium was 
then switched to the standard aCSF solution (same concentrations as above except 
MgSO4 and CaCl2 adjusted to 1.3 mM and 2.4 mM respectively).  A gravity-fed 
superfusion system that used a Cole Palmer Masterflex L/S compact pump to bring the 
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perfusate back to the upper beaker to be recirculated was used.  Later when the 
neurochemicals were added, they were added to the upper beaker.  Glass suction 
electrodes were then placed on the left lumbar 2 (l-L2) ventral root and up to 7 muscles 
of the hindlimb, after which the preparation was allowed to recover for about 1 hour 
before experimentation at room temperature.  Activity was amplified (10,000x), band-
pass filtered at 10-3,000 Hz, digitized at 5kHz (Digidata 1321A, 16-bit; Axon 
Instruments), and captured on a computer with the pCLAMP acquisition software (v8-9, 
Molecular Devices; Union City, CA).   
5.3.2 Recordings from the ventral root and muscles 
Recordings were obtained from the following muscles: tibialis anterior (TibA; ankle 
flexor), medial gastrocnemius (MGas; ankle extensor), semitendinosus (SemT; knee 
flexor / hip extensor), semimembranosus (SemM; knee flexor / hip extensor), vastus 
medialis (VasM; knee extensor), rectus femoris (RecF; knee extensor / hip flexor), and 
adductor magnus (AddM; hip adductor).  Some of the muscles (e.g. TibA) were often 
recorded bilaterally.  
The left L2 ventral root was always recorded for two reasons: for comparison of 
ventral root activity profile in relation to that obtained in the isolated spinal cord 
preparation reported above, and because its reliable recruitment allowed a common 
comparison between experiments where muscle EMG recruitment was variable.    
In 21 experiments, which always included recordings from the left L2 ventral root 
and 7 muscle EMGs, 7.1 ± 2.2 recorded channels were active at some point during the 
experiment (Table 5.1).  However in a given experiment some muscles were active only 
in the presence of a specific neurochemical.  For the channels that were inactive, I cannot 
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rule out whether there was damage to them, although I can comment that r-RecF, was the 
least likely muscle to be active in general.   




Number of experiment where 
the ventral root/muscles was 
active during at least one drug 
application 
Number of experiment from 
which the ventral root/muscle 
was recorded 













5.3.3 Motor activity and motor patterning experiments 
Rhythmic motor activity was evoked by two different types of experiments.  First, 
tryptamine, tyramine, octopamine, PEA, or 5-HT was co-applied with NMDA.  In 
experiments were the TAs and NMDA were co-applied, an application of 5-HT and 
NMDA was also performed for the sake of later comparison.  Second, 5-HT and NMDA 
were co-applied to obtain ongoing LLA, after 10-20 minutes tryptamine, tyramine, 
octopamine, and PEA were added.  Typically there were 3-7 drug co-applications per 
experiment, lasting 20-60 minutes each.  Within each experiment, the amines were 
applied in random order.  The order did not appear to affect the output.  A wash with 
aCSF was performed between all drug co-applications, lasting a minimum of 30 minutes, 
long after baseline had been reached.  Recorded files were 5 minutes long and continuous 
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from the start of the 5 minute baseline until right before the drugs were washed out of the 
bath.   
5.3.3.1 Neurochemicals 
All neurochemicals were stored in 10mM or 100mM stock solutions at -20°C and 
were thawed, then diluted into a circulating bath (100mL) to achieve the final desired 
concentration in the chamber.  The following neurochemicals obtained from Sigma-
Aldrich (St. Louis, MO) were used: 5-HT (20-50 µM), N-methyl-D-aspartate (NMDA) 
(3-5 µM), tyramine (40-100 µM), octopamine (40-100 µM), PEA (50-100 µM), and 
tryptamine (50 µM). 
5.3.3.2 Analysis 
Electrophysiological data analysis was performed using custom software, 
SpinalMOD, written in MATLAB (The MathWorks).  Frequency, peak amplitude, and 
phase were calculated.  Briefly, to calculate onset and offset of a burst, the data was 
rectified, then low-pass filtered, creating a burst envelope.  A custom algorithm was 
constructed to detect burst onset and offset.  
Typically 10 consecutive representative bursts were selected for analysis.  When 
bouts of episodic bursting contained less than 10 bursts consecutively (see Figure 5.3) 
non-consecutive bursts were selected for analysis.  In these cases, the different bouts of 
bursting were pooled.  Calculations made this way allowed for more reliable statistical 
comparisons between conditions.  In the experiments where a TA was added to ongoing 
5-HT and NMDA LLA, the 10 cycles were chosen immediately preceding TA 
application while 10 cycles after the addition of the TAs were chosen once the modified 
rhythm stabilized 
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Since the hindlimbs were pinned down and there were no movement to base timing, 
muscles are classified as flexors and extensors based on terminology from previous 
studies (Kiehn and Kjaerulff 1996).  For the phase diagrams, step cycles are defined in 
reference to the onset of the left L2 ventral root, which are generally considered to 
represent primarily flexor activity.  Left L2 ventral root was chosen due to its pattern 
stability and my ability to consistently acquire recordings from it.  Muscles on the left 
side that were in phase with left L2 ventral root are considered active during the flexor 
phase, while those that are out of phase were active during the extensor phase.  The 
opposite is true of muscles on the right side.  Those that were active with left L2 ventral 
root are considered active during the extensor phase, while those out of phase were active 
during the flexor phase.   
Using MATLAB, a paired Student’s t-test was used for statistical comparison of 
frequency and amplitude, while a Watson-William’s test was used for the phase 
diagrams. A significance level set at p<0.05.  The data are reported as mean ± SD.    
5.4 Results 
5.4.1 Trace amines can produce locomotor activity 
Previously in the isolated spinal cord preparation, I found that the TAs in the presence 
of NMDA produced distinct rhythmic motor patterns.  I wanted to further investigate how 
these unique patterns translated to motor coordination patterns in the hindlimb.  Here, in 
the isolated rat spinal cord with attached hindlimbs, NMDA was applied at 
concentrations that never produced rhythmic motor locomotor-like activity (LLA) on its 
own (3-5 µM; n=7/7).  In the presence of NMDA, 5-HT (n=22/22), tryptamine 
(n=10/11), tyramine (n=14/14), octopamine (n=10/11), and PEA (n=14/14) almost 
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always recruited rhythmic motor activity.  As expected, the overall patterning was similar 
to that found in the isolated spinal cord reported in the previous chapter, including the 
ability to change phenotype over time.  The same three main patterns were produced, but 
with some differences: 
5.4.1.1 The trace amines produced three main patterns 
5.4.1.1.1 Trace amines produce a continuous locomotor-like activity pattern 
First, tryptamine (n=10/10), tyramine (n=10/14), octopamine (n=5/10), and PEA 
(n=8/14) all produced a continuous LLA pattern (Figure 5.1A) with frequency values 
that were statistically indistinguishable from 5-HT (n=22/22) (Figure 5.2), similar to 
what was found in the isolated spinal cord.   The mean frequency values were 
numerically slightly higher for tryptamine, octopamine, PEA, and 5-HT than in the 
isolated spinal cord without hindlimbs, but not statistically different.   
5.4.1.1.2 Trace amines produce a slow continuous locomotor-like activity pattern  
Second, octopamine (n=1/10) and PEA (n=1/14) produced a slow continuous LLA 
pattern with significantly slower frequency than the faster continuous LLA pattern 
(Figure 5.1B and Figure 5.2D, middle left).  Although this pattern was only seen in 
tyramine (n=5/24) in the isolated spinal cord, it was never seen in the hindlimb attached 
preparation (n=0/14). 
5.4.1.1.3 Tyramine, octopamine, and PEA produce episodic activity patterns 
Third, tyramine (n=5/14), octopamine (n=5/10), and PEA (n=8/14), but not 




Figure 5.1: Trace amines and 5-HT induced locomotor-like activity 
A. 5-HT, tryptamine, tyramine, PEA, and octopamine can all produce a LLA pattern in the presence of 
NMDA.  The pattern and the phase are similar.  B. Octopamine and PEA also produce a slower locomotor-
like activity pattern.  In this and subsequent figures, the upper traces in black for each trace has been 
rectified and low-pass filtered.  Vertical dotted lines are provided as a visual aid to examine motor 
coordination in this and subsequent figures.  Abbreviations in this and the following figures are as follows: 
left L2 ventral root (l-L2), tibialis anterior (TibA; ankle flexor), medial gastrocnemius (MGas; ankle 
extensor), semitendinosus (SemT; knee flexor / hip extensor), semimembranosus (SemM; knee flexor / hip 
extensor), vastus medialis (VasM; knee extensor), rectus femoris (RecF; knee extensor / hip flexor), and 




Figure 5.2: Frequencies vary depending on the type of bursting   
Note 5-HT and tryptamine only produced LLA, while tyramine, octopamine, and PEA produced other 
types as well.  The regular and slow frequency parts of episodic LLA are different components of the same 
experiments.  LLA stands for locomotor-like activity.  The slow LLA and the slow frequency bouts of 
episodic pattern were significantly slower than the LLA and Regular frequency bursts of episodic pattern.  
(* indicates p<0.05) 
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bouts of bursts with quiescent periods between them (Figure 5.3).  The frequencies of the 
bursts within the bouts for tyramine and octopamine were statistically indistinguishable 
from 5-HT LLA, similar to the isolated spinal cord (Figure 5.2, middle right); however, 
PEA was statistically faster than the frequency of 5-HT (p < 0.01).  When the frequencies 
were compared to the isolated spinal cord, tyramine and octopamine were statistically 
indistinguishable with values that were numerically slightly higher, while PEA was 
statistically faster (p<0.01).  As in the isolated spinal cord, the frequencies of the bouts 
were very slow in comparison to the locomotor rhythm (Figure 5.2, right).  The mean 
frequency values were numerically greater than reported in the isolated spinal cord, but 
not statistically different.   
As in the isolated spinal cord, episodic bursting was characteristically variable.  
Overall there were 1-26 bursts within the bouts of activity and a break of 5-120 seconds 
between bouts during the quiescent periods.  Another aspect that was variable was the 
patterning.  The episodic pattern can be subdivided into distinct varieties.  The most 
common pattern observed involved concurrently active bouts of LLA with the quiescent 
periods on ventral root and the muscles (Figure 5.3A and Figure 5.3C, right).  This was 
seen in tyramine (n=5/5), octopamine (n=4/5), and PEA (n=5/8).  Seen less commonly 
was alternation of the bouts between the ventral root and the muscles on the right and left 
sides of the body (Figure 5.3B).  This was seen for tyramine (n=1/5), octopamine 
(n=2/5), and PEA (n=2/8).  There were a couple other notable varieties of episodic 
patterning.  In one experiment, the left L2 ventral root rhythmicity was continuous yet the 
r-SemM muscle was episodic (Figure 5.3C, left side).  In another experiment with slow 
LLA, multiple higher frequency bursts replaced a single slow burst seen on the other 
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Figure 5.3: Tyramine, PEA, and octopamine produce episodic rhythmic motor bursting patterns  
These episodic patterns have bouts of locomotor-like bursting that were interrupted by relatively quiescent 
periods.  A. Typically, when tyramine, PEA, and octopamine produced an episodic pattern, the bouts were 
concurrently bursting on the ventral root and muscles (also see the right half of C).  B. Occasionally, 
octopamine and PEA produced episodic bouts of bursting that alternated on the right and left side.  C. 
Once, for octopamine there was continuous bursting on one channel and episodic bursting on another.  D. 
Once, for PEA there was a slow LLA pattern where one channel, r-TibA, had bursting within the episodes 
during the time of the long bursts on the other channels (highlighted).  C&D. For tyramine, octopamine and 
PEA there were a few experiments where the pattern changed over time with no additional intervention.  
The upper traces in black for each trace have been rectified and low-pass filtered. 
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channels (Figure 5.3D, highlighted).  In another the opposite occurred, where a slow 
burst replaced a bout of higher frequency bursting replaced (Figure 5.3B, highlighted).   
5.4.1.1.4 Trace amines induced bursting could change phenotypes over time 
The pattern of motor rhythmicity spontaneously changed phenotype over time 
(Figure 5.3C and D).  This was seen in tyramine (n=2/14), octopamine (n=2/10), and 
PEA (n=2/14).  This included patterns that started out as continuous and changed to 
episodic or vice versa, as well as patterns that start out continuous and changed to slow 
LLA (Figure 5.3D).   
5.4.1.2 Phasing of muscles in 5-HT and the trace amines 
Overall, the 5-HT/NMDA phasing was consistent with what has been found 
previously for 5-HT, where tibialis anterior, an ankle flexor, was active during the flexor 
phase, and medial gastrocnemius, an ankle extensor, was active during the extensor phase 
(Figure 5.4A).  Semimembranosus and semitendinosus, both knee flexor and hip 
extensors, were usually both active during the extensor phase, while rectus femoris, a 
knee extensor and hip flexor was active during the flexor phase.  The only difference 
observed from an earlier report was that adductor magnus was active during either the 
extensor (n=1/2) or flexor phase (n=1/2) rather than just the extensor phase (Kiehn and 
Kjaerulff 1996). 
Phase diagrams revealed differences in phasing during continuous locomotion of the 
TAs as compared to that observed for 5-HT, showing that different muscles were affected 
more by certain TAs (Figure 5.4B).  It should be first emphasized that the left L2 ventral 
root did not have any significant changes in phasing for any of the TAs, and thus 
provided a strong standard for comparisons between muscles under the different 
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Figure 5.4: Phase diagrams for 5-HT and the trace amines 
A. 5-HT. B. Tryptamine, tyramine, octopamine and PEA. The phase diagrams show the relationship 
between the phases for regular LLA patterns.   All phases are in reference to the onset of the l-L2 ventral 
root.  Bars represent the average burst duration of muscles normalized to cycle duration.  Burst onset is on 
the left and burst termination on the right for the TA compared to 5-HT.  The numbers of rats used to 
obtain the diagrams are given in the middle.  The phase diagram for 5-HT underlays the phase diagrams of 
the TAs in B.  Significant shifts in the average phase of the TAs compared with 5-HT are indicated as * for 
p<0.05 and ** for p<0.01. 
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neurochemical conditions.  In comparison to 5-HT, all TAs preserved the muscles in their 
respective flexor and extensor phase without evidence of phase conversions (i.e. between 
flexor and extensor activity phases); however, there were shifts in the average phase 
within the dominant activity period.  In all cases, these were leftward shifts towards 
earlier in the phase.  For tryptamine this occurred with tibialis anterior, semitendinosus, 
and semimembranosus.  For tyramine, there were shifts in phase for tibialis anterior and 
rectus femoris.  For octopamine, there were shifts in semitendinosus and 
semimembranosus. There were no significant shifts observed with PEA.    
Unlike for continuous locomotion, TA muscle activity phase conversions were 
observed in a given TA during episodic patterning compared to continuous TA 
locomotion.  For example, during tyramine induced episodic bursting, the extensor right 
medial gastrocnemius muscle can shift into the flexor phase (Figure 5.3A), and for 
octopamine, the right semimembranosus muscle is shifted almost entirely into the flexor 
phase rather than being almost entirely in the extensor phase (Figure 5.3C, right).  There 
did not appear to be changes in phase for the episodic bursting when there was alternation 
of the bouts between the right and left sides for octopamine and PEA (Figure 5.3B). 
5.4.1.3 Amplitude of TAs compared to 5-HT 
In order to examine the relative motor pool recruitment of the TAs compared to 5-HT, 
the percent difference in peak amplitude in the same preparation was examined.  Overall, 
the TAs appeared to have decreased amplitudes with tryptamine exhibiting the least 
difference (Figure 5.5).   Pooling continuous and episodic bursting together, all four of 
the TAs had significantly decreased amplitudes for left L2 ventral root when compared to 
5-HT in the same experiments.  Examining tibialis anterior, there was a trend for 
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decreased amplitude for tyramine, octopamine, and PEA.  This was significant for left 
tibialis anterior and right tibialis anterior during tyramine and right tibialis anterior during 
octopamine induced LLA (Figure 5.5).  Overall the sample sizes were too small to 
individually compare most of the muscles.  When grouping all of the muscles together, 
EMG amplitudes were lower for all four TAs compared to 5-HT.  This difference was 
significant for tyramine (p<0.001, n=13), octopamine, (p<0.05, n=9), tryptamine (p<0.05, 
n=10), but not PEA (p= 0.15, n=14).   
5.4.2 Trace amines modulate ongoing locomotor activity 
Aromatic-L-amino acid decarboxylase (AADC) is the rate limiting enzyme in the 
production of TAs, but not the monoamines.  This highly regulated enzyme can undergo 
rapid changes in its activity via phosphorylation, which can changes the levels of the 
TAs, but not the monoamines, allowing minute to minute regulation of TA synthesis 
(Berry et al. 1996).  In Chapter 3, I found that AADC expression is widespread 
throughout the spinal cord, meaning that TA synthesis is also widespread.  Unlike the 
monoamine, the TAs are produced in the spinal cord, but not typically stored in vesicles, 
leading to a high turnover rates (Berry 2004; Burchett and Hicks 2006).  This high level 
of TA regulation makes it an ideal candidate for modulating motor activity.  It is possible 
that the TAs act as an additional modulatory layer to further alter ongoing 
monoaminergic based activity in the spinal cord.  To examine this I tested whether the 
TAs can modulate ongoing 5-HT/NMDA LLA.  As will be described below, I found that 
the TAs altered locomotor patterning, frequency, and amplitude.  The most striking 
changes were to subgroups of tyramine and octopamine, where dramatic changes to 
patterning were observed.   
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Figure 5.5: Differences in burst amplitude of the trace amines compared to 5-HT   
The percent change in left L2 ventral root (l-L2) ENG and muscle EMG amplitude of the TAs/NMDA 
compared with 5-HT/NMDA in the same experiment was calculated and are shown for individual 
experiments as either diamonds for continuous LLA or squares for episodic LLA.  The decreases in 
amplitude of the l-L2s were significant for all of the TAs (tyramine, octopamine, PEA, and tryptamine). * 
indicates p<0.05, and ** indicates p<0.01. 
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The trace amines either maintain locomotor-like activity or produce episodic patterning 
when added to ongoing locomotion 
Adding the TAs to ongoing 5-HT/NMDA LLA led to two main responses.  First, the 
continuous locomotor-like pattern produced by 5-HT/NMDA was maintained after the 
addition of the TAs (Figure 5.6).  All TAs could have this response.  In fact for 
tryptamine (n=12/12) and PEA (n=11/11), this was the only response seen.  However, for 
tyramine (n=8/12) and octopamine (n=3/7) maintaining the continuous pattern was not 
the only response.  
The second response was the conversion from continuous locomotor-like pattern 
produced by 5-HT/NMDA to and episodic pattern due to the addition of tyramine 
(n=4/12) and octopamine (n=4/7) (Figure 5.7).  Thus, tyramine and octopamine could 
convert the phenotype of 5-HT locomotion. This is interesting in relation to the section 
above describing the TA induced patterning in the absence of 5-HT.  Here, the incidence 
of episodic patterning was similar for all TAs except PEA.  For PEA, the episodic 
activity that was previously evoked (8/14 animals) was now completely suppressed in the 
presence of 5-HT (0/11). 
5.4.2.1.1 Trace amines alter the frequency and amplitude of ongoing 5-HT locomotor-
like activity  
For ongoing continuous 5-HT/NMDA LLA monitored at the L2 ventral root, PEA 
increased frequency (11±12%; p<0.05) without changing amplitude (p=0.19), while 
tryptamine increased amplitude (10±11%, p<0.01) without changing frequency (p=0.6) 
(Figure 5.8, and Figure 5.9).  For octopamine and tyramine, when continuous and 




Figure 5.6: Effects of the trace amines on normal 5-HT evoked locomotor-like activity 
When the TAs were added to ongoing LLA, continuous LLA can be maintained with the pattern and the 
phasing between recorded muscles remaining largely comparable.  Note however that for any given 




Figure 5.7: Tyramine and octopamine can convert continuous 5-HT locomotion into the episodic 
pattern 
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Figure 5.7: continued 
These episodic patterns have bouts of locomotor-like bursting that were interrupted by relatively quiescent 
periods.  A&B. For tyramine and octopamine, the most common pattern was where some of the muscles 
and/or ventral root converted to episodic bursting while others maintained a more continuous form of 
bursting.  C. For tyramine, there was the conversion to concurrent episodic locomotor bursting.  D. For 
octopamine, there was episodic bursting that alternated between the right and left sides.  E. For tyramine, 
continuous 5-HT/NMDA LLA may be modulated into episodic bursting by tyramine and then back to 
continuous bursting with no further intervention 
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(61±42%; p<0.01) with tyramine exhibiting a similar trend for increase (48±65%; 
p=0.12) (Figure 5.8).  Tyramine and octopamine also increased the amplitude of the left 
L2 ventral root when added to ongoing 5-HT/NMDA LLA (14±12%, p<0.05; and 
11±12%, p<0.05; respectively) (Figure 5.9).   
Assuming L2 ventral root amplitude reflects flexor muscle activity, this implies that 
the TAs, tryptamine, tyramine and octopamine, facilitated flexor activity (Kiehn and 
Kjaerulff 1996).  Based on this, I would conclude that the TAs generally facilitate flexor 
activity with a clearly significant facilitation from tyramine and tryptamine during 
continuous locomotion (Figure 5.9).  However, EMG amplitude for the ankle flexor 
tibialis anterior actually decreased in amplitude with tyramine (p<0.05) with a similar 
trend observed with tryptamine (p=0.08). One explanation for this discrepancy is that the 
large majority of tibialis motoneurons exit from the L3 spinal segment (Nicolopoulos-
Stournaras and Iles 1983).  On the other hand, hip and knee flexors appear to exit L2 
(iliacus, rectus femoris, pectineus, and gracilis).  Of these, I occasionally recorded from 
rectus femoris (knee extensor/hip flexor) which was always active during the flexor phase 
of locomotion.  While the sample sizes are too small to make statistical comparison, 
rectus femoris did appear to increase in amplitude in the presence of tryptamine and 
tyramine supporting the notion that these TAs increase hip flexions while concomitantly 
decreasing ankle flexion (i.e. tibialis anterior). 
For tryptamine, muscles that can act as knee extensors and active during the extensor 
phase (semimembranosus and semitendinosus) also underwent a significant reduction in 






Figure 5.8: The frequency of the motor rhythm increases significantly when octopamine and PEA are 
added to ongoing 5-HT locomotor like activity 
Tyramine also tended toward increases in frequency, while tryptamine has no affect.  In one of the tyramine 
experiments (labeled same experiment above), episodic LLA eventually converted to continuous LLA.  The 
frequency of this experiment was the average of the episodic and continuous LLA and was denoted by a 






Figure 5.9: Percent change in burst amplitudes after adding the TAs to ongoing 5-HT locomotor-like 
activity 
The increases in amplitude of l-L2 ventral root ENG were significant for tyramine, octopamine, and 
tryptamine.  * indicates a p<0.05. 
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5.4.2.1.2  Tyramine and octopamine convert continuous locomotor-like activity to 
episodic patterns  
In a subset of experiments, tyramine (n=4/12), and octopamine (n=4/7) converted 
continuous 5-HT/NMDA LLA into episodic bursting (Figure 5.7). The patterns produced 
were similar to those observed when the TAs and NMDA were applied alone (Figure 
5.3).  There were a number of different ways that this pattern manifested itself. 
First, the most common pattern observed was where some muscles and/or ventral root 
converted to episodic bursting while others maintained a more continuous form of 
bursting.  This was seen for both tyramine (n=2/4) and octopamine (n=3/4).  For 
example, while the left L2 ventral root and right rectus femoris bursting are continuous, 
right semimembranosus and right adductor magnus have episodic bursting (Figure 5.7A 
and B).   
Second, the simplest behavior seen with tyramine (n=1/4) was the conversion to 
concurrent episodic locomotor bursting (Figure 5.7C).  This was by far the most 
common episodic activity pattern seen when the TAs were applied without 5-HT in the 
section above (see Figure 5.3).   
Third, episodic bursting that alternated between the right and left sides was seen only 
once (with octopamine and had some LLA overlap during transition periods; Figure 
5.7D).  When the TAs were applied without 5-HT as reported above, this form of 
bursting was observed for tyramine (1/5), octopamine (2/5), and PEA (2/8), and in the 
isolated cord, it was observed for octopamine (2/9) and PEA (1/7).   
Finally, a pattern never observed previously was seen once for tyramine (1/4).  There 
were alternating bouts that were not associated with flexor/extensor or left/right 
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coordination (right tibialis anterior alternating with left L2 ventral root, right 
semimembranosus, and right semitendinosus; Figure 5.7E, middle). Additionally, the 
type of pattern could change over time. This was seen for tyramine (n=2/4).  For 
example, continuous 5-HT/NMDA LLA may be modulated into episodic bursting by 
tyramine and then back to continuous bursting with no further intervention (Figure 
5.7E).   
5.4.2.2 Trace amines maintain the locomotor phase relations established by 5-HT 
Adding the TAs to ongoing 5-HT/NMDA did not significantly change the phasing for 
any muscle compared for either the continuous or episodic result (Figure 5.10). 
5.5 Discussion 
In this, study, I examined the effects of the TAs on muscle activity recorded in the in 
vitro isolated rat spinal cord with intact hindlimbs.  I found that consistent with the 
patterns observed using ventral root recordings in the isolated spinal cord, the TAs 
recruited the same predominant patterns: regular continuous locomotion, a slow rhythmic 
activity whose coordination pattern was consistent with recruitment of locomotor circuits, 
and episodic patterns that included locomotion.  One difference, however, was that the 
episodic patterns produced were more numerous in the attached hindlimb preparation.  
Since I hypothesized that the TAs would have distinct differentiable actions on motor 
pool recruitment during rhythmic motor behaviors, I examined differences in recruitment 




Figure 5.10: Summary of phasing before and after adding the trace amines to ongoing 5-HT induced 
locomotor-like activity 
Adding the TAs to ongoing 5-HT/NMDA LLA did not significantly change the phasing.  The mean phase 
is shown on the y-axis.  On the left is the phase for 5-HT/NMDA LLA, and on the right is the phase once 
the TA has been added to the ongoing 5-HT/NMDA LLA.  Open circles or open diamonds indicate an 
experiment where the root or muscle was present before and after the TA was added; there is a line between 
the circles or diamonds to demonstrate the change for that experiment.  When muscle EMG activity was 
present only before or emerged only after, it is indicated by a filled in circle or diamond.  All phases are in 
reference to the onset of the l-L2 ventral root.   Experiments without a l-L2 are not included. 
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Further, I examined the ability of the TAs to modulate ongoing 5-HT/NMDA 
locomotor-like activity, since the TAs may predominantly be acting as modulators of 
ongoing locomotion.  I demonstrated that the TAs modulated the ongoing pattern, and 
that there were differences between the TAs.  All TAs but tryptamine increased 
locomotor frequency, and all TAs but PEA increased the L2 ventral root amplitude.  The 
most pronounced effects to motor coordination produced with 5-HT locomotion by the 
TAs were to a subgroup of tyramine and octopamine applications where dramatic 
changes in patterning were observed.   
Overall, given the widespread expression of the synthesis enzyme for the TAs and 
their high turnover rates, I think that the TAs act to locally modulate the neurons in which 
they are currently being made.  Unlike the monoamines, which are not produced in the 
spinal cord, the TAs can react to the cellular environment to change the output and add 
flexibility to motor control mechanisms.  It is possible that the widespread range of 
effects seen by bath application of the TAs does not reflect endogenous actions occurring 
during normal behavior; however, they give clues to how the TAs ca act as modulators in 
the spinal cord, even if exaggerated.  In this regard, the possibility that they could be used 
pharmacologically for therapeutic strategies could be explored.  
5.5.1 TAs can produce locomotor activity 
5.5.1.1 Comparison the output produced by the isolated spinal cord preparation with 
and without attached hindlimbs  
Here, the TAs in the presence of sub-locomotor concentrations of NMDA produced 
patterns consistent with those observed using ventral root recordings in the isolated spinal 
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cord.  The same predominant patterns were observed; namely, regular continuous 
locomotion, a slow rhythmic activity whose coordination pattern was consistent with 
recruitment of locomotor circuits, and episodic patterns that included locomotion. 
Despite having an almost identical in vitro experimental arrangement, there were 
several major differences between isolated and the hindlimb-intact rhizotomized 
preparations.  First, the proportions of the different patterns were different.  Unlike in the 
isolated spinal cord where the slow rhythmic pattern was produced 5 of 24 times by 
tyramine, it was never produced in the attached hindlimbs preparations.  Conversely, 
octopamine and PEA, which never produced the pattern in the isolated spinal cord, each 
produced the pattern once in the attached hindlimb preparation.  This difference is less 
surprising, given the low occurrence.  Additionally, while episodic patterning was 
dominant for octopamine and PEA in the isolated spinal cord, its expression incidence 
was equal to regular continuous locomotion in the attached hindlimbs. Second, there was 
a trend towards higher frequencies in the attached hindlimb preparation, with PEA being 
significantly faster.  Third, the episodic patterns produced in the attached hindlimb 
preparation were more numerous than in the isolated spinal cord, which could be partially 
reflecting the number of channels from which I was recording.  By adding the complexity 
of muscles, the output could be increased, since it has been previously suggested that use 
of ventral root activity may not reflect recruitment of individual muscles (Cowley and 
Schmidt 1994b).  A prime example being where I found that the ventral root was 
continuously bursting while at least one muscle was having different actions (Figure 
5.3C, left) 
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That there were differences between the preparations is interesting given that there 
was no sensory feedback from the muscles since the dorsal roots were cut.  An interesting 
and perhaps decisive difference in experimental set-up between the isolated spinal cord 
and the attached hindlimb preparation was the addition of a superfusion system rather 
than static bath, which likely increased tissue oxygenation by increasing the flow rate.  
Increasing flow rate has been shown to affect the locomotor-like activity (Wilson et al. 
2003).  
5.5.1.2 Trace amines produce continuous locomotor-like activity pattern 
The general phasing of muscle characteristics of 5-HT and TA induced continuous 
locomotion were similar to that seen in adult rat (de Leon et al. 1994; Gruner and Altman 
1980; Gruner et al. 1980) and in previous work in the isolated spinal cord with one 
hindlimb attached (Kiehn and Kjaerulff 1996).  While there were sometimes distinct 
amine-dependent shifts in the timing within the phase, tibialis anterior, vastus medialis, 
and rectus femoris were active at some point during the flexor phase, and medial 
gastrocnemius, semitendinosus and semimembranosus were active during the extensor 
phase.  The major differences in phasing between 5-HT and tyramine were to muscles 
acting during the flexor phase (tibialis anterior, an ankle flexor, and rectus femoris, a 
knee extensor / hip flexor), which were both active earlier in the phase than during 5-HT.  
This presumably causes the leg to be move forward earlier.  The biggest differences with 
octopamine were to muscles active during the extensor phase (semitendinosus and 
semimembranosus, both knee flexor/hip extensor), which were both active earlier in the 
phase than 5-HT.  This presumably causes the leg to pull into the equivalent of stance 
phase earlier.  Tryptamine also shifted muscles to earlier in the stage both flexors (tibialis 
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anterior) and extensors (semitendinosus and semimembranosus, both knee flexor/hip 
extensor).   
The exact behavior represented by each of these shifts in patterns is not clear.  With 
the limited behavior of the neonate, there are very few patterns to which these results can 
be compared.  Previous work has suggested that late flexion of rectus femoris observed in 
5-HT rhythms is most consistent with swimming.  Of the patterns examined, this appears 
to be the pattern to which the TAs are most similar (de Leon et al. 1994; Kiehn and 
Kjaerulff 1996).  However, all of the TAs have rectus femoris active earlier in the flexor 
phase rather than later as seen with swimming.  DA has been observed to be the most 
similar to walking (de Leon et al. 1994; Kiehn and Kjaerulff 1996).  Galloping is another 
interesting behavior to consider; however, there is almost co-contraction of tibialis 
anterior and gastrocnemius, which is not seen in TA induced patterning.  In neonatal rats, 
crawling is actually the dominant pattern until the middle of the second week postnatal 
since the rats are not strong enough to pull their bellies off of the ground (Westerga and 
Gramsbergen 1990); however, there are not enough muscles to make meaningful 
comparisons with the available EMGs (Juvin et al. 2005).  
5.5.1.3 Tyramine, octopamine, and PEA produce episodic activity patterns 
The more intriguing pattern to reflect on is the episodic pattern.  I do not know the 
significance of these various patterns of activity or if they are actually relevant, but there 
are a number of interesting possibilities to consider.  First, they could represent simply 
the starting and stopping of locomotion.  Interestingly, normal rodent locomotion is not 
continuous as seen with 5-HT, but periodic as observed with the TAs (De Bono et al. 
2006; Rodnick et al. 1989).  Second, it could be part of a different behavior such as 
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scratch, copulation, or orgasm (Carro-Juarez and Rodriguez-Manzo 2005; 2006; 
Robertson et al. 1985).  Third, the TAs may be playing a role in development.  Episodic 
spontaneous bursting has been observed during development in chick, mouse, and rat 
many facilitate the formation of functional synaptic connections (Bekoff et al. 1975; 
Hanson and Landmesser 2003; Nakayama et al. 2004; O'Donovan et al. 2008; Whelan et 
al. 2000).  Interestingly, in the developing rat embryo, AADC positive neurons are 
observed on day 12 of development in all cells of the notochord and in neuroepithelial 
cells of the ventral neural tube.  AADC was enzymatically active, and these cells were 
tyrosine hydroxylase negative, which indicates that it is likely that the TAs are being 
produced in these cell and could be playing a role in development (Teitelman et al. 1983).   
5.5.1.4 Amplitude of trace amines compared to 5-HT 
As compared to that observed with 5-HT, I observed a decreased amplitude of the left 
L2 ventral root for all of the TAs and tibialis anterior for tyramine and octopamine.  
While Kiehn and Kjaerulff (1996) did not observe consistent changes in amplitude 
between DA and 5-HT (Kiehn and Kjaerulff 1996), Klein et al. (2010) did see higher 
amplitude for adductor magnus in cauda equine stimulation evoked patterns than 5-
HT/NMDA evoked patterns (Klein et al. 2010) consistent with my work that there can be 
changes. 
The observed smaller EMG amplitude for the TAs compared with 5-HT may be 
related to the excitability of the motoneuron pool.  Indeed, 5-HT is known to depolarize 
motoneurons (Hochman and Schmidt 1998).  In Chapter 4, I showed that while 
tryptamine and tyramine directly depolarize motoneurons, the percent increase over 
baseline was much smaller than 5-HT.  Also, PEA and octopamine do not significantly 
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change the activity of motoneurons.  Therefore, while 5-HT increases excitability in the 
motoneurons and the neurons at the level of the CPG, the TAs appear to more 
preferentially CPG neurons. This could easily explain why the TAs have decreased 
amplitudes compared with 5-HT.  If PEA and octopamine are more selective recruiters of 
the CPG, these may be preferred in clinical strategies clinically where motoneurons are 
already over-excited and there is the desire to just recruit the CPG. 
5.5.2 TAs modulate ongoing locomotor activity 
5.5.2.1 The TAs can alter the frequency and amplitude of ongoing locomotor-like 
activity  
When the TAs are added to ongoing 5-HT/NMDA LLA, I observed consistent 
increases in the frequency for tyramine, octopamine, and PEA which implies that they are 
having modulatory effects on interneurons that control frequency.  The increase in 
frequency supports facilitation at the level of the rhythm-generator CPGs (Rybak et al. 
2006b). One possible group of interneurons that has been identified are the V1 
interneurons, which when either inactivate or deleted lead to an inability to burst or step 
at higher frequencies (Gosgnach et al. 2006).  Since tryptamine does not change the 
frequency of ongoing 5-HT locomotion, it is presumed that it is not acting on these 
interneurons.   
PEA does not have actions on left L2 ventral root amplitude.  Unlike the other TAs, 
PEA never had an effect on motoneurons as reported in the last chapter, and therefore, it 
is plausible that it would not act to increase amplitude here.  Surprisingly, there were no 
significant changes in amplitude for any of the muscles after the addition of the TAs.  
This is likely due to the small sample size.  The addition of tryptamine and tyramine led 
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to trends towards increases in amplitude for rectus femoris, supporting the notion that 
these TAs increase hip flexions.  Trends towards decreases were seen for tibialis anterior 
(ankle flexor) and semimembranosus and semitendinosus (both knee extensors).   
5.5.2.2 Tyramine and octopamine produce episodic bursting patterns  
Tyramine and octopamine dramatically modulated on-going 5-HT locomotor-like 
activity by converting it to episodic bursting.  Like with the TAs alone, there is a huge 
amount of variability in the patterning produced.  This is potentially a good thing.  
Variability and flexibility allow the spinal cord to adapt depending on the 
neuromodulatory state of the system and the requirements of the system (Klein et al. 
2010).  The modulatory state of the TAs is readily changed by varying the amount of 
aromatic amino acids, the activity of AADC, or the activity level of the monoamine 
oxidases, and this variability could account for some of the different patterns seen.  Many 
of the different possibilities as to what could be happening are discussed above.  
I demonstrated that one important advantage of the isolated spinal cord with hindlimbs 
attached is that it provides a more accurate representation of the distinct motor patterns 
produced by the TAs than ventral root recordings.  I showed examples where ventral root 
recordings alone did not accurately report what was happening in the hindlimb muscles.  
For example, continuous L2 ventral root activity could be coincident with episodic EMG 
(Figure 5.7A and B).  Interestingly this was the dominant pattern in the presence of 5-
HT, yet was only seen once with the TAs applied without 5-HT.  As a result of the EMG 
the more complex nature of the TAs was revealed.  Similarly, it is likely that the unique 
pattern produced by DA seen in Chapter 4 could demonstrate important complexities in 
the DA motor pattern. 
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5.5.3 Conclusions 
This chapter provides evidence that overall, the TAs are capable of facilitating 
ongoing locomotor output.  The TAs can produce unique patterning as well as alter motor 
patterns produced by 5HT.  The most pronounced effects on coordination to 5-HT 
locomotion by the TAs were to a subgroup of tyramine and octopamine applications 
where dramatic changes in patterning were observed.  While it remains to be seen 
whether these effects are seen normally, the TAs do appear to be produced endogenously, 
and therefore controlling their release and/or receptor activation may provide new 
therapeutic strategies for the management of spinal cord dysfunction after spinal cord 
injury, and therefore, warrants further study to determine their efficacy. 
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CHAPTER 6  
DISCUSSION AND CONCLUSIONS 
6.1 Summary 
Trace amines (TAs) named for their low endogenous concentrations in mammals, are 
related to the classical monoamine transmitters, but have been understudied and thought 
of as false transmitters.  They share structural, physiological, pharmacological, and 
metabolic similarities with the monoamines, including synthesis by the aromatic-L-amino 
acid decarboxylase (AADC) enzyme.  In 2001, a new class of receptors preferentially 
activated by the TAs, termed trace amine-associated receptors (TAARs), was discovered 
establishing a mechanism for TA actions independent of classic monoaminergic 
mechanisms. While the TAs and some of their receptors are present in the mammalian 
central nervous system (CNS), their physiologic role remains uncertain.  I hypothesized 
that the TAs are found intrinsically in the spinal cord and that they are able to modulate 
spinal neural networks.   
Using immunohistochemistry, numerous spinal neurons were identified that express 
AADC, the TAs (octopamine, tryptamine, and tyramine), and TAARs (TAAR1 and 
TAAR4).  Similar results were seen for AADC and TAAR1 with in situ hybridization. 
The most consistent observation was for labeling D cells associated with the central canal 
and in motoneurons. Overall, these results provided evidence for the presence of an 
anatomical substrate onto which the TAs could have intrinsic biological actions in the 
spinal cord. 
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Using exogenous application of the TAs in the isolated spinal cord in vitro, and in vivo 
in the mid-thoracic chronically spinalized, I showed that the TAs could induce rhythmic 
locomotor-like activity.  TA injection-induced hindlimb motor rhythms observed in 
chronic spinalized animals, supports TA spinal actions independent of the descending 
monoaminergic systems.  In the presence of NMDA, TA applications recruited a variety 
of rhythmic motor patterns in the isolated spinal cord. This ranged from locomotor 
activity indistinguishable from 5-HT/NMDA induced locomotion to complex patterns 
including an episodic form of locomotion where there were locomotor bouts with 
intervening quiescent periods.  
TA actions of pattern generating circuits: (i) had slower kinetics of activation than 5-
HT and NA, (ii) were attenuated in the presence of monoamine transport inhibitors, and 
(iii) had increased intracellular labeling even when incubated in a nominally Na+-free 
solution. Together these results suggest that the TAs required transport into neurons to 
exert their actions, and that transport occurred by Na+-dependent monoamine transporters 
as well as additional Na+-independent transporters.  
Finally, I used the in vitro isolated spinal cord with attached hindlimbs to record 
electromyographic (EMG) activity from various hindlimb muscles: (i) to compare the 
relationship between the TAs and serotonin (5-HT) evoked motor coordination, and (ii) 
to examine the ability of the TAs to modulate ongoing 5-HT and NMDA locomotor-like 
activity.  The TAs produced both the continuous and episodic patterns on muscles as 
observed in ventral root recordings, but EMG recordings provided more detailed insight 
into specific muscle actions.  The TAs also generally increased both frequency and 
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amplitude of ongoing 5-HT locomotor frequency, with tyramine and octopamine also 
particularly able to alter 5-HT motor coordination patterns. 
6.2 Mechanisms involved in trace amine modulation of spinal cord motor function 
6.2.1 Trace amines are intrinsically produced in the spinal cord 
My immunohistochemistry results confirmed previous analysis of tissue samples 
(Boulton et al. 1977; Juorio 1988; Karoum et al. 1979; Spector et al. 1963) and 
demonstrated that the TAs are present in the spinal cord.  Two not mutually exclusive 
options explain their presence.  First, some TAs could arise from dietary sources 
(Gardner et al. 1996; Ghozlan et al. 2004) with subsequent transport across the blood 
brain barrier via transporters. This is known for PEA and tryptamine but not tyramine 
(Oldendorf 1971).  Indeed, the L-type amino acid transporters (LATs), which transport 
PEA, were found at the blood-brain barrier (Segawa et al. 1999).  Octopamine transport 
has not been studied.  
A second and probably more widespread mechanism is via endogenous synthesis in 
the spinal cord by AADC from the aromatic amino acid precursors, which were also 
found in many foods (Gardner et al. 1996).  It has been shown that meals cause 
physiologic-size changes in aromatic amino acid concentrations (Fernstrom 1990) that 
cross the blood brain barrier (Oldendorf 1971), likely via LATs (Segawa et al. 1999).  
The raised levels of the aromatic amino acids in the brain increase the synthesis of the 
monoamine transmitters (Fernstrom and Wurtman 1971; Wurtman et al. 1974) and so, 
while not explicitly studied, must also be increasing the synthesis of the TAs as the same 
essential synthesis enzyme is involved (AADC).   
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With AADC as the rate-limiting enzyme for the synthesis of TAs (Berry et al. 1996; 
Dyck et al. 1983), events that regulate AADC activity should alter TA levels.  Indeed, 
changes in AADC activity produced proportional changes in TA production (Jones et al. 
1983; Juorio 1982; Juorio et al. 1991a; Juorio et al. 1991b).  Thus, rapid changes in 
AADC activity by phosphorylation can change TA levels and fine tune their actions, thus 
allowing minute to minute regulation (Berry et al. 1996).  My results demonstrated 
widespread AADC labeling in the spinal cord, indicating that the TAs can be produced 
all over the spinal cord, thus giving a substrate for widespread TA production. 
TA labeling was located in the same locations as AADC, including labeling in central 
canal cells, ventral stream cells emanating from the central canal, ventral funiculus, 
ventral horn interneurons, and motoneurons. The observed labeling pattern varied 
between animals, the most common pattern being a widespread diffuse labeling. 
Nonetheless, there was a subset of animals with more selective and intense labeling in 
ventral horn interneurons.  With TA synthesis dependent on the dietary availability of 
aromatic amino acids and the modifiable levels of AADC activity in different cells based 
on their phosphorylation status, the observed variability in TA labeling would be 
expected.   If there were both a high level of aromatic amino acids and increased activity 
of AADC, there should be a higher level of the TAs in the spinal cord.  However, a low 
supply of aromatic amino acids and/or low activity of AADC would lead to less TA 
synthesis and consequent labeling.  This variability could be an advantage for the 
modulation of spinal motor function. 
In addition to AADC, octopamine further requires DBH, which is located only in 
descending neurons, implying that octopamine is only produced in descending 
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noradrenergic neurons. However, another enzyme, called monooxygenase, DBH-like 
1(Moxd1) has comparable function (Chambers et al. 1998; Xin et al. 2004) and so could 
also theoretically convert tyramine to octopamine.  Moxd1is strongly expressed in the 
mouse spinal cord including in presumed motoneurons and around the central canal 
(Appendix A.1) (Allen_Spinal_Cord_Atlas 2009).  Further studies will be required to 
determine if Moxd1 does in fact produce octopamine, and hence, if octopamine is 
producing intrinsically in the spinal cord.  
6.2.2 Aromatic-L-amino acid decarboxylase positive neurons represent a intrinsic 
trace aminergic system 
As stated above, I found widespread AADC labeling in the spinal cord, including 
expression around the central canal, the ventral funiculus, and in ventral neurons, 
including motoneurons.  The strongest labeling was consistently found around the central 
canal in cells consistent with D1 cells (Jaeger et al. 1984a; Jaeger et al. 1983).  Co-
labeling of the TAs with AADC in the central canal cells provides strong evidence that 
the D cells are in fact trace aminergic as had been previously hypothesized (Berry 2004; 
Jaeger et al. 1983).   
D1 cells project at least one of their processes into the lumen of the central canal, 
which makes them part of a group of CSF-contacting neurons (Jaeger et al. 1983; Vigh et 
al. 2004).  The specific role of the D cells and whether they are specifically involved in 
locomotion will need further investigation, although one intriguing hypothesis is that D1 
cells function to monitor and transport aromatic amino acids from the CSF and then 
synthesize TAs to intrinsically increase their activity (via TAs intracellularly activating 
Gs-coupled TAARs) . This increased activity could then be synaptically relayed to the 
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motor system.  Indeed, it should be noted that CSF-contacting cells present in zebrafish 
larva can initiate slow swimming by optogenetic stimulation and that these neurons 
provide the necessary tone for spontaneous forward swimming (Wyart et al. 2009). 
Importantly, I showed that D cells and their white matter projection system were 
maintained after chronic spinalization demonstrating that that the white matter tract is 
part of an intrinsic spinal aminergic system.  
The presence of other AADC+ neurons elsewhere in the spinal cord, based on both in 
situ hybridization and immunohistochemistry, demonstrated that there are other 
populations of cells in the spinal cord also capable of synthesizing TAs. This includes 
motoneurons. 
6.2.3 Trace amine-associated receptors provide a substrate for trace amine actions 
in the spinal cord 
I found that both TAAR1 and TAAR4 were widely expressed in the neonatal rat spinal 
cord, including in the central canal, ventral interneurons, and motoneurons.  TAAR 
expression was found in the same locations as AADC and the TAs, providing a 
mechanism though which the TAs can produce intrinsic modulatory actions.  As has been 
observed before for TAAR1 in HEK cells (Bunzow et al. 2001; Miller et al. 2005), I 
observed cytoplasmic labeling for TAAR1 and TAAR4, both of which are activated by 
the TAs.  Tyramine and PEA activate TAAR1, while PEA and tryptamine activate 
TAAR4 (Borowsky et al. 2001).  The cytoplasmic location of the ligand and the receptor 
(e.g. tyramine and TAAR1) supports intracellular activation of signal transduction 
pathways, as suggested previously (Miller et al. 2005).  Since the TAARs are 
intracellular, access to them is limited.  Hence, in order to have actions on them, the TAs 
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must either be produced in the cells from their aromatic amino acids precursors, or be 
taken up by transporters (described below).  Importantly, this form of intrinsic 
neuromodulation does not require release from synaptic vesicles, and could explain why 
the TAs do not appear to be concentrated in vesicles.  It could also explain the relatively 
trace amounts of TAs found in the CNS, as TA actions would not require storage as long 
as their production was in the vicinity of the intracellularly located TAARs.  This also 
means that access to the TAARs in cells not producing TAs would be limited by cell 
membrane transporters, and would explain the low potency of the TAs for TAAR4 
expressed in cell lines not containing such transporters (e.g. HEK cells in (Borowsky et 
al. 2001).  An exclusive intracellular location of TAARs may also explain why other 
studies failed to identify TAAR ligands despite the prediction that they must be small 
molecular weight compounds structurally similar to the TAs (Lindemann et al. 2005; 
Lindemann and Hoener 2005).  Almost all assays have assumed cell surface expression 
of the receptor. 
Currently, the role of the TAARs in the spinal cord is unknown.  However, it is known 
that they that they are Gαs-coupled proteins able to activate cyclic adenosine 
monophosphate (cAMP) (Borowsky et al. 2001; Bunzow et al. 2001).  There are a 
number of classes of downstream substrates which cAMP signaling can activate 
including transcription factors, voltage-gated ion channels, ion pumps, and 
neurotransmitter receptors, all of which are candidates after TAAR activation (Greengard 
2001).   
6.2.4 Evidence of trace amine actions on descending monoaminergic terminals  
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In my work, one possible mechanism by which the TAs could exert their action then, 
is by transporter-mediated TA uptake at descending monoaminergic terminals.  It has 
been reported that TAs can facilitate monoamine transmitter efflux in the CNS via 
reverse transport (Paterson et al. 1990; Sulzer et al. 2005).  This monoamine efflux could 
contribute to the bursting I see in my experiments.  TAs uptake is facilitated by 
monoamine transporters, which are greatly enhanced by TA activation of TAAR1 (Xie et 
al. 2007).  Further, PEA activation of TAAR1 is required for monoamine efflux via the 
monoamine transporters, suggesting an important modulatory role of TAAR1 in 
monoamine transporter function (Xie and Miller 2008).  In my experiments, I observed 
that inhibition of monoamine transport significantly attenuated motor actions for the TAs 
but not for 5-HT or NA (Figure 4.6 and 4.7).  This suggests then that a significant 
component of TA-evoked actions is likely due to monoamine transmitter efflux from 
descending terminals.  However, TA induced motor rhythmicity remained after 
monoamine transporter block indicating that TAs are binding at sites at least partly 
independent of descending monoamine presynaptic terminals (Figure 4.11).   
6.2.5 Possible trace amine action at monoamine receptors 
One site of TA-evoked actions that are independent of presynaptic descending 
terminals is on monoamine receptors. Tryptamine directly activates 5HT2 and 5HT7 
receptors (Boess and Martin 1994), the same critical receptors required 5-HT induced 
locomotion (Liu et al. 2009; Liu and Jordan 2005; Madriaga et al. 2004).  This would 
explain why tryptamine and 5HT evoked similar locomotor patterns with similar 
sensitivity to block with methysergide. However, in comparison to tryptamine, all other 
TAs appear to have very low affinity to the monoamine receptors tested, such that the 
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applied doses would not be expected to have direct actions (Peddi et al. 2003; Shen et al. 
1993; U'Prichard et al. 1977). Thus, tyramine, PEA and octopamine must also be acting 
at additional sites. 
6.2.6 Trace amine actions through transporters found in the spinal cord  
I showed that there is widespread expression of somatic TAAR1 and TAAR4 
receptors. They are located intracellularly consistent with earlier observations for TAAR1 
(Bunzow et al. 2001; Miller et al. 2005; Xie et al. 2007). To activate these receptors, the 
TAs require a transport mechanism. This was demonstrated by (Xie et al. 2007) 
associated with the monoamine transporters. As monoamine transporters are not found in 
spinal neurons (Appendix A.4), in order for the TAs to exert their actions alternate 
transport systems must be present. I showed that the TAs can be transported into spinal 
neurons via a Na+-independent mechanism. Multiple Na+-independent plasma membrane 
transporters have been shown to transport PEA, tyramine, and tryptamine and are widely 
expressed in the spinal cord (Appendix Figure A.5 and Figure A.6), providing an 
intrinsic substrate for independent actions within spinal neurons (Figure 4.11).  These 
plasma membrane transporters were the L-type amino acid transporters (LATs), the 
organic cation transporters (OCTs), and the plasma membrane monoamine transporter 
(PMAT).  PEA can be transported via LATs, tyramine via OCTs and PMAT, and 
tryptamine via PMAT.  Currently, octopamine transport has not been tested at these 
transporters.  Importantly, since these transporters have bidirectional transport, the TAs 
can be synthesized in one neuron, and transported into nearby neurons.  This allows 
modulatory actions via TAARs in neurons not endogenously synthesizing TAs (i.e. 
AADC negative).  In my experiments, it is reasonable to assume that exogenous 
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application of relatively high TA concentrations would be sufficient to activate TAAR1 
and TAAR4 in spinal neurons (Borowsky et al. 2001; Bunzow et al. 2001).  Given their 
widespread distribution and the similarly widespread presence of required Na+-
independent transporters, broad modulation of spinal circuits would be expected. 
6.2.7 Differences in the trace amines  
While the TAs are similar to each other in many ways, there are differences in 
structure, synthesis, storage, transport, receptor activation, and degradation.  Many of 
these differences are highlighted in the Table 6.1 below. 
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Table 6.1: Differences between the trace amines 
tryptamine tyramine octopamine PEA 
structurally similar to 5-HT yes no no no 
structurally similar to DA and NA no yes yes yes 
immunohistochemical evidence that 
the TA is found in the spinal cord 




1st synthesis enzyme AADC AADC AADC AADC 




synthesized in descending terminals yes yes yes yes 
synthesized in blood vessels yes yes no yes 








transported via monoamine 
transporters 
yes yes yes yes 
immunohistochemical evidence that 
transported into spinal cord neurons 




transporter known to transport the TA 






activates TAAR1, which is found in 









activates TAAR4, which is found in 
the spinal cord 
yes no no yes 
increases in cAMP with co-
expression of  monamine transporters 
and TAAR1 over just monoamine 
transporters 
yes yes yes yes 
actions on 5-HT receptors yes no no no 
action on catecholamine receptors no no no no 
degraded by MAOA yes yes yes no 
degraded by MAOB, which is not 
found in spinal cells 





6.2.8 Mechanisms associated with TAAR activation and signaling 
Previous reports suggest that the monoamine receptors, 5-HT2, 5-HT7, D1, and α1, are 
involved in mediating actions on the locomotor network (Gabbay and Lev-Tov 2004; Liu 
et al. 2009; Liu and Jordan 2005; Madriaga et al. 2004).  An interesting and very 
plausible role for the anatomical substrate created by the widespread expression of 
AADC, the TAs, and the TAARs would be as an activity amplifier / reinforcement 
mechanism.  In this scenario, descending monoamine transmitters known to promote 
locomotion activate G-proteins, leading to downstream signal transduction pathways 
capable of phosphophorylating AADC (Figure 4.11).   
5-HT7 and D1 both activate the Gsα subunit, which stimulates adenylate cyclase (AC) 
to produce cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). 
cAMP, a second messenger, activates protein kinase A (PKA, cAMP-dependent protein 
kinase) (Gervasi et al. 2007), and PKA phosphorylates AADC (Duchemin et al. 2000).   
5-HT2 and α1 both activate the Gqα subunit, which stimulates phospholipase C (PLC) 
to hydrolyzes phosphatidylinositol 4,5-biophosphate (PIP2) into two second messengers, 
diacyl glycerol (DAG) and inositol triphophate (IP3).  IP3 causes the release of calcium 
from intracellular stores, leading to the activation of Calcium/calmodulin-dependent 
protein kinase type II (CaMKII) (Dash et al. 2007).  CaMKII phosphorylates AADC 
(Neff and Duchemin 2002). 
As many of my in vitro experiments also used NMDA, intracellular cascades 
following NMDA receptor activation could also potentially increase TA levels. NMDA 
receptor activation-induces Ca2+ entry into the neurons, which activates CaMKII and 
nitric oxide synthase (NOS) (Matsumura et al. 2010) (Figure 4.12).   CaMKII 
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phosphorylates AADC (Neff and Duchemin 2002).  NOS produces nitric oxide (NO), 
which can lead to inhibition of MAO activity (Muriel and Perez-Rojas 2003), and thereby 
reducing TA degradation.  Further, NO leads to the activation of cGMP-dependent 
protein kinase (PKG) (Schlossmann and Hofmann 2005), which can then phosphorylate 
AADC (Duchemin et al. 2010). 
The aforementioned phosphorylations of AADC increase its activity and cause an 
increase in the levels of TAs (Berry 2004; Duchemin et al. 2000; Duchemin et al. 2010; 
Neff and Duchemin 2002), leading to activation of the TAARs.  This could then 
transform the externally-generated increase in neuronal excitability to a self-sustaining 
intrinsic mechanism where TAAR induced increases in G proteins produce a positive 
feedback continued phosphorylation of AADC and TA production. In this scenario, 
activity is amplified and self-sustaining until terminated by Gi-coupled pathways (e.g. 
5HT1 receptors).  Thus, the TAs and their receptors may act as an activity switch which 
leads to cellular changes in excitability based on the environment, AADC activity, and 
receptor activation.  These details support a tight interdependence of the TAs with the 
monoamines on spinal motor function. If true, the downstream role of the TAs suggests a 
refinement of monoamine-induced activity ongoing locomotor pattern, not necessarily the 
initiation of it.  This implies that the monoamines and the TAs work together, but that 
each has its own role.   
It is important to emphasize that in this scenario, other pathways independent of the 
monoamine and their receptors that also co-activate the same signal transduction 
pathways could also recruit the TAARs leading to the unique intrinsic modulatory actions 
of the TAs.  
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6.2.9 TA actions in the spinal cord on a network level 
Tryptamine, tyramine, octopamine, and PEA all recruited locomotor-like patterns 
similar to that observed for 5-HT as well as more complex episodic locomotor rhythms.  
Based on flexor/extensor and left/right coordination during the continuous locomotor-like 
pattern, the TAs are likely acting at the level of the central pattern generator (CPG) to 
produce the patterning (Figure 4.10). 
Both continuous and episodic locomotor phenotypes could be observed within 
individual animals indicating that the episodic pattern involves activation of additional 
cellular/network interactions that influence the output of the spinal locomotor central 
pattern generator.  Assuming that these different modulatory actions were due to actions 
at distinct spinal cord sites, there are three possible levels of network neurons that could 
be affected by tyramine, octopamine, and PEA to give the unique episodic patterns 
(Figure 4.10).  In all cases, it was assumed that the CPG level produced the regular 
locomotor-like activity pattern, which was then further modulated to produce the unique 
episodic bursting.  The first level where the modulation could be occurring would be 
neurons that project onto the CPG.  These neurons could produce a slow alternation of 
excitatory and inhibitory drive to the CPG, thus causing the waxing and waning of 
activity.  The second level where the modulation could be occurring would be in neurons 
within the CPG where two events co-exist with distinct time courses.  For example, one 
could be associated with synaptic network interactions occurring at the locomotor 
frequency while a second could be via non-synaptic biochemical pathways occurring at a 
slower frequency (Katz and Clemens 2001).  As the slow rhythm changes, locomotor 
frequency changes (e.g. Figure 4.4E).  The third level where the modulation could be 
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occurring would be in neurons downstream of the CPG (e.g. motoneurons).  In this case, 
locomotor frequency would be unchanged during the rhythm, but amplitude would 
alternate between more excitable and less excitable states.  I think that since there appears 
to be coordination between the bouts of bursting across flexors/extensors and left/right 
alternation, that the first two possibilities are more likely.  
6.3 The trace amines function as neuromodulators 
Neuromodulation is a substance that alters the cellular and synaptic properties of a 
neuron and alters the subsequent neurotransmission, so that even with the same input, the 
output will be different (Katz 1999; Katz 1995; Katz and Frost 1996). Thus, it allows the 
circuit to become more flexible (Katz 1995).  As a general guideline rather than a firm 
definition, neuromodulation is mediated by metabotropic receptors (Katz 1999; Katz 
1995).   
The first type is extrinsic neuromodulation.  It is usually thought to originate from 
sources extrinsic to the circuit being affected and therefore not a part of the circuit itself.  
This is considered the ‘conventional’ form (Katz 1995)and is typified by the descending 
classical monoaminergic neurons as they project to the spinal cord and potently modulate 
spinal sensory, autonomic, and motor activity (Hochman et al. 2001; Millan 2002; 
Schmidt and Jordan 2000).  
A second type of neuromodulation is intrinsic neuromodulation and not as widely 
recognized.  During intrinsic neuromodulation, neuromodulatory substances can also be 
released by neurons that are intrinsic to a circuit, and can affect other neurons and 
synapses within the same circuit. One functional consequences of intrinsic 
neuromodulation is that it operates whenever the circuit is active because it is an integral 
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part of the circuit and as such its actions are proportional to the amount of activity within 
the circuit itself (Katz and Frost 1996).   
A third type of neuromodulation has been referred to as biochemical integration, 
which modulates the neuron in which it acts.  During biochemical integration, the 
biochemical intracellular signals (e.g. second messengers like cAMP) are integrated to 
affect the cellular and synaptic properties of the neuron, often across different time scales 
(Katz and Clemens 2001).  
I have demonstrated that the TAs are intrinsic to the spinal circuits and can affect the 
activity of spinal motor circuits.  The possibility must be considered that that TAs act as 
both intrinsic neuromodulators as well as a biochemical integrators.   
Under normal conditions, I hypothesize that the TAs act as part of a biochemical 
activity monitor that sets the excitatory ‘tone’ of the neuron to regulate its output. This 
form of biochemical integration may control the excitability of spinal neuronal networks 
via TAARs, and as such, should be an additional route that can be explored for 
therapeutic manipulation after spinal cord injury.  It may turn out that the TAs are better 
at temporally modulating the spinal function or easier to manipulate than the 
monoamines.   
6.4 Relevance of the trace amines an intrinsic neuromodulatory system  
While the TAs are potentially important modulators of CNS function, most studies 
aimed at understanding their functional role on the neural systems were undertaken 
decades ago in the mammalian spinal cord. The seminal discovery in 2001 of a new 
family of G-protein coupled receptors preferentially activated by TAs (Borowsky et al. 
2001; Bunzow et al. 2001) rekindled interest in this dying field (Berry 2004; Branchek 
 183
and Blackburn 2003; Davenport 2003; Kim and von Zastrow 2001; Premont et al. 2001).  
However, without an identifiable circuitry for these traces substances, there was little real 
physiological experimentation that can be accomplished.  Perhaps this has prevented the 
predicted resurgence of studies on TAs (Berry 2004; Branchek and Blackburn 2003; 
Davenport 2003; Kim and von Zastrow 2001; Premont et al. 2001),  leaving their 
physiological role as speculative (Berry 2004).  
The research presented here was one step towards establishing the TAs as bona fide 
endogenous neuromodulators with their own actions.  These studies improve our 
understanding of the TAs by establishing a spinal cord substrate for TA to have intrinsic 
biological actions on the spinal motor circuitry.   
The TAs appear to be the first irrefutable amine neuromodulatory system intrinsic to 
the mammalian spinal cord.  Since the TAs can modulate sensory (Bowman et al. 1964; 
Reddy et al. 1980) and motor systems, control of their release and/or receptor activation 
may provide new therapeutic strategies for the management of spinal cord dysfunction, 
including after loss of descending monoaminergic systems as occur after spinal cord 
injury.    
6.5 Future studies 
In order to further establish the how the TAs are functioning in the spinal cord, future 
studies are necessary. 
(i) To demonstrate that endogenous production of the TAs can produce spinal cord 
actions, in preliminary work I have shown that blocking TA degradation with MAO 
inhibitors caused rhythmic motor activity similar to endogenous application of the TAs 
(see Appendix B). 
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(ii) To further establish the requirement of transporters in spinal neurons in spinal 
motor function transport inhibitors for the LATs, OCTs, and PMAT should be used.  
Recently, transport inhibitors were tested for PMAT, and sertraline was found to be the 
most potent (Haenisch and Bonisch 2010).   
(iii) To demonstrate that dietary alterations in aromatic amino acids have functional 
consequences on motor circuits, in preliminary work I observed that applications of the 
aromatic amino acids could increase motor activity and that phenylalanine could activate 
rhythmical activity (not shown). 
(iv) To investigate behavioral relevance of TAs on spinal motor behavior in adult rats 
to more closely approximate spinal cord injuries in adults, injections of the TAs into 
spinalized adult rats in vivo should be investigated to determine if they too have rhythmic 
locomotor hindlimb movements that could suggest clinical application.  
(v) Interestingly, I found that dopamine was similar to the TAs both by having a 
unique pattern as well as its longer time for burst initiation.  A new study in PLoS one 
just came out showing that A11 is likely L-dopa-ergic (Barraud et al. 2010), which opens 
the possibility that L-dopa is released from A11and transported into other neurons to 
make dopamine intracellularly.  
 (vi) Unfortunately, TAAR antagonists are currently unavailable; however, they 
should be tested when they do become available.   
(vii) Also, future studies should address the role of the TAs during development.  With 
only AADC activity and no TH activity early in development, the TAs could be playing 




ALLEN SPINAL CORD ATLAS  
The Allen Spinal Cord Atlas (http://mousespinal.brain-map.org) provides a 
comprehensive searchable RNA in situ hybridization database of gene expression of the 
mouse spinal cord at postnatal days 4 and 56 (Allen_Spinal_Cord_Atlas 2009).  Spinal 
cord in situ hybridization expression patterns obtained from the Allen Spinal Cord Atlas 
of the synthesis enzymes, degradative enzymes, trace amine-associated receptors, and 
transporters associated with the monoamine and putative trace amine neuromodulators 
are in the following figures.  Expression for each gene is marked as absent or present 
based on the annotation index designation.  However, on several occasions, overt reaction 






Figure A.1: Allen Spinal Cord Atlas in situ hybridization of synthesis enzymes  
AADC, aromatic amino acid decarboxylase (also called dopa decarboxlase); TH, tyrosine hydroxylase; 




Figure A.2: Allen Spinal Cord Atlas in situ hybridization of degradation enzymes  






Figure A.3: Allen Spinal Cord Atlas in situ hybridization of trace amine-associated receptors and 
trace amine receoptor 3  




Figure A.4: Higher magnification of select TAARs 
A. Higher magnification and contrast enhanced images of TAAR1 and TAAR4 show clear reaction product 
in motoneurons at both P4 and P56.  B. In addition, weak labeling for TAAR2, TAAR3, TAAR5, and 





Figure A.5: Allen Spinal Cord Atlas in situ hybridization of monoamine and vesicular transporters 
A. Expression results for the high affinity monoamine transporters SERT, NET and DAT. B. The vesicular 
monoamine transporter 2 (VMAT2) is expressed in P4 spinal cord but reported as absent in the adult. 
Labeling at P4 Higher magnification and contrast enhanced image of VMAT2 in the neonate shows 




Figure A.6: Allen Spinal Cord Atlas in situ hybridization of organic cation transporters and the 
plasma membrane monoamine transporter 
A. The organic cation transporters, OCT1-3, are widely expressed in spinal neurons in both neonate and 
adult mouse spinal cord. B. The low affinity plasma membrane monoamine transporter is preferentially 
expressed in intermediate gray and ventral horn regions in both neonate and adult mouse spinal cord 






Figure A.7: Allen Spinal Cord Atlas in situ hybridization of L-amino acid transporters  




EVIDENCE FOR TRACE AMINE PRODUCTION IN THE SPINAL 
CORD 
B.1 Introduction 
TAs are synthesized from aromatic amino acids via aromatic amino acid 
decarboxylase (AADC) and further by dopamine-b-hydroxyase (DBH) for octopamine.  
A defining feature that makes TAs ‘trace’ amines is their lack of sequestration in synaptic 
vesicles and consequent rapid degradation by monoamine oxidases (MAOs), their 
presumed primary mechanism for termination.  Two different types of MAO, named A 
and B, have been characterized.  Both MAOA and MAOB are found in the spinal cord, 
with MAOA found in motoneurons (Luque et al. 1995; Saura et al. 1992).  MAOB has a 
high affinity for PEA, while the other TAs are degraded by both (Bortolato et al. 2008; 
Shih et al. 1999) 
The MAOs do not have short-term effects on the release of the classical monoamine 
transmitters (Berry 2004; Cragg et al. 2000; Houdouin et al. 1990) and therefore, can be 
used to study the faster effects of increased intracellular TAs on neural function. 
B.2 Methods 
All experimental procedures complied with the NIH guidelines for animal care and the 
Emory Institutional Animal Care and Use Committee.   
B.2.1 Immunohistochemistry 
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The spinal cord was isolated from rats who had been intraperitoneally injected with 
Fluorogold 24 hours prior to sacrifice to retrogradely label most spinal motoneurons 
(Ambalavanar and Morris 1989) (Merchenthaler 1991).   
Isolated spinal cords were incubated in one of four different treatments for 2 hours: (1) 
control, (2) in the presence of aromatic amino acid precursors phenylalanine, tyrosine, 
and tryptophan (all at 100 µM), (3) the TAs (all at 100 µM), and (4) the TAs plus MAOA 
and MAOB inhibitors clorgyline and deprenyl, respectively (both at 100 µM).  
Subsequent tyramine immunolabeling and densitometry was performed on lateral MNs to 
measure changes in expression. 
The spinal cords were then post-fixed for 1 hour in Lana’s fixative than cryoprotected 
in 10% sucrose, 0.1M PO3 until sectioned into 10 um thick sections on a cryostat and 
processed for immunohistochemistry.  All incubations and washes were performed in 
0.1M PO3-buffered saline containing 0.3% triton X-100 (PBS-T).  Tissue was washed 
overnight in PBS-T at 4°C followed by incubation in primary antibody for 48-72 hours.  
Slides were then washed three times for 30 minutes and incubated in secondary antibody.  
The primary antibody was following Rabbit anti-tyramine 1:1000 (Chemicon) and the 
secondary antibody was cy3 anti-rabbit (Jackson Immunoresearch). 
Densitometry was performed on lateral MNs using the Neurolucida Software at a scale 
of 1700x magnification.  Omission and absorption controls were blank. 
B.2.2 Electrophysiology  
B.2.2.1 General setup 
Sprague-Dawley rats postnatal (P) day 0-5 were decapitated, eviscerated, and placed 
in a bath containing oxygenated (95% O2, 5% CO2) artificial cerebral spinal fluid (aCSF) 
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containing the following (in mM): 128 NaCl, 1.9 KCl, 1.2 KH2P04, 26 NaHCO3, 2.4 
CaCl2, 1.3 MgSO4, and 10 glucose (pH of 7.4).  The spinal cord was exposed by a ventral 
vertebrectomy and carefully dissected out of the body cavity leaving the dorsal and 
ventral roots attached.  The spinal cord was secured with insect pins to a chamber with 
Sylgard (Dow) on the bottom.  Glass suction electrodes were applied to dorsal and/or 
ventral roots, after which the preparation was allowed to recover for at least 1 hour before 
experimentation at room temperature.  The ventral root electroneurographic activity was 
amplified (10,000x), band-pass filtered at 10-3,000 Hz and digitized at 5kHz (Digidata 
1321A, 16-bit; Axon Instruments). Band-pass filter frequency settings were selected with 
consideration to observed frequency components with the low-pass filter set ant mush 
greater than the Nyqist frequency. Data was captured on a computer with the pCLAMP 
acquisition software (v8-9, Molecular Devices; Union City, CA).     
B.2.2.2 Neurochemicals 
Neurochemicals, which were stored in 10mM or 100mM stock solutions at -20°C, 
were added to the bath (typically 30mL) to achieve the final concentration in the 
chamber.  Neurochemicals were obtained from Sigma-Aldrich (St. Louis, MO), including 
NMDA (5 µM) and tyramine (10µM). 
The following monoamine oxidase inihibitors were used: nialimide (non-specific 
MAOA and MAOB inhibitor; usually at 10 mM), clorgyline (MAOA inhibitor; up to 
dose of 100 µM), and deprenyl (MAOB inhibitor; up to a dose of 100 µM).  
The aromatic amino acids were used: phenylalanine (100 µM), tyrosine (100 µM), and 




Figure B.1: MAO inhibitors can increase endogenous trace amines 
Tyramine expression was increased in motoneurons following pre-incubation in the presence of MAO 
inhibitors.  Changes were quantified using densitometry in lateral motoneuronal tyramine labeling after 
incubations in control, aromatic amino acids, the TAs, and the TAs plus the MAOs inhibitors clorgyline 




B.3.1 Monoamine oxidase inhibitors can cause an accumulation of tyramine  
To examine the effects of metabolism on tyramine expression, spinal cords were 
incubated in control aCSF, aromatic amino acids, TAs, and TAs plus MAO inhibitors 
(Appendix Figure B.1) with subsequent tyramine immunolabeling and densitometry to 
measure changes in expression.  Tyramine expression did not increase in the presence of 
aromatic amino acids suggesting that their concentration was not rate limiting (n=2).  
Tyramine increased, albeit not significantly, after incubation in the TAs alone (n=2).  
TAs and MAO inhibitors led to a significant increase in tyramine immunolabeling (n=2; 
p<0.01), indicating that tyramine was accumulating in motoneurons since its degradation 
was being blocked. 
B.3.2 Actions of monoamine oxidase inhibitors support an endogenous role for the 
trace amines  
 Since MAO inhibitors can cause tyramine to accumulate in motoneurons and, 
importantly, they do not have short-term effects on the release of the classical 
monoamine transmitters (Berry 2004; Cragg et al. 2000; Houdouin et al. 1990), the MAO 
inhibitors can be used to study the faster effects of increased intracellular TAs on neural 
function.  Deprenyl, clorgyline, and nialamide were tested since they are used clinically, 
so any observed actions on spinal circuits may have clinical relevance. 
When applied alone to the bath, the MAO inhibitors were able to produce slow burst 
of activity with nialamine (n=1/4) and sudden transient increase in spontaneous activity 
lasting several minutes with clorgyline and deprenyl (n=3/5).  These observations suggest 
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Figure B.2: MAO inhibitors can increase neuroactivity 
A. The bath was incubated in 100 µM clorgyline, 100 µM deprenyl, and 2 µM NMDA.  Subsequent 
addition of 2 µM NMDA resulted in the expression of long-lasting L5 left-right alternating ventral root 
activity. The L2 ventral roots remained silent, suggesting selective recruitment of the extensor half-center. 
B. The MAOA and MAOB inhibitor, nialamide, converted NMDA-evoked spontaneous ventral root 




that amplifying endogenous concentrations of TAs promote motor activity but are 
insufficient to recruit locomotion. 
In the presence of NMDA at doses that did not evoke consistent activity, clorgyline 
and deprenyl produced stable left/right L5 alternation that lasted for the 25 minute 
duration of the recording (0.1 Hz; n=1/1; Appendix Figure B.2A).  Similarly, nialamide 
recruited rhythmical motor activity (n=2/4): one displaying right/left L2 flexor alternation 
(0.075 Hz) that lasted over 1 minute and the other episodic LLA  lasting over 15 minutes  
at 0.21 Hz (Appendiz Figure B.2B). Intriguingly, in the two animals where nialamide 
with NMDA did not produce rhythmicity, application of the aromatic amino acid 
precursors (tyrosine, tryptophan, and phenylalanine) led to pronounced increases in motor 
activity; in one, clear busting events lasted for the 25 minute duration of the recording.  
This did not happen in the absence of nialamide implying that increased levels of 
aromatic amino acids are capable of synthesizing TAs via AADC, which in the absence 
of degradation, can elevate TAs levels to exert a biological action on the motor system.  
B.4 Discussion 
B.4.1 MAO inhibitors increase endogenous trace amines and can increase 
neuroactivity  
As MAOA is distributed throughout the P4 mouse spinal cord (Appendix Figure 
A.2), and AADC also has widespread expression, the application of MAO inhibitors 
should increase TA levels.  Indeed, the incubation experiments show that MAO inhibitors 
do increase the levels of TAs.  Also, application MAO inhibitors alone were able to 
increase activity.  That they do not always increase activity, could be due to other factors 
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in the spinal cord, including not enough aromatic amino acids available to make more or 
not enough AADC activity to convert the aromatic amino acids to TAs. 
Further, the MAO inhibitors were capable of recruiting rhythmic motor activity in the 
presence of NMDA including the wax and wane episodic activity so characteristic of 
tyramine, octopamine, and PEA bath application.  To support the idea that the state of the 
spinal cord matters, adding aromatic amino acids to the bath after MAO inhibitors where 
unable to produce rhythmic activity did produce bursting in one cord.  Together these 
actions strongly support endogenous production of the TAs in the spinal cord, and that at 
high enough local concentrations they are able to affect motor function. 
Interestingly, while both MAOA and MAOB are found in the in spinal cord using 
immunohistochemistry and radioligands to look at expression of the enzymes (Luque et 
al. 1995; Saura et al. 1992), examining the in situ hybridization in the Allen Spinal Cord 
Database shows that only MAOA, and not MAOB, is expressed in the spinal cord, 
meaning MAOB is likely found in the descending monoaminergic terminals (Appendix 
Figure A.2) (Allen_Spinal_Cord_Atlas 2009).  This has implications regarding 
especially the local concentration of PEA, which is preferentially degraded by MAOB 
(Bortolato et al. 2008; Shih et al. 1999).  If PEA is produced in, say motoneurons, where 
there is no MAOB, it must be transported out of the neuron and into another neuron 
where it can be degraded, possibly implying a higher concentration in the cell that 




SPINALMOD ALGORITHM FOR BURST DETECTION 
function [begmarks,endmarks] = BurstDetection(filtered, BurstThresh, ... 
    MinBurstDur, MinPeriod, BurstStart, MinInterBurst,EndMin, sampfreq) 
  
%These formulas convert the time inputed by the user into sample points 
%more easily used by the computer. 
if BurstStart==0 
    BurstStart=1; %Prevents the program from stopping b/c it can't handle 0 
else 
    BurstStart=BurstStart*sampfreq;%Start time of the 1st burst 
end 
if MinPeriod==0 
    MinPeriod=1; 
else 
    MinPeriod=MinPeriod*sampfreq;%Minimum period btw bursts 
end 
if MinBurstDur==0 
    MinBurstDur=1; 
else 




    MinInterBurst=1; 
else 
    MinInterBurst=MinInterBurst*sampfreq;%Min. time btw bursts 
end 
if EndMin==0 
    EndMin=1; 
else 
    EndMin=EndMin*sampfreq; 
    %Minimum time btw fluctuations at the end of the burst  
end 
  
%Cuts off all the filtered data before the beginning of the burst, 
%thus reducing the number of false positives for the start of the burst 
cutfiltered=filtered(BurstStart:end); 
%Checks whether the filtered data is above the Burst Threshold and 
%returns the indicies of the filtered data that are above threshold 
y=[find(cutfiltered>BurstThresh)];%Indicies of points above threshold 
%Creates arrays of the filtered data to be compared with each other to 
%find the points that cross threshold and indicate the start or end of a 
%burst 
abovethresh=cutfiltered(y);%All values that are above the threshold 
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%The following will test the to see if the points before and after the 
%indicies above threshold exist 
q=find(cutfiltered); 
if q(1)==y(1) 
    %Filltered data one point before the threshold points 
    testbeg=[cutfiltered(y(1)) cutfiltered(y(2:end)-1)]; 
    %Filtered data one point after the threshold points 
else 
    testbeg=cutfiltered(y-1); 
end 
if q(end)==y(end); 
    testend=[cutfiltered(y(1:end-1)+1) cutfiltered(y(end))]; 
else 
    testend=cutfiltered(y+1); 
end 
%ii=1;iii=1; I=1;Burst=false;endmarks=[];%Used for initialization 
  
%The following finds the bursts. 
%For the onset, it checks all points above threshold with the point 
%immediately before it.  If the point before is below threshold, it is 
%marks an onset, and then, it starts to look for the end of the burst.  It 
%checks all points above threshold with the point immediately after it.  If 
%the point after is below threshold, it marks a potential end.  It then 
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%takes a number of end points to see if the difference btw them is greater 
%than a user inputted EndMin, the minimim distance btw the burst and the  
%next point to cross the threshold, which hopefully is hte next burst. 
%MinInterBurst is the minimum distance btw the end of the burst and the 
%beginning of the next.  If so, it marks the first point as end. Then, it 
%goes back to find the next onset making sure the value is greater than the 
%user inputted MinPeriod, the minimum distance btw bursts. To do this, it 
%goes back a number of points so that it does not miss the first point. 
if BurstStart==1 
    BurstStart=0; 
else 







    %The following code looks for the beginning of a burst 
    if (Burst==false) && (abovethresh(i)>testbeg(i)) &&... 
            (testbeg(i)<BurstThresh) && (ii==1 ) %this looks for the first burst's 
beginning 
        begmarks(ii)=y(i)+BurstStart; 
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        ii=ii+1; 
        Burst=true;%true indicates that the beginning of a burst has been marked 
    elseif (Burst==false)&&(abovethresh(i)>testbeg(i))&&... 
            (testbeg(i)<BurstThresh)&&... 
            (y(i)-(begmarks(ii-1)-BurstStart) > MinPeriod) &&... 
            (y(i)-(endmarks(iii-1)-BurstStart) > MinInterBurst) 
        begmarks(ii)=y(i)+BurstStart; 
        ii=ii+1; 
        Burst=true; 
    end 
     
    %The following code looks for the end of a burst 
    if (Burst==true) && (abovethresh(i)>testend(i)) &&... 
            (testend(i)<BurstThresh) &&... 
            ((y(i)-(begmarks(ii-1)-BurstStart)) > MinBurstDur) 
        em(I)=y(i)+BurstStart; 
        if I>1 && ((em(I)-em(I-1))>=EndMin) 
            endmarks(iii)=em(I-1); 
            a=find(y==(endmarks(iii)-BurstStart)); 
            iii=iii+1; 
            Burst=false;%false indicates that the end of a burst has been marked    
            I=1; 
        else 
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            I=I+1; 
        end 
    end 
     
    %The following code goes back and check the point for the beginning of 
    %a burst 
    if isempty(a)==0 
        for b=a:i 
            if (Burst==false)&&(abovethresh(b)>testbeg(b))&&... 
                    (testbeg(b)<BurstThresh)&&... 
                    ((y(b)-(begmarks(ii-1)-BurstStart)) > MinPeriod) &&... 
                    ((y(b)-(endmarks(iii-1)-BurstStart)) > MinInterBurst) 
                begmarks(ii)=y(b)+BurstStart; 
                ii=ii+1; 
                Burst=true; 
            end 
        end 
        a=[]; 
    end 
     
    %The following code double checks for the end of a burst 
    %This portion of the code was added later to fix the EMG problem... 
    if (Burst==true) && (abovethresh(i)>testend(i)) &&... 
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            (testend(i)<BurstThresh) &&... 
            ((y(i)-(begmarks(ii-1)-BurstStart)) > MinBurstDur) 
        em(I)=y(i)+BurstStart; 
        if I>1 && ((em(I)-em(I-1))>=EndMin) 
            endmarks(iii)=em(I-1); 
            iii=iii+1; 
            Burst=false;%false indicates that the end of a burst has been marked    
            I=1; 
        else 
            I=I+1; 
        end 
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